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ABSTRACT OF THE DISSERTATION
NUCLEOSIDE ANALOGUES FOR POSITRON EMISSION TOMOGRAPHY
IMAGING AND TO STUDY RADIATION MEDIATED GENERATION OF
RADICALS FROM AZIDES
by
Maria de Cabrera
Florida International University, 2019
Miami, Florida
Professor Stanislaw F. Wnuk, Major Professor
Gemcitabine is a potent anticancer cytidine analogue used to treat solid tumors. Its
efficacy is diminished by rapid deamination to a toxic uridine derivative by cytidine
deaminase. To overcome this limitation and add radioactive nuclei (18F or 68Ga) for PET
imaging, I synthesized two 4-N-alkylgemcitabine analogues i) bearing β-keto tosylate
moiety for subsequent 18F-fluorination and ii) having SCN-Bn-NOTA chelator to complex
68

Ga. The first was synthesized by replacement of tosylamide in 4-N-tosylgemcitabine with

1-amino-10-undecene,

followed

by

elaboration

of

terminal

alkene

through

dihydroxylation, regioselective tosylation and oxidation. Subsequent fluorination using KF
in presence of 18-Crown-6 at 75°C for 1 hr gave 4-N-alkylgemcitabine fluoromethyl
ketone. The second was synthesized by analogous replacement of tosylamide with N-Boc1,3-propanediamine, followed by deprotection with TFA. The reactive terminal amine was
condensed with SCN-Bn-NOTA, giving 4-N-alkylgemcitabine-SCN-Bn-NOTA ligand,
which efficiently complexed Ga or 68Ga for in vivo PET studies in rats.

vii

Clofarabine is a highly effective chemotherapeutic adenosine analogue used for
treatment of acute lymphoblastic leukemia. Clofarabine undergoes rate limiting
phosphorylation from its 5'-monophosphate to 5'-diphosphate by purine monophosphate
kinase, and possible dephosphorylation of its respective 5'-monophosphate by 5'nucleotidases. Synthesis of clofarabine diphosphate prodrugs, and potentially their

18

F-

radiolabeled analogues, were undertaken to overcome these limitations. Successful
synthesis of model adenosine diphosphate prodrug, by coupling adenosine monophosphate
with bis(benzoyloxybenzyl) phosphoramidite in presence of 5-phenyl-1-H-tetrazole
activator was achieved.
The aminyl radical generated from azide moiety in 3'-azido-3'-deoxythymidine (3'AZT) or 5-azidomethyl-2'-deoxyuridine (AmdU), upon addition of radiation-produced
electrons, is thought to be the source of their radiosensitizing effects. Herein, I report
synthesis of azido-modified purine and pyrimidine analogues for EPR study of formation
of reactive aminyl radical in guanine, adenine and cytidine bases. The EPR studies of
electron addition to 2-azidoguanosine (i.e. 2-azidoinsoine), protected 4-azidocytidine and
4-tetrazolocytidine analogues clearly establish that the position of the azide in base moiety
dictates reactivity. The azide directly attached to nucleobases at ortho/para position to ring
nitrogens produce stable RN3•- that does not rapidly convert to aminyl radical, except in
the excited state. Hence, these did not display much radiosensitizing effects in in vivo
biological studies in MDA-MB-231, MCF7 and U87 cell lines.
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1 INTRODUCTION
Anti-cancer properties of nucleoside analogues
Cancer is the second leading cause of death in the United States. Cancer cells display
uncontrolled growth and spread across the body causing various health issues, or even
death. Because of the increased metabolism of cancer cells compared to normal cells,
replication of DNA occurs much more frequently in these cells. Replication of DNA
requires nucleotides, the building blocks of DNA, whose precursors are nucleosides. On
the basis of the fact that cancer cells require more nucleosides, many nucleoside analog
(NA) chemotherapeutic agents have been developed.1 These NAs mimic regular
nucleosides in their uptake and metabolism. They enter the cell through different
membrane transporters and are phosphorylated into their active nucleoside triphosphate
forms. The triphosphate form of these drugs can be incorporated onto DNA, where their
small modifications cause strand breakage and ultimately cell death.2

Figure 1. Selected examples of nucleoside analogue drugs
1.1.1 Gemcitabine: biological activity
Gemcitabine (2′,2′-difluoro-2′-deoxycytidine, dFdC, Figure 1) is a chemotherapeutic
cytidine analogue synthesized by Hertel et al.3 that is used in the treatment of non-small
cell lung, pancreatic, bladder, and breast cancer.4,5 Gemcitabine is a hydrophilic drug, and
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requires human equilibrative nucleoside transport proteins (hENTs) to be taken through the
cell membrane.4 It is then activated in the cell by monophosphorylation with deoxycytidine
kinase (dCK) into its monophosphate form.6,7 Gemcitabine 5'-monophosphate (dFdCMP)
is further phosphorylated by uridine/cytidine monophosphate kinase (UMP/CMP kinase).4
Then, dFdCDP is phosphorylated to gemcitabine 5'-triphosphate (dFdCTP) by nucleotide
diphosphate kinase (NDP kinase) and can serve as a substrate for DNA incorporation. Once
incorporated, gemcitabine causes chain termination during replication and repair
processes, thus triggering apoptosis.4
Gemcitabine 5'-diphosphate (dFdCDP) serves as a potent inhibitor of both subunits of
ribonucleotide reductase (RNR; Figure 2), the enzyme that is responsible for converting
ribonucleoside diphosphates into 2’-deoxyribonucleoside diphosphates.8 By inhibiting
RNR, gemcitabine decreases the bioavailability of naturally occurring deoxynucleoside
diphosphates (dNDPs), and subsequently deoxynucleoside triphosphates (dNTPs) in the
cell, furthering gemcitabine’s ability to compete with dCTP for incorporation into DNA. 9
Because of the depletion of dCTP pools in the cell, feedback inhibition of dCK is disrupted,
which allows further monophosphorylation of gemcitabine. The increasing pools of
gemcitabine 5'-monophosphate becomes highly toxic for cancer cells that are replicating
rapidly and require a large amount of nucleotide building blocks for DNA synthesis.10

Figure 2. Mode of inhibition of ribonucleotide reductase by nucleoside analogues11
2

Although gemcitabine is quite successful in treating certain tumors, it does experience
some limitations in vivo in terms of metabolism and cytotoxicity. For example, gemcitabine
is significantly hydrophilic, causing its rapid excretion once administered and it is inactive
in the body until it can be mono-, di-, and tri-phosphorylated to serve as a substrate for
DNA incorporation. The rate-limiting step in its metabolism is its monophosphorylation
from gemcitabine into gemcitabine 5'-monophosphate by deoxycytidine kinase (dCK).
Gemcitabine 5'-monophosphate can also undergo dephosphorylation by 5'-nucleotidases
back into the inactive parent drug.6,7 Finally, gemcitabine can be highly toxic to normal
cells as a result of its rapid deamination into its toxic 2'-deoxy-2',2'-difluorouracil (dFdU)
derivative by deoxycytidine deaminase (dCDA).6,12,13
1.1.2 Clofarabine: biological activity
Clofarabine [2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine, Cl-F-araA, Figure 1] is an adenosine analogue that is used for the treatment of pediatric acute
lymphoblastic leukemia (ALL). Clofarabine was synthesized by Montgomery et al.14 in
order to prevent the dose toxicity found in similar anticancer drugs fludarabine phosphate
(9-β-ᴅ-arabinofuranosyl-2-fluoroadenine-5'-O-phosphate) and cladribine (2-chloro-2'deoxyadenosine). Toxicity of fludarabine phosphate and cladribine was found to be the
result of their susceptibility to glyosidic bond cleavage.15 Presence of the fluorine in
arabino configuration at the 2'-position of sugar moiety prevents formation of inactive
and/or toxic purine derivatives, while the presence of chlorine at 2-position of adenine base
prevents deamination by adenosine deaminase.14
Entrance of clofarabine into the cell occurs mainly by human equilibrative nucleoside
transport protein 1 (hENT1) and human concentrative nucleoside transport protein 3
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(hCNT3), although, at high concentration and long exposure times, it can undergo passive
diffusion through lipid membranes.15,16 Clofarabine is a better substrate for dCK than 2'deoxycytidine, and thus is activated in the nucleus through monophosphorylation by the
kinase.17 Clofarabine is further phosphorylated by purine nucleotide monophosphate
kinase into its diphosphate form, and then triphosphorylated for incorporation onto DNA
(Figure 3).15 Clofarabine 5'-triphosphate is also an RNR inhibitor, and like gemcitabine,
lowers the availability of naturally occurring dNTPs, making its incorporation much more
rapid.11,18,19

Figure 3. Mode of action of clofarabine15
Clofarabine, like gemcitabine, has some limitations in terms of metabolism and
cytotoxicity. Unlike fludarabine and other common NA drugs that experience rate-limiting
monophosphorylation by dCK, clofarabine undergoes rate-limiting phosphorylation from
clofarabine 5'-monophophate to clofarabine 5'-diphosphate by purine nucleotide
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monophosphate kinase.15,20 Thus, accumulation of clofarabine 5'-monophosphate which
can be incorporated onto DNA and causes some cytotoxicity, but slows the formation of
clofarabine 5'-triphosphate which is required for RNR inhibition and the self-potentiating
mechanism which increases its anti-cancer activity.21 Moreover, clofarabine 5'monophosphate can be dephosphorylated back to the inactive parent metabolite by 5'nucleotidases present in the cell.15,20,22,23
Nucleoside prodrugs
Prodrugs are derivatives of parent drugs that can be transformed chemically or
enzymatically in vivo to release the parent drug.24 The main aim of prodrugs is to improve
the physicochemical properties of the parent drug. Because of their high polarity, NA drugs
usually suffer from poor bioavailability and low intestinal permeability. Prodrugs, then, are
employed to increase the lipophilicity of these drugs, which allows facilitated transport into
the cells (often without the need for nucleoside transporters), improve oral absorption, or
target specific tissues.25-27
Several gemcitabine prodrugs have been developed through hydrolyzable acyl
modifications on the exocyclic 4-N-amine or 5'-hydroxyl groups, to combat its rapid
deamination and excretion.28-33 Examples of 4-N-acyl modified gemcitabine include
LY2334737 A30 and squalenoyl B29 analogues, which improve uptake and bioavailability
of gemcitabine (Figure 4).34,35 Furthermore, esterification at the 5' position of gemcitabine
accelerates uptake of the drug into tumor cells (e.g., CP-4126; C).31 Gemcitabine analogues
have also been designed as theragnostic delivery systems with cellular specificity and
imaging capabilities; these include H-gemcitabine32 and gemcitabine-coumarin-biotin
conjugates,36 among others.37,38
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Figure 4. Important example of gemcitabine prodrugs
Most nucleoside drugs and prodrugs undergo rate limiting monophosphorylation by
dCK. Because of this rate-limiting process, several nucleotide prodrugs (ProTides) have
been modified to bypass a phosphorylation event through hydrolysable phosphoramidate
modifications at the 5' position.39 The best example of this highly successful approach, is
the development of anti-viral Hepatitis C drug: Sofosbuvir (D).39,40 Figure 5 shows some
common examples of ProTides synthesized in recent literature for the enhancement of
cellular metabolism.
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Figure 5. Examples of important ProTides/DiPPro analogues reported in literature
Several types of nucleotide prodrugs have been reported in literature over the last
decade. These can be divided into two sub-categories:
1. Dr. McGuigan's phosphoramidate prodrugs (ProTides)41-45, and
2. Dr. Meier's diphosphate prodrugs (DiPPro).46,47
McGuigan's approach, as seen in sofosbuvir (D)40, gemcitabine (E)48 and clofarabine (F)45
ProTides, involves the addition of a phosphoramidate unit to the 5'-OH of the parent
nucleoside drug. These prodrugs are designed to release the 5' monophosphorylated parent
drug by a specific in vivo metabolism. The process begins by cleavage of the ester bond of
the amino acid derivative modification by action of esterase or carboxypeptidase type
enzymes (Figure 6).49 Following the cleavage, cyclization spontaneously occurs displacing
aryl modification and creating an unstable anhydride ring. The ring can then be opened in
7

the presence of water. Finally, a phosphoramidase-type enzyme can hydrolyze the P-N
bond, releasing the 5' monophosphorylated parent drug. The unmasked monophosphate
form of the drug can then be released to be di- and triphosphorylated in the cell and serve
as a substrate for DNA incorporation.49

Figure 6. Proposed in vivo metabolism of McGuigan's ProTides49
The Meier DiPPro approach, as seen in ProTide G, utilizes a bis(acyloxybenzyl)
phosphoramidite unit to couple with nucleoside 5'-monophosphates. Once coupled, a
P(III)-P(V) bond forms which can be oxidized to give P(V)-P(V) bond in which βphosphate still contains lipophilic bis(acyloxybenzyl) modifications.50-53 Cellular
metabolism of the DiPPro begins with esterases cleavage, which allows release of the
bis(acyloxybenzyl) moiety as a para-quinone methide byproduct leaving unmasked
nucleoside diphosphate (Figure 7).46 Although more lipophilic modifications on the ester
are preferred for efficiency of uptake, lipophilic modification create a more stable ester
bond that undergoes a slower esterase cleavage. Slower esterase cleavage causes release of
the entire β-phosphate unit leaving the monophosphorylated nucleoside analog drug. To
avoid the cleavage of the phosphorous anhydride bond, asymmetric bis(acyloxybenzyl)
8

modifications are preferred with less lipophilic (shorter carbon chain) modification and one
more lipophilic (longer carbon chain) modification on the β-phosphate. The less lipophilic
alkyl ester will then be released quickly, leaving a negative charge on the β-phosphate,
making cleavage of the phosphorous anhydride bond difficult. The more lipophilic
bis(acyloxybenzyl) modification can then be metabolized releasing

the unmasked

nucleoside diphosphate, which can be further phosphorylated to its triphosphate form and
serve as a precursor for DNA incorporation.51

Figure 7. Proposed in vivo metabolism of Meier's DiPPro51
Positron Emission Tomography (PET) imaging
Positron Emission Tomography (PET) is a non-invasive imaging technique which has
become increasingly useful for the diagnosis and staging of human disease, as well as, for
drug discovery. Positron Emission Tomography is an important tool in medicinal chemistry
because of its ability to monitor disease biology and response to treatments. 54 The PET
method utilizes drugs labeled with neutron-deficient isotopes (i.e., radionuclei) that
stabilize by converting a proton into a neutron and emitting a positron (such as 11C, 13N,
15

O, or 18F).55 A positron is a subatomic particle of equal mass and charge magnitude than

an electron, but bears a positive charge.56 The emitted positron loses energy as it travels
9

through the body and eventually annihilates with an electron. The interaction of the
oppositely charged positron and electron causes two gamma rays to discharge at 180° from
one another (i.e., collinear emission). These photons are detected simultaneously, within a
few nanoseconds, by a ring detector around the patient. In this way, the specific location
of the radiotracer, molecule containing the radionuclei, can be determined and an image
formulated. The accumulation of the radiotracer in the body is determined by the nature
and metabolism of the radiotracer.56,57

Figure 8. Positron annihilation and subsequent detection of photons in PET imaging58
One of the most common positron emitting nuclides used for PET imaging is Fluorine18 (18F) because of its long half-life (109.77 minutes) as compared to other positronemitting radionuclei. The long half-life of

18

F allows sufficient time for the synthesis of

radiotracers, as well as, the possibility of transportation outside a radiochemical facility.55
The 18F radioisotope is made in one of two ways:
1. The irradiation of

20

Ne with deuterium particles followed by its α-decay; with F2

added to keep fluorine oxidized, which allows for use of
nuclear reactor (cyclotron).59

10

18

F directly from the

2. The irradiation of 18O enriched water with protons in a cyclotron, where the 18F ion
formed can be removed using distillation or a resin column.59
The most common radiotracer currently used for PET imaging is 2-deoxy-2-[18F]-Dglucose (18FDG, Figure 9), which is metabolized similarly to glucose in the body. It is taken
into the cell with glucose transporter available in all living cells and phosphorylated
irreversibly by hexokinase. However, it cannot be further metabolized because of the
fluorine present at the 2-position and remains trapped in the cell. Cells with higher glucose
consumption, such as cancer cells, will accumulate 18FDG and create a contrasting image
with the surrounding environment.54 Unfortunately, 18FDG is metabolized quickly and is
not as useful in imaging tumors with slow proliferation or brain tumors, since glucose
accumulates in all brain cells as consequence of their high metabolic requirements.59
1.3.1 Overview of PET imaging agents
Nucleoside- and carbohydrate-based 18F-PET imaging agents
To monitor specific tumor sites in the body and get accurate data for drug efficacy,
several nucleoside-based PET radiotracers have been developed (Figure 9).60 Nucleosidebased radiotracers are particularly useful to image cancer growth and treatment because
they are involved in DNA synthesis.61 These radiotracers are labelled with 11C or

18

F

radionuclides and are substrates for key enzymes in DNA synthesis, such as kinases. Most
of the known PET imaging radiotracers are designed from pyrimidine nucleoside
analogues.61
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Figure 9. Important nucleoside- and carbohydrate-based PET imaging radiotracers
One important example is 1-(2-deoxy-2-[18F]fluoro-β-D-arabinofuranosyl)cytosine
[18F-FAC, Figure 10], which was developed as a noninvasive predictor probe of tumor
response to gemcitabine and was utilized for PET imaging of dCK activity.62-65 The 18FFAC was developed because the synthesis of gemcitabine involves the incorporation of a
geminal difluoro unit in the early synthetic stages,3,66 and the preparation of 2'-[18F]dFdC
still appears to be not feasible mainly because of the short half-life of

18

F isotope.67

Although FAC generally follows the known ex vivo biodistribution of gemcitabine, it is
missing the geminal difluoromethylene unit at C2' which is critical for the anticancer
properties of gemcitabine, its inhibitory activity of RNR,9 and other physicochemical
properties.68-70
Recent literature showed the efficient synthesis of 1,1-[18F]difluorination of alkenes
using non-carrier added [18F]-fluorine and fluoroalkenyl(4-methoxyphenyl)iodonium
triflates.71 Such a method may be extremely useful for future labelling of fluoronucleosides, and other drugs containing a difluoro motif, because of its rapid reaction time
(20 minutes), and compatibility with automated synthesis units.71 The alkene functionality
also leaves room for a number of post-labelling modifications.71
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Figure 10. Examples of nucleoside-based PET radiotracers
Another important nucleoside-based PET imaging agent which has been reported
recently is 18F-clofarabine (18F-CFA; Figure 10).65 The analogue is fluorinated with 18F at
the C2' position retaining the original sugar modification necessary for RNR inhibition and
anticancer activity. The 18F-CFA was found to be a good probe for dCK activity in mice
and humans, giving increased signal in tissues with increased dCK activity, such as cancer
cells. Accurately monitoring dCK activity is of critical importance in determining efficacy
of nucleoside prodrug anticancer agents.65
68Ga

based radiopharmaceuticals

Recent advances in aza-crown ethers bifunctional chelators with the ability to bind
gallium generated significant interest in

68

Ga-based radiopharmaceuticals72-76 and

radiotracers.76,77 As a metal salt, gallium has been reported to possess anti-proliferative
properties in various cancer cells mainly attributed with its ability to mimic Fe3+.78-80
Among bifunctional chelators, NODA-SA81 (1,4,7-triazacyclononane-1-succinic acid-4,7diacetic acid) and NODA-GA82 (1,4,7-triazacyclononane-1-glutamic acid-4,7-diacetic
acid), which possess a NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) complexation
site, have a coordination cavity highly accommodating to Ga(III) (ionic radius, 0.65 Ǻ).
Also, anti-TF (Tissue Factor) antibody (ALT-836) conjugated to 4-isothiocyanatobenzyl13

NOTA (SCN-Bn-NOTA) labelled with

64

Cu showed uptake in pancreatic cancer cells

overexpressing TF and has been advanced to Phase I clinical trials as a combination therapy
with gemcitabine.83 Conjugation of SCN-Bn-NOTA with cyclic Arg-Gly-Asp -D-Tyr-Lys
[c(RGDyK)] and chelated with

68

Ga gave a radiotracer for diagnosis of angiogenesis

(Figure 11).77 These results encouraged us to investigate 4-N-alkylgemcitabine analogues
conjugated with aza-crown ether chelators for 68Ga-labelling.

Figure 11. Example of c(RGDyK)-SCN-Bn-NOTA chelator with 68Ga-radiolabel77
Radical induced DNA damage in radiotherapy
Typical cellular activity in the body causes formation of reactive oxygen species
(ROS), such as the hydroxyl radical (•OH), that either adds to DNA bases or abstracts an
H-atom from the sugar-phosphate backbone84,85 causing oxidative damage.84 The damage
can cause an increase in the rate of DNA mutations and uncontrolled cell proliferation,
which have all been linked to cancer initiation and proliferation.86,87 In general,
nucleobases are much more reactive to oxidation than the sugar-phosphate groups in
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nucleotides.88 As a result of having the lowest ionization potential and redox potential,85,8995

the guanine base (in 2'-deoxyguanosine) undergoes oxidation more readily than other

bases or the sugar-phosphate backbone.96 Pulse radiolysis studies in neutral aqueous
solutions at room temperature have shown the reaction of •OH with guanine or with
adenine eventually leads to the same guanyl or adenyl radical that is produced via direct
one-electron oxidation of these bases followed by deprotonation.85,89,97,98 Therefore,
understanding the mechanism of oxidative damage on dGuo and other nucleosides, then,
is of high interest in the field of cancer research and treatment.
Most commonly, cancers are treated using either surgical, radiotherapeutic,
chemotherapeutic methods, or combinations of the three methods. Unfortunately, surgery
and chemotherapy can lack efficacy because of toxicity or lack of selectivity.99,100 Thus,
the use of radiotherapy is becoming important, especially in combination with
chemotherapy (chemoradiotherapy).100,101 Chemoradiotherapy involves the delivery of a
sensitizer to the tumor followed by irradiation, which usually forms radicals which can
interact with cellular DNA.99 The combination causes irreparable damage to the DNA
inside cells, ultimately causing necrosis, apoptosis, or senescence.99,100
The downfall of chemoradiotherapy, is the hypoxic environment that is found in many
tumor cells. The lack of O2 in these causes a large decrease in the efficacy of ionizing
radiation because of decreased formation of the oxygen radicals that usually aid in initial
DNA damage.99,102 Luckily, solvated electrons can be formed in as much quantity in
hypoxic cells, as •OH is formed in oxygenated cells.99,103 The driving force of research in
the area is the generation of radiosensitizers, like some modified nucleosides, which can
incorporate onto DNA and have a high electron affinity. These sensitizers can undergo
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dissociative electron attachment via their reaction with radiation-produced electrons, which
leads to radicals which can destroy cellular DNA.99

Figure 12. Proposed mechanism of aminyl radical formation in 3'-AZT104
One example of a drug which has chemoradiotherapeutic effects is 3'-AZT (3'-azido3'-deoxythymidine, Figure 12), which is used as an anti-viral in the treatment for HIV. It
was found that HIV patients with cancer, taking 3'-AZT, responded better to treatment for
solid tumors than cancer patients without HIV. It was discovered that these radiosensitizing
effects are caused azido group present at the 3' position of AZT that has high electron
affinity and can capture an electron to form an unstable azide anion radical (RN3•-, H) when
irradiated with electrons. The species can then lose N2, leaving a nitrene anion
radical (RN•-, I) which upon protonation becomes an aminyl radical (RNH•, J). The formed
aminyl radical is thought to be responsible for the DNA damaging effects of 3'-AZT in
tumor cells.104
Previously, our lab in collaboration with the Sevilla-Adhikary lab at Oakland
University has studied the formation of the elusive aminyl radical in both the sugar105 and
base moiety106 of nucleosides. Recently, two classes of azido modified pyrimidine
analogues were studied. One class contains an azidomethyl group at C5 which includes: 5azidomethyl-2'-deoxyuridine (AmdU) and cytidine (AmdC, Figure 13, Panel A). The azido
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group in AmdU was found to undergo dissociative electron attachment resulting in a
nitrene anion radical, which undergoes rapid protonation to form a π-aminyl radical.
Subsequent abstraction of a proton from a nearby AmdU precursor molecule was then
found to form an α-azidoalkyl radical, that underwent unimolecular β-N2 elimination to
form the more stable σ-iminyl radical. A similar mechanism and σ-iminyl radical formation
was seen in AmdC. AmdU was found to have radiosensitizing properties elective for
treatment of EMT6 breast tumor models. The second class possesses an azidobinyl group
at C5 position that includes: 5-(1-azidovinyl)-2'-deoxyuridine (AmvU) and cytidine
(AmvC, Figure 13, Panel B). These analogues were found to form a π-aminyl radical that
easily tautomerized to the stable σ-iminyl radical.106
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Proposed mechanism for the formation of π-aminyl radical from AmdU, followed by its
biomolecular conversion to a σ-iminyl radical (Panel A). Tautomerization of π-aminyl
radical from AvdU to σ-iminyl radical (Panel B).
Figure 13. Proposed mechanism for formation of π-aminyl radical and σ-iminyl radical
from AmdU and AvdU.106
1.4.1 Radical formation on the guanine base caused by DNA oxidation
Many research groups have been interested in understanding the chemistry of purine
nucleosides oxidation; including mechanism, intermediates and products under different
oxidative conditions. The radical chemistry of oxidative damage of purines is studied either
to understand its reaction with •OH, or via one-electron oxidation.89 Experimentally, oneelectron oxidation can be studied using a strong oxidant such as SO4•-.85,89,97
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The most common structure studied of the reaction of guanine with •OH is 8-oxo-7,8dihydro-2'-deoxyguanosine (8-oxodGuo). The 8-oxodGuo is only one of the many
products of guanine oxidation and is used as a biomarker for oxidative stress. The 8oxodGuo is formed by reaction with hydroxyl radical, singlet oxygen or one-electron
oxidants.96,107-109 Figure 14 shows the mechanism of formation of the main 6,8-diketo
tautomer of 8-oxodGuo made via reaction of guanine by •OH.

Figure 14. Formation of 8-oxoguanine by reaction with •OH
The •OH has a high reduction potential (2.3 V at pH 7);85,91,110 however, it does not
cause direct one-electron oxidation.91,110 Theoretical studies on one-electron oxidation by
•OH have shown that solvation of the -OH, produced after electron transfer to •OH,
accounts for most of the reduction potential of •OH. As a result, the initial electron transfer
step that is involved in the direct one-electron oxidation by •OH becomes slow.110,111 Thus,
reaction of •OH with purine nucleosides occurs by its direct addition to the double bonds
of the guanine ring. Thus, for many years, it was thought the 8-OxodGuo was the main
product of guanine oxidation. However, it is now understood that it is just one of many
intermediates, and undergoes further oxidation to form imidazolone and oxazolone
products.109,112,113
1.4.2 Studies on the formation of guanyl and adenyl aminyl radical
The accepted mechanism of the reaction of •OH with the guanine base is the addition
of •OH at C4 leaving a radical at C5 (i.e. L, Figure 15), which undergoes dehydration to
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form neutral radical M.113,114 The radical M forms from deprotonation of the guanine cation
radical, G(N1-H)•. Guanine cation radical (G•+) is known to undergo competitive
reactions: (a) deprotonation leading to G(N1-H)• formation (i.e., phototropic equilibria of
G•+), and (b) nucleophilic addition of water at C8 leading to G•-OH followed by oneelectron oxidation to form 8-oxo-guanine.90-95,97,109 Pathway (a) was thought to be the
major pathway (~65%), while pathway (b) was thought to be the minor pathway
(17%).114,115 In 2009, studies by Chatgilialoglu and co-workers proposed that the main
pathway of hydroxyl radical oxidation of guanine is not the addition at the C4 position, but
rather a hydrogen abstraction from the exocyclic NH2 moeity to form an aminyl radical
[G(N2-H)•; e.g., radical N].115 The N-centered neutral aminyl radical formation was
proposed because of the formation of a broad peak around 610 nm obtained from pulse
radiolysis with optical absorption experiments of 8-bromoguanine O.115 Under oneelectron oxidation conditions, using SO4•- as the oxidant, it was found that guanine formed
its radical cation followed by loss of hydrogen to form radical N, which is a tautomer of
M, giving the same optical absorption at 610nm.89,115

Figure 15. Chatgilialoglu's proposed •OH oxidation mechanism of guanine base115
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Similar to guanine, adenine usually forms •OH adduct at the C4 and C8 positions, with
the former being oxidizing and the latter being primarily reducing. The C4-OH adducts of
adenine can further interact with the environment to make a variety of products, most of
which are unknown.84,116 As with guanine, the formation of 8-hydroxyadenine is quite
common especially in the presence of oxygen.84,117 Another common byproduct formed
both from reaction with •OH and under one-electron oxidation conditions, with a strong
oxidant such as SO4•-, is an N6 centered aminyl radical that is the deprotonated adenine
cation radical. Although, under one-electron oxidation conditions, a cation radical is
formed first, which upon deprotonation converts to the aminyl radical.89
Many attempts have been made, by Chatgilialoglu115,118 and others to identify the
aminyl radical formed from guanine, and N6 position of adenosine, using photochemical
precursors. However, characterization of these radicals employing Electron Paramagnetic
Resonance (EPR) or Electron Spin Resonance (ESR) spectroscopy were never achieved.
One example is Dr. Wagner's group, who demonstrated the formation of N6 aminyl radicals
by photolysis of 6-N-phenylhydrazones of 2'-deoxyadenosine in the presence of H-donors,
like glutathione (Figure 16, P).119 Evidence from high-performance liquid chromatography
(HPLC), mass spectrometry (MS), and NMR indicated the formation of the aminyl radical
formation because of the detection of 2'-deoxyadenosine, and benzaldehyde byproduct.119
More recently, Dr. Greenberg's group identified the aminyl radical by photolysis of the
hydrazine modifications of the 2-N-positon of guanine (Q) and 6-N-positon of adenosine
(R). Also, the Greenberg group showed the compatibility of these hydrazine analogues for
solid-phase oligonucleotide synthesis, and thus, their utility for studying the aminyl
radical's reactivity in nucleic acids.120 They determined formation of the adenyl aminyl
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radical by identification of 2'-deoxyadenosine and 8-diphenylamide-2'deoxyadenosine
products. The guanyl aminyl radical was identified by formation of 2'-deoxyguanosine and
corresponding 8-dipheynyl substituted byproduct. Interestingly, the guanyl aminyl radical
was more thermodynamically stable and reacted less than the adenyl aminyl radical with
PhN• radical.120 Although these groups both studied the formation of the aminyl radical in
a variety of ways, there was no conclusive EPR results which could unequivocally
characterize the aminyl radical.119,120

Figure 16. Formation of aminyl radical from hydrazines120 and hydrazones119
1.4.3 Radical formation in DNA oxidation of pyrimidine bases
Pyrimidine bases, thymidine and cytidine in DNA, also interact with ROS in the cell
and form several reactive byproducts.84 A common reaction of the •OH with pyrimidines
involves addition to the C5-C6 double bond or by abstraction of H in methyl group of
thymidine. A variety of different byproducts form depending on the redox properties, with
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C5-OH adducts being reducing and C6-OH adducts being oxidizing, and environment of
each new radical that is made.84,121 The most common products made from the oxidation
of cytidine and thymine under anoxic conditions is cytosine glycol and thymine glycol
(Figure 17).84 The H-atom abstraction from methyl group of thymidine causes formation
of an allyl radical which ultimately leads to the formation of 5-hydroxymethyluracil, in the
absence of oxygen.84,122 These byproducts can further interact with their environment and
other radicals to form additional species.84

Figure 17. Common byproducts of pyrimidine oxidation under anoxic conditions
Under one electron oxidation conditions, thymidine forms a cation radical, much like
purine bases, which quickly undergoes addition of water to form an OH adduct or
deprotonates.110,123 Usually, the •OH adds onto the C5 position of thymidine, leaving a C6
radical, which then tautomerizes to the C6 OH adduct with radical site at C5 (Figure 18).110

Figure 18. Addition of hydroxy anion to one-electron oxidized thymidine110
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Greenberg's group found that abstraction of hydrogen from C5 methyl group of
thymine base in poly(dA-T) DNA sequences occurs, not from deprotonation or hydration
of the thymidine cation radical, but rather from interaction with an adenosine N6 aminyl
radical.124 Since purines have lower reduction potentials than pyrimidines, they form
radical cations more readily than pyrimidines. Thus, they are the main source of radical
induced damage on DNA. The N6 aminyl radical of adenosine can cause abstraction of a
C5 methyl hydrogen of 5'- flanking thymidines, leading to the allyl radical formation and
this radical eventually produces the 5-formyl-2'deoxyuridine.124
One electron-oxidation of cytidine, using SO4•-, was found to form a neutral aminyl
radical at the N4 position by a radical cation intermediate.123 In 2015, Adhikary-Sevilla et
al. showed that the cytidine cation radical preferentially deprotonated to form an aminyl
radical syn to the carbonyl moiety. The syn-aminyl radical then tautomerizes to the iminyl
σ-radical (Figure 19). The mechanism was found to prevail over addition of water to the
C5-C6 bond that is seen in thymidine.125 Theoretical calculations also illuminated the
ability of the iminyl radical to form in double-stranded DNA through radiation induced
ionization-deprotection processes as proposed employing pulse radiolysis studies.125,126

Figure 19. Cytidine syn aminyl radical tautomerization to iminyl radical125

24

Azido modified nucleosides
Many azido-substituted nucleosides have been synthesized as anti-viral or anti-cancer
agents, and a prodrugs to increase efficacy of NA drugs.127-131 Perhaps the most important
example is 3'-azido-3'-deoxythymine (AZT) which was synthesized in 1964 as a possible
anti-cancer agent, yet in 1987 was approved in record time as an anti-viral treatment for
acquired immune deficiency syndrome (AIDS). Although AZT's mode of action was
driven by the azido modification on the sugar moiety, other nucleoside analogues have
been synthesized with azido modification in the base.132,133

Figure 20. Common application of azido-modified nucleoside analogues
Both azido-substituted purines and pyrimidine nucleosides have been studied for their
use in several areas of chemistry (Figure 20). For biological activity of certain azido
modified analogues, it is essential that the azide is in its linear form and can interact with
key enzymes. For example, the 6-azido modified purine prodrugs of 9-(β-ᴅarabinofuranosyl)adenine (ara-A, Vidarabine)128 or 4-azido modified pyrimidine prodrug
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of 1-(β-ᴅ-arabinofuranosyl)cytosine (ara-C)130 whose efficacy requires that azide be
available for reduction to amine by enzymatic action. Other azido nucleoside analogues,
such as 2, 6, or 8-azido modified purines, and 4- or 5- azido modified pyrimidines are
synthesized to use for click-reactions, where the triazole click products can be used for
fluorescence imaging of cancer cells134,135, as adenosine receptor antagonists,136 inhibitors
of key enzymes for treatment of the tuberculosis bacterium,137 or anti-viral agents.138,139
Azide group in azido-modified nucleosides can often cyclize with nitrogen atoms present
in the pyrimidine or purine ring to form tetrazole tautomers. The formation of the tetrazole
often results in lack of prodrug activity, or low yield during click reactions because the
stability of the cyclic tetrazole derivative often affects reactivity.130,140
1.5.1 Synthesis and properties of azido modified nucleosides
Synthesis of azido modified purine nucleosides
1.5.1.1.1 2-Azidopurine nucleosides
Synthesis of 2-azidopurine nucleoside analogues has been undertaken in order to study
their anti-viral properties,141 or their use for determining protein-DNA/RNA
interactions.142,143 The analogues have been synthesized either from adenosine or
guanosine precursors. For example, oligonucleotides containing 2-azido-2'-deoxyinosine
(i.e., 3, Scheme 1) has been synthesized from their protected 2-fluoro-2'-deoxyinosine
precursor (i.e., 1).143 The azido group is highly reactive during oligonucleotide synthesis
undergoing Staudinger reduction with phosphoramidite reagent. Thus, incorporation of
azido-modified nucleosides onto DNA/RNA has not been fully developed.144,145
Preparation of 3 began by protection of the 6 position of guanosine using 2-(4nitrophenyl)ethyl (NPE), followed by diazotization/fluorination. Then, the 2-fluoro-2'-
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deoxyinosine 2-cyanoethyl phosphoramidite precursor 1 was synthesized for solid phase
synthesis. After solid-phase elongation and treatment with 1,8-diazabicyclo[5.4.0]undec7-ene (DBU) a ODN fragment 2 was prepared. Finally, reaction with lithium azide (LiN3)
in dry dimethylformamide gave desired azido analogue 3. Subsequent deprotection with
ammonia lead to removal from solid support and formation of oligonucleotides containing
2-azido-2'-deoxyinosine.143

Scheme 1. Synthesis of 2-azido-2'-deoxyinosine from 2-fluoro-2'-deoxyinosine
The 2-azidopurine analogues have also been synthesized from guanosine and 2'deoxyguanosine by diazotization of the C2 amino-group followed by replacement with
azide. Guanosine derivatives were first converted into their protected 6-chloropurine
analogues or 6-O-mesitylated analogues to improve solubility in organic solvents.142,146
The method was first reported by Higashiya et al. for the synthesis of 2-azido-2'deoxyadenosine (Scheme 2). Diazotization of the amino group in 4 with isoamyl nitrite,
followed by azidation with azido-trimethyl silyl (TMS-N3) gave 5.146 Similarly, the 6-Omesitylated analogue 7 was treated with tBuONO/TMS-N3 gave 2-azido analogue 8.142 In
either case, 6-modified derivatives were converted to 6-NH2 (adenosine; e.g., 6 and 9)
derivatives using concentrated ammonia reagents.142,146
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Scheme 2. Approaches towards synthesis of 2-azidoadenosine and 2-azido-2'deoxyadenosine
The 2-azidoadenosines have also been synthesized from their 2-chloroadenosine
precursors (i.e. 10, Scheme 3). Thus, compound 10 was converted to 2-hydrazino 11,
followed by treatment with NaONO/AcOH in acidic medium to yield 12. The
tautomerization to tetrazole 12a was documented by two sets of signals present on NMR,
where tetrazole peaks are more deshielded. Table 1 shows NMR peaks for azido/tetrazole
tautomers of 2-azidoadenosine analogues.141

Scheme 3. Synthesis of 2-azidopurine nucleoside and its tetrazole tautomer
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Table 1. 1H NMR Chemical Shifts of Azido/Tetrazole (A/T) Tautomers of 2-azidoadenine
nucleosides
R1
R2
Azido form
Tetrazole form
Δδ (ppm)
Ratio A/T

OH
OH
8H,
8.28
8H,
8.56
0.28

6NH2,
7.67
6NH2,
9.46
1.79
67:33

OH
H
8H,
8.25
8H,
8.53
0.28

6NH2,
7.60
6NH2,
9.40
1.80
65:35

H
H
8H, 8.29
8H, 8.59

6NH2,
7.60
6NH2, 9.4

0.30

1.80
67:33

Alternatively, synthesis of 2-azidoadenosine analogues 15 has also been achieved from
N6-methyl-2-iodoadenosine analogue 14 by reaction with CuSO4/sodium ascorbate
catalyst in the presence of ւ-proline, Na2CO3, and NaN3 in a mixture of water/t-butanol
(Scheme 4). Compound 15 showed high affinity for A3 adenosine receptor, with some of
its click products being full antagonists. The N6-methyl-2-azidoadenosine derivative 15
had to be isolated to proceed with click-reactions. Tautomerization to the tetrazole
derivative 15a was seen in about 17% for N6-methyl-2-azidoadenosine 15.136

Scheme 4. Synthesis of 2-azido-N6-methyladenosine from 2-iodo-N6-methyladenosine and
its equilibrium with its corresponding tetrazole
1.5.1.1.2 8-Azidopurine nucleosides
The 8-azidoadenosine analogues have been explored for their use in photochemical
cross-linking that determine protein-nucleic acid interactions.143 Synthesis of 8azidoadenosine derivatives has been achieved from the reaction of 8-bromoadenosine with
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sodium azide.147 Incorporation of azido-modified nucleosides onto DNA/RNA is an area
has not been fully developed because of the high reactivity of the azide moiety during solidphase synthesis, although post-synthetic modifications have been achieved.144,145
To synthesize oligodeoxynucleotides (ODN) containing 8-azido-2'-deoxyadenosine,
substitution with azide was explored after preparation of the phosphoramidite derivative
16 (Scheme 5). The N6-position of 8-bromo-2'-deoxyadenosine was protected with base
labile dimethylformamidine, which can be introduced without the need to protect sugar
hydroxyls. Then, regioselective protection of the 5'-hydroxyl with dimethoxytrityl (DMT),
and subsequent reaction with N,N-diisopropyl-O-2-cyanoethylchlorophosphine formed
phosphoramidite analogue 16. Displacement of bromide with azide employing lithium
azide in DMF at 70°C yielded 8-azido-2'-deoxyadenosine derivative 17.143

Scheme 5. Synthesis of 8-azidoadenosine monomer for the synthesis of ODN via solidphase synthesis
1.5.1.1.3 6-Azidopurine nucleosides
Synthesis of 6-azidopurine analogues can be accomplished from their respective
inosine derivatives for use as Ara-A prodrugs,128 or as anti-viral agents.131 These methods
have been developed to improve upon previous protocols which included chlorination of
the 6-position of inosine followed by replacement with azide,140 which gave low to
moderate yields as a consequence of decomposition.128,148 Using O6-(benzotriazole-l30

yl)inosine149 19 as a precursor, several 6-azidopurine analogues of type 20 were
synthesized either by displacement of O-benzotriazole by sodium azide or by reaction with
polymer supported azide (Scheme 6). The use of polymer supported azide was especially
useful in synthesis of deprotected 6-azidopurine analogues due to its solubility in aqueous
solvent. Table 2 shows reaction conditions and yield for several 6-azidopurine nucleoside
analogues.140

Scheme 6. Synthesis of 6-azidopurine nucleosides from inosine derivatives
Table 2. Conditions for synthesis of 6-azido substituted nucleosides from inosine
R1
R2
Reagent

TBDMS TBDMS
H
OTBDMS
NaN3
NaN3

Solvent
Temp.
Time
Yields

DMSO
40°C
2h
99%

DMSO
40°C
3.5h
96%

Ac
H
NaN3

Ac
OAc
NaN3

H
H
Polymer
supported,
N3-

H
OH
Polymer
supported,
N3-

DMSO
Rt
1h
95%

DMSO
Rt
1h
75%

H2O
50°C
3.5h
59%

DMF
50°C
5h
70%

Alternatively, reaction of acetylated inosine analogues 21 with diphenyl phosphoryl
azide (DPPA)/DBU gave acetylated 6-azidopurine nucleosides 23, with formation of
phosphorylated intermediate 22 (Scheme 7). Tautomerization of 6-azidopurine analogues
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(e.g., 24 to 24a, Figure 21) to their tetrazole counterparts was observed, with concentration
of the tetrazolyl isomer increasing with increasing dielectric constant of the solvent.140

Scheme 7. Alternative synthesis of 6-azidopurine nucleosides from inosine derivatives

Figure 21. Azido-tetrazole tautomer of 6-azidopurine nucleosides
Synthesis of azido modified pyrimidine nucleosides
1.5.1.2.1 4-Azidopyrimidine nucleosides
Most literature on synthesis of azido-modified pyrimidine nucleosides focus on
synthesis of 4-azidopyrimidine nucleosides, 5-azidouridine , and 5-azidomethyl uridine
anlogues.150-153 The 4-azidpyrimidine nucleoside analogues have been made for their use
as prodrugs for anti-viral and anti-cancer drugs, such as, 1-(β-D-arabinofuranosyl)cytosine
(ara-C),151 or as possible therapeutic agents.150 Synthesis of 4-azidopyrimidine nucleosides
depends on generating a good leaving group at the 4-position of the pyrimidine ring
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followed by replacement with azide. De Napoli et al. achieved this conversion using
protected 4-chloro-2'-deoxypyrimidine nucleoside derivative 26 followed by replacement
with azide with NaN3 in anhydrous DMF solvent to give protected 4-tetrazolo-2'deoxypyrimidine nucleoside 27 (Scheme 8).150 They found that 27 exists completely in
the tetrazole form, even after deprotection, and confirmed this through NMR and UV
experiments.150

Scheme 8. Synthesis of protected 4-tetrazolopyrimidine nucleoside150
Alternatively, Kotra et al. synthesized protected 4-azidopyrimidine nucleoside
analogue 30 by substitution of the 4-OH of protected arabino uridine 28 with a 1,2,4triazole leaving group using Divakar-Reese method (POCl3/1-H-1,2,4-triazole/Et3N/ACN)
to give 29, followed by replacement with azide (LiN3/DMF, Scheme 9). They found by
NMR, UV, and X-Ray Crystallography studies that cyclization of the azide moiety
occurred during deprotection of acetylated azido nucleoside 30 with HCl/MeOH to form
tetrazolo product 31. Attempts at deprotection of 30 with other common methods, such as,
MeOH/NH3, MeOH/NaOMe, or EtOH/NaCN afforded complete decomposition. The
tetrazole compound 31 did not display any transformation to ara-C during
biotransformation studies.154
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Scheme 9. Synthesis of 4-azido and 4- tetrazolopyrimidine nucleoside from protected
arabino uridine151
1.5.1.2.2 5-Azidouridine analogues
The interest in 5-azidouridine analogues (e.g. 35, Scheme 10) arises from their
photochemical properties, which can be used in the study of proteins and enzymes.155
Synthesis of 5-azido-2'-deoxyuridine was undertaken by nitration of the 5-position of 2'deoxyuridine with nitrosonium tetrafluoroborate, followed by reduction to an amine using
Zn/HCl, and then diazotization/replacement with azide with NaONO/HCl/NaN3.156,157
However, the synthesis leads to low overall yield of product 35 (roughly 10-20%), and
requires extensive purification of 5-amino-2'-deoxyuridine analogue (e.g., 34) and use of
nitrosonium tetrafluoroborate that is hydroscopic and expensive.152 Alternatively, access
to 34 can be achieved by treatment of 5-bromouridine with liquid ammonia at high
temperature for several days, but that can be tedious and unsafe.158
To simplify synthesis of 5-amino-2'-deoxyuridine precursor 34, Gourdain et al.
developed a benzylamination/reduction protocol. Benzylamination was achieved using a
5-benzylamine at 90°C, followed by catalytic hydrogenolysis with ammonium
formate/10% Pd/C catalyst to give 34. Subsequent diazotization/replacement with azide
using standard NaNO2/1N HCl/NaN3 at 0°C caused cleavage of the glycosidic bond, so

34

Gourdain et al. used a milder condition of NaNO2/AcOH/NaN3 at 0°C to afford 40% of 5azido-2'-deoxyuridine (AdU) 35.152

Scheme 10. Gourdain et al. synthesis of 5-azido-2'-deoxyuridine152
1.5.1.2.3 5-Azidomethyl-2'-deoxyuridine analogues
The 5-azidouridine analogues are quite unstable, decomposing in roughly 4 hours in
aqueous media;159 however, stable azido-modified pyrimidine nucleoside analogues have
been synthesized for the purpose of creating new triazole "click" products. One such
analogues is AmdU153 that was later synthesized from protected 2'-deoxythymidine 36 by
bromination of 5-CH3 using N-bromosuccinamide (NBS), CCl4, and azobisisobutyronitrile
(AIBN; Scheme 11) to give 37. Then, immediate replacement of bromo with azide was
achieved using NaN3 in DMF at high temperature gave protected AmdU 38.160
Deprotection of 38 with tetra-n-butylammonium fluoride (TBAF) gave AmdU 39.161
Recently, Wen at al. used 38 as a starting material to synthesize AmdC 41 by treatment
with 2,4,6-triisopropylbenzenesufonyl chloride (TIPBSCl) in the presence of TEA/DMAP
to yield an aryl sulfate, which was replaced with ammonia using NH4OH, and deprotected
with TBAF.106
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Scheme 11. Synthesis of AmdU 39 and AmdC 41106,160
1.5.2 Click-chemistry of azido modified nucleosides
Click-chemistry of azido modified purine nucleosides
Click-chemistry refers to several linking reactions which are simple, high yielding,
versatile, and require minimal purification. One example are cycloadditions, or more
specifically 1,3-dipolar cycloadditions, such as those which occur between azides and
terminal alkynes to yield triazole products.162 Formation of triazole-substituted purines by
click chemistry has been a large area of research in recent years because of their utility for
drug discovery,136,163-165 drug delivery,166,167 and cellular imaging.134,135,168-171
A variety of 2-triazolepurine nucleosides have been synthesized for their use as A3
adenosine receptor antagonists,136 or as fluorophores for cellular imaging.134,135,171 The
synthesis of 1,2,3-triazol-1-yl analogues of N6-methyladenosine 42 were synthesized using
copper-sulfate/sodium ascorbate catalyst, and an alkyne in a water/butanol mixture to give
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43. This solvent system allowed for the precipitation of product from the reaction
mixture.136

Scheme 12. Synthesis of 2-triazole substituted purine nucleosides
Synthesis of 2-triazolyl derivatives of adenosine were also synthesized using protected
2,6-diazidopurine analogue 44 using two methods: 1) by regioselective reduction of 6azido moiety with CuSO4/sodium ascorbate catalyst followed by click reaction, or 2) by
formation of 2,6-ditriazolyl product, followed by regioselective replacement of 6-triazonyl
with aqueous ammonia (Scheme 13).134,171 The click-reaction of 2-azido group with
alkynes to make 1,2,3-triazoles have good yields regardless of the azido-tetrazole
equilibrium seen in 2-azido purines. The use of methanol/water/acetic acid solvent system
rather than tert-butanol/water/acetic acid system afforded increased reactivity. Study of the
synthesis of compounds 44 and 47 by these two methods allowed for the conclusion that
CuSO4/sodium ascorbate catalyst affords first the reduction at C6 position, although further
reaction reduces the C2 position also (Scheme 14).134

37

Scheme 13. Regioselective synthesis of 2-triazole substituted adenine nucleosides from
2,6-diazido precursors

Scheme 14. Synthesis of 2,6-ditriazole substituted purine nucleosides followed by
regioselective amination
Extensive studies have been conducted to evaluate the effect of azido-tetrazole
tautomerization on the formation of triazole click-chemistry products in protected 6-azido2'-deoxyadenosine 50 (Scheme 15).140 Previous literature suggests that low yield for
formation of certain triazole products are caused by a shift in the equilibrium towards the
tetrazole tautomer (as in 50a).172 Synthesis of triazole compound 51 was attempted using
a variety of solvents and several copper-catalysts in order to determine the most successful
conditions. It was found that using biphasic (dichloromethane/water) system was
imperative for a successful reaction. Furthermore, despite nearly 82% of tetrazole tautomer
50a (18% azido tautomer 50) present, during reaction with phenylacetylene in the biphasic
system proceeded efficiently. Reduction of the azide functionality to amine was observed
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under several reaction conditions. Table 4 summarizes the results obtained from these
studies.140

Scheme 15. Azido/tetrazole tautomerization of 6-azidopurine nucleosides and their
reactivity towards click- reactions
Table 3. Conditions for the click-reactions of 6-azidopurine nucleosides
Catalyst

Solvent

Conditions

CuSO4/Na ascorbate
CuSO4/Na ascorbate
CuSO4/Na ascorbate
CuSO4/Na ascorbate
CuSO4/Na ascorbate
Cu(Phen)(PPh3)Br
Cu(PPh3)Br
CuIMes
CuIPr
CuCl
CuTC
Cu/C + 2 equiv.
Et3N
Cu/C
Cu/C

1:1 t-BuOH/H2O
1:1 THF/H2O
1:1 Toulene/H2O
1:1 CHCl3/H2O
1:1 CH2Cl2/H2O
1:1 CH2Cl2/H2O
1:1 CH2Cl2/H2O
1:1 CH2Cl2/H2O
1:1 CH2Cl2/H2O
1:1 CH2Cl2/H2O
1:1 CH2Cl2/H2O
1,4-dioxane

rt, 3.5h
rt, 6h
rt, 6h
rt, 2h
rt, 3.5h
rt, 24h
rt, 15h
rt, 20h
rt, 24h
rt, 5h
rt, 6h
rt (15h), 60°C
(1.5h)
rt, 23h
rt, 2.5h

1,4-dioxane
1:1 CH2Cl2/H2O

Substrate, Yield,
Reduction
63%, 26%, 11%,
46%, 30%, 24%
67%, 22%, 11%
78% product
81% product
46% product
73% product
60%, 29%, 11%
NR
76% product
63% product
0%, 51%, 38%
NR
NR

Synthesis of triazole products by strain-promoted click-chemistry from 8azidoadenosine derivatives was achieved using cyclopropyl cyclooctyne (OCT) in a
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mixture of acetonitrile/water (3:1) at ambient temperature (Scheme 16). High yield was
achieved for these reactions (above 90%) in methanol, ethanol, or Opti-MEM I cell culture
media with roughly 60% conversion within 20 minutes.135 Addition of bulky triazole
substituents in the 8-position of adenosine forces the molecule into a predominantly syn
confirmation because of the electrostatic repulsion between the 8-position substituent and
the ribose moeity.173,174 Triazoles 53 possess moderate fluorescence emissions and were
utilized for cellular imaging.135

Scheme 16. SPAAC "click" reactions between azido nucleosides and cyclooctyne
Click-chemistry of azido modified pyrimidine nucleosides
A variety of articles have been published in which pyrimidine nucleosides are modified
with alkyl chains bearing a terminal alkyne that can be reacted with azido-modified
molecules.175-181 However, our focus in the present section will be the formation of triazole
adducts from pyrimidine nucleosides modified with azide at the base part and their reaction
with alkynes. Two types of click-reaction are usually undertaken with azido-modified
pyrimidine nucleosides for the purpose of cellular imaging; copper(I)-catalyzed azidealkyne cycloaddition (CuAAC)182 or strain-promoted azide-alkyne cycloaddition
(SPAAC).168
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In 2014, Neef et al. were able to metabolically incorporate azido modified nucleosides
onto living cells and perform cycloadditions with fluorescent alkynes, which allowed for
sensitive detection of DNA replication. These studies focused mainly on catalyst free
SPAAC reactions in vivo. The 5-modified pyrimdine nucleoside derivative are compatible
with cellular enzymes for DNA incorporation but click-chemistry of 5-azido-2'deoxyuridine is particularly troublesome given the short stability of the compound in
aqueous media. Because of this use of 5-(azidomethyl)-2’-deoxyuridine (AmdU) was used
because it is stabile in physiological conditions.
The AdU and AmdU samples were incubated with HeLa cells that express low-fidelity
thymidine kinase for 24 hours, followed by treatment with AlexaFluor 488 (Figure 22) or
bicyclo[6.1.0]nonyne (BCN) AlexaFluor 488 alkyne in the presence of copper(I) in order
to form CuAAC or SPAAC "click" products. The cells were then imaged, and compared
with 4′,6-diamidino-2-phenylindole (DAPI) stained cells. Cells incubated with AdU could
not be detected with imaging, but the ones treated with AmdU were detected.161 The
Luedtke group then did studies on phosphotriester AmdU derivatives' reaction with
AlexaFluor 594 alkyne and their incorporation onto wild-type HeLa cells and animals. The
5’-bispivaloyloxymethyl (POM) AmdU derivatives showed in Figure 23 displayed the best
chemical stability, metabolic incorporation, and lower toxicity.183

41

Figure 22. AdU and AmdU images after incubation with AlexaFluor 488 alkyne161

Figure 23. POM-AmdU images after incubation with AlexaFluor 594 alkyne183
Similarly, Ren et al. incorporated 5-azidomethyl dUTP and 5-trans-cyclooctyne dUTP
analogues onto DNA by primer extension, reverse-transcription and PCR amplification.
They found that 5-azidomethyl dUTP was a better substrate for incorporation than the 5trans-cyclooctyne dUTP analogues, but cycloaddition reaction between the cyclooctyne
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and tetrazine Cy3-dye was more efficient than SPAAC reaction with 55 (Scheme 17).184
Zayas et al. showed efficient synthesis of triazole "click" products by SPAAC reaction with
5-azido-2'-deoxyuridine. The resulting cyclooctyne nucleosides displayed moderate
fluorescent properties.135

Scheme 17. Synthesis of 5-trans-cyclooctyne dUTP analogues184
1.5.3 Azido-tetrazole chemistry
A tetrazole is a five-membered heterocyclic ring containing four nitrogen atoms and one
carbon atom. The tetrazole ring contains 6π-electrons in a planar confirmation with bond
lengths similar to that of benzene. It possesses strong electron-withdrawing properties,
making it deactivating as a substituent on benzene.185 Tetrazoles are very important
because of their varied applications, including serving as, lipophilic spacers in
pharmaceuticals, in specialty explosives, in photography systems, and as a precursor to
many nitrogen containing heterocycles.186
Tetrazoles are often formed from an imine in which double bonded carbon is substituted
by an azido group. Several factors affect whether these types of molecules are found as
cyclic tetrazoles or acyclic azides.187 For example, the type of substituent (R or R1, Figure
24) effects the equilibrium since electron-withdrawing substituents tend to favor the azide
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form, while electron donating substituents stabilize ring closure. Another factor affecting
the equilibrium is temperature, since cleavage of the tetrazole ring is an endothermic
process; meaning the azide form is favored at higher temperatures. Finally, basic solvents
strongly favor the tetrazole form by increasing electron density of the carbon-nitrogen
double bond, while acidic solvents favor the azide form through electron depletion.
Generally, polar solvents tend to favor the tetrazole form, while non-polar solvents lean the
equilibrium towards the azide.187

Figure 24. Azido-tetrazole equilibrium187
Tetrazoles and their tetrazolinyls radicals have been studied for many years because of
their stability.188 The EPR has shown that tetrazolinyl radicals remain in the cyclic
confirmation, and not as the open-chain isomers.188-190 These radicals are so stable that they
do not interact with oxygen at ambient conditions and their inertness is further increased
by electron-withdrawing properties of substituents at R1 (Figure 20).191 Under weakly
acidic conditions, the tetrazolinyl radicals undergo decomposition to form either tetrazoles
or open-chain formazans.191
The azido-tetrazole tautomerization has also been studied in depth in purines and
pyrimidines. 192-196 It has been found that the electron-density of the imino nitrogen pair
and steric effects are important factors, aside from temperature and solvent, in the ratio of
either isomer.197 In Figure 25, the different tautomeric forms of 2-azidopurines and 4azidopyrimidines is shown. The percentage in solution of each tautomer was found to be
dependent on the solvent, as well as, properties of R1 and/or R2 substitution [electron
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withdrawing group (EWG), electron donating group (EDG), sterically demanding group
(SDG)].192-196

Figure 25. Azido-tetrazole equilibria in 2-azidopurines and 4-azidopyrimidines194,196
Azido/tetrazole tautomerization of 4-azidopyrimidine nucleosides
For 4-azidopyrimidine nucleosides, there is only one feasible confirmation in which
tetrazole tautomerization can occur (e.g., T; Figure 26), and it was found to be the
predominant tautomer, as seen through UV and 1H/13C NMR data. The 1H NMR data
showed that the protons in the tetrazole form were more deshielded, causing peaks from
H5 and H6 protons to have chemical shifts closer together than would be expected for the
corresponding azide tautomer. A similar effect is seen in 13C NMR.130,150,196 The tetrazole
isomer, in this case, is so stable that it was found to remain intact even under acidic pH
(~2). Moreover, at a basic pH (~11), analogue T was found to form a 2',6-anhydro
linkage.151
Interestingly, 4-azido substitution in a 2',3',5'-tri-O-acetyl protected arabino
pyrimidine nucleoside is found in the acyclic azido form (e.g., S; Figure 26). However,
when deprotected using HCl/MeOH, the tetrazole isomer (e.g., T) is exclusively formed.
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To confirm which isomer was formed, UV data acquired in methanol showed λmax for the
azido form at 266 nm and 255 nm, and λmax for the tetrazole form at 267.5 nm and 257.5
nm. Moreover, for 4-azido-5'-O-benzoyl-2',3'-dideoxy-2-fluoro-β-ᴅ-arabinofuranosyl
derivative, deprotection with MeOH/NH3 provided the tetrazole tautomer without
decomposition.130

Figure 26. Azido-tetrazole tautomerization in 4-azidopyrimidine nucleosides
The azido/tetrazole moiety is considered a latent amino functionality, which is
interesting in the study of photosensitizing198,199 or one-electron oxidation of nucleobases.
Considering that azido-modified nucleosides cannot be incorporated onto DNA by
conventional solid-phase nucleotide synthesis due to the Staudinger reaction between the
azide and phosphoramidite [P(III)] units, it is interesting and important to study the
incorporation of tetrazole nucleoside analogues onto DNA.142 Some methods have been
developed by which to incorporate azido-modified nucleosides onto DNA, yet these
methods remain to be developed for large scale use.200 Tetrazole derivatives; however, are
highly stable and will not react with the P(III) moiety. Recent literature reports the
synthesis of a dinucleotide containing two 4-tetrazolopyrimidine nucleotides (Figure
27).199
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Figure 27. Synthesis of phosphoramidite precursor for the solid phase synthesis
containing 4-tetrazolo pyrimidine base199
Tetrazole nucleosides have been studied extensively for their photochemical properties.
In 2006, Dr. Clivio's group studied the photochemical base expansion of 4-tetrazolo
pyrimidines, finding that they form useful 1,3,5-triazepin-2,4-dione nucleosides under
aqueous conditions. These "fat pyrimidine" analogues are not only useful as therapeutic
agents, but also as probes for the biological study of nucleic acids.198 The di(4tetrazolouracil) dinucleoside monophosphate has also been studied for the formation of
dicytosine cyclobutene product, which is known to be responsible for DNA mutation in
skin cancers.199
Azido/tetrazole tautomerization of azidopurine nucleosides
For azido-modified purine nucleosides, formation of cyclic tetrazole tautomers is
possible with both N1 and N3 positions. In Figure 28, several azidopurine nucleosides are
shown, along with their possible tetrazole isomers. The azido-tetrazole isomers of 6-
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azidopurine nucleosides have been reported, and studied extensively for their ratios in
varied solvents.134,140 Both 2-azidoadenosine and 2-azidoinosine analogues have been
studied, yet the formation of the tetrazole isomer has only been reported for adenosine-type
analogues.141,143,146,171 Moreover, 8-azidoadenosine and 8-azidoguanosine have been
synthesized for a variety of applications, yet their tetrazole isomers have not been
described.135,201

Figure 28. Azido-tetrazole isomers in 2-, 6-, 8-azido substituted purine nucleosides
The 2-azidoadenosine analogues can potentially exhibit two tetrazole tautomerizations,
one pertaining to the N3 position, as in V, and one with the 1N position, as in W (Figure
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28). Although 2-azidoadenine analogue has been reported to exist in all three analogous
forms (azido U, tetrazole V and W),195 2-azidoadenosine and 2-azido-2'-deoxyadenosine
only exists in forms U and W.141,142 Presence of analogues U and W were confirmed by 1H
NMR (Table 4), where the anomeric protons (H1') were found to be relatively close
together with only 0.14 ppm difference. If the tetrazole form V was present, the proximity
of the tetrazole to the anomeric proton would have caused significant deshielding.142

Table 4. 1H NMR Chemical Shifts for Azido/Tetrazole Tautomers of 2-azidopurine
nucleosides in Deuterated Solvents
R1
R2
Position
Form U
Form W
Δδ
Ratio U/W

OH
OH

OH
H

H
H

6-NH2
8-H
7.67
8.28
9.46
8.56
1.79
0.28
67:33

6-NH2
8-H
7.60
8.25
9.40
8.53
1.80
0.28
65:35

6-NH2
8-H
7.60
8.29
9.40
8.59
1.80
0.30
67:33

Dehydro
Dehydro
6-NH2
8-H
7.58
8.08
9.39
8.35
1.81
0.27
66:34

The C6 azidopurine nucleosides exhibit tautomerization as shown in Figure 28 (X →
Y). The ratio of isomer formation in different solvents and temperature has been studied
(Table 5). These studies found, similarly to those with other azidopurine derivatives, that
the isomers could be easily identified by the deshielding effects of the tetrazole moiety on
the H2 and H8 signals in 1H NMR. At higher temperatures, azido analogues were found
primarily in the azido isomer (X), while when dissolved in polar solvents the azido
analogues were found primarily in the tetrazole isomer (Y).139
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Table 5. 1H NMR Chemical Shifts for Azido/Tetrazole Tautomers of 6-azidopurine
nucleosides in Deuterated Solvents
R1
R2

Ac
H

Ac
OAc

H
H

Peak
CDCl3 (A)
CDCl3 (T)
Ratio (A/T)

H2
8.67
9.53

H8
H1'
8.18 6.47
8.40 6.59
56.9:43.1

H2
8.68
9.54

H8
H1'
8.15 6.21
8.38 6.33
61.9:38.1

H2
-

THF-d8 (A)
THF-d8 (T)
Ratio (A/T)

8.60
9.81

8.35 6.48
8.52 6.62
14.1:85.9

8.62
9.83

8.35 6.27
8.52 6.41
16.9:83.1

8.57
9.78

CD2Cl2 (A)
CD2Cl2 (T)
Ratio (A/T)

8.65
9.54

8.19 6.48
8.42 6.60
27.5:72.5

8.67
9.56

8.16 6.22
8.41 6.36
31.4:68.6

-

-

Acetone-d6 (A)
Acetone-d6 (T)
Ratio (A/T)
DMSO-d6 (A)

8.68
9.95

8.53 6.57
8.71 6.73
6.2:93.8
-

8.70
9.97

8.53 6.36
8.71 6.52
7.6:92.4
-

-

DMSO-d6 (T)

10.2

Ratio (A/T)

-

8.87
0.9:99.1

6.61

10.2

8.88
1.9:98.1

50

6.46

H8
-

H
OH
H1'
-

H2
-

H8
-

H1'
-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10.1

8.88

6.57

10.2

8.93

6.15

8.46 6.48
8.68 6.64
15.1:84.9

0.1:99.9

0.9:99.1

-

2 RESEARCH OBJECTIVES
The first aim of this dissertation is the synthesis and evaluation of nucleoside analogues
which can serve as substrates for incorporation of radionuclei suitable for Positron
Emission Tomography imaging. The objective is to synthesize two classes of gemcitabine
analogues with lipophilic 4-N-alkyl chain i) bearing β-keto sulfonate moiety for subsequent
18

F-fluorination (e.g., 56; Figure 29), and ii) conjugated to SCN-Bn-NOTA chelator for

68

Ga complexation (e.g., 65).

Figure 29. Proposed 4-N-alkyl gemcitabine analogues suitable for radiolabeling
The targeted 4-N-alkyl analogs should increase lipophilicity of gemcitabine, which can
increase uptake into the cell and decrease toxicity to healthy cells. Unlike 4-N-alkanoyl
gemcitabine analogues, whose hydrolyzable modifications has been shown to slowly
release the parent drug in vivo, 4-N-alkyl modified analogues of gemcitabine lack
hydrolysis of the side chain in the cell. The lack of hydrolysis prevents enzymatic
deamination of gemcitabine and makes these analogues useful for addition of radiolabels
that allow for PET imaging.33
The synthesis of 4-N-alkyl gemcitabine bearing a β-keto tosylate moiety 56 involves
the addition of an 11-carbon alkyl chain bearing a terminal alkene. The elaboration of the
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terminal alkene to β-keto tosylate involves dihydroxylation, tosylation and oxidation. The
analogue 56 should provide efficient

18

F- fluorination given the reactivity of the β-keto

tosylate and avoid defluorination, seen in previous analogues,33 as a result of the lack of
hydrogens at β-carbon. The synthesis of 4-N-alkyl-NOTA-gemcitabine chelator 65 begins
by 4-N-alkylation of gemcitabine followed by condensation with the SCN-Bn-NOTA
chelator. The procedure should provide a novel analogue useful for chelation of 68Ga for
use as a PET radiotracer.
Because of our experience with synthesis of

18

F-radiolabelled fluoro-nucleoside

analogues, the second aim of the dissertation is the synthesis of clofarabine 5'-diphosphate
ProTides (e.g., I; Figure 30) and potentially their 18F-radiolabelled analogues II.65 These
analogues can be used to bypass the rate-limiting phosphorylation steps that lower their
efficacy. To synthesize clofarabine 5’-diphosphate Pro-Tides, certain specification should
be taken into consideration: 1) α-phosphate should contain no modification because
negative charge on oxygen avoids release of clofarabine monophosphate by cleavage of
the phosphorous anhydride bond, and 2) β-phosphate should contain lipophilic
modifications that allow uptake of ProTide into the cell and can be metabolized to release
unmasked clofarabine 5'-diphosphate. The synthesis of these ProTides involves synthesis
of clofarabine 5'-monophosphate, followed by coupling to a reactive phosphoramidite
species. Addition of 18F-radiolabel can be attempted using methods similar to those used
for synthesis of 18F-clofarabine.202
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Figure 30. Proposed structure of clofarabine 5'-diphosphate ProTides
The final aim of this dissertation is to synthesize several azido-modified purine and
pyrimidine nucleosides (e.g., III-VI; Figure 31) for the study of aminyl radical formation
during addition of radiation-produced electrons. The azide functionality is known to have
a very high electron affinity, which has been utilized for its radiosensitizing potential in
drugs such as 3'-AZT for the treatment of cancer in HIV patients104 and recently reported
by our research lab for AmdU.106 The radical responsible for the radiosensitizing effect of
these analogs is the nitrogen centered aminyl radical (•NH), which is formed when an azide
captures an electron. The aminyl radical can then interact with different DNA bases,
ultimately causing DNA breakage and cell death. I propose, then, that synthesis of three
classes of nucleosides modified with azide group directly attached to the base moiety
should allow characterization of the aminyl radical by EPR. The first class of compounds
are 2-azidoinosine analogues (e.g. IV), which could be prepared by deamination of 2azidoadenosine analogues (e.g. III), for elucidation of the elusive guanyl aminyl radical.
The second class of compounds includes 6-azidoadenosine analogue (e.g. VI) that can be
used to characterize the adenyl aminyl radical. The final class are 4-azidouridine analogues,
which can be used to elucidate the cytidyl aminyl radical.
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Figure 31. Structure of proposed azido modified nucleosides for study of aminyl radical
Since, as discussed in introduction (Sec. 1.4.5), it is known that base-modified azido
nucleosides exist in equilibrium with the corresponding tetrazoles (e.g., VII and VIII,
Figure 32). Investigating reactivity and chemistry of the tetrazole derivatives upon addition
of radiation-produced electrons is of much interest as well. The tetrazole analogues are
expected to produce the same aminyl radical as their azido counterparts, thus producing
the same characteristic EPR spectra. Study of the aminyl radical formation from tetrazole
derivatives is especially important since these derivatives can be incorporated onto DNA
by solid-phase synthesis199, unlike their unstable azido counterparts. If EPR studies are
successful, biological studies of the tetrazole analogues will be done in order to test for
anti-cancer activity in vivo.

Figure 32. Azido-Tetrazole equilibrium in 4-azidopyrimidine nucleosides
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3 RESULTS AND DISCUSSION
Synthesis of 4-N-alkyl gemcitabine analogues
3.1.1 4-N-Alkylgemcitabine with β-keto tosylate moiety
Our first target was a 4-N-alkyl gemcitabine analogue bearing a β-keto tosylate moiety
for subsequent 18F-radiolabeling for PET imaging (e.g., 56; Figure 33). The addition of an
11-carbon alkyl chain to the 4N position of gemcitabine was chosen as a means to increase
lipophilicity for increased cellular uptake,27,203 as well as, to avoid deamination by dCDA.32
The lack of hydrolysis exhibited by 4-N-alkyl modifications on the cytosine base causes a
low amount of phosphorylation and DNA incorporation, but allows for chemical
modifications, such as, addition of a radiolabel (18F).33 The β-keto tosylate moiety not only
activates the α-carbon, and therefore, facilitates fluorination, but also avoids possible in
vivo defluorination due to the lack of hydrogens in the β-carbon.

Figure 33. 4-N-Alkylgemcitabine derivative bearing β-keto tosylate moiety for subsequent
fluorination
Our lab has already reported 4-N-acyl and 4-N-alkyl gemcitabine analogues with
terminal leaving groups, which can be used for 18F-radiolabeling (Figure 34). However, the
4-N-acyl analogue IX showed cleavage of the amide linkage under fluorination conditions
used in 18F labeling (KF/K2CO3/K2.2.2/CH3CN/110 °C).33,204 On the other hand, we found
that incorporation of

18

F-radiolabel on 4-N-alkylgemcitabine analogue XI produced
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fluorinated XII successfully, yet showed loss of 18F during in vivo mice studies.204 In order
to overcome these drawbacks, our lab also synthesized 4-N-alkyl gemcitabine analogues
with a silicon-fluoride acceptors moieties that have shown to be good substrates for

18

F-

labeling (e.g., XIII → XIV).205

Figure 34. Gemcitabine analogues suitable for 18F-radiolabelling
4-N-Alkyl β-keto tosylate gemcitabine analogue: Synthesis
The main steps in synthesis of 4-N-alkyl gemcitabine derivatives suitable for
fluorination involves displacement of 4-N-tosylamine group from gemcitabine with
commercially available 1-amino-10-undecene, followed by elaboration of the terminal
olefin into β-keto tosylate precursor (e.g., 56; Figure 33). Thus, synthesis of 56 began by
alkylation of gemcitabine 57 through tosylation of the 4-exocyclic amine with TsCl, using
transient protection with TMS-Cl/pyridine and subsequent deprotection in the presence of
MeOH/NH3, to afforded 4-N-tosylgemcitabine 58 (90%; Scheme 18).33 Then, treatment of
58 with 1-amino-10-undecene and Et3N in 1,4-dioxane effected displacement of the ptoluenesulfonamido group from the C4 position of the cytosine ring to give 4-N-(10undecenyl) derivative 59 (85%).33

56

Scheme 18. Synthesis of 4-N-alkylgemcitabine with terminal alkene
The terminal alkene was then elaborated through a series of steps to β-keto tosylate
functionality. Synthesis began with benzoylation of 59 using benzoyl chloride (BzCl),
dimethylamino pyridine (DMAP), and 2,6-lutidine to yield 3' and 5' protected 4-N-alkyl
gemcitabine 60 (86%, Scheme 19). This was followed by dihydroxylation of 60 with
catalytic OsO4 in the presence of N-methylmorpholine N-oxide (NMO) produced terminal
vicinal diol 61 (96%). Terminal vicinal diol 61 was then converted to β-keto tosylate 56 by
regioselective tosylation of the primary hydroxyl followed by oxidation of the secondary
hydroxyl. Thus, treatment of 61 with tosyl chloride (TsCl) gave regioselectively tosylate
62 (62%), along with unchanged 61 (20%), but no notable formation of ditosylated product.
Tosylate 62 was found to be somewhat unstable, decomposing in a few months, even when
kept in dry conditions in refrigerator. Oxidation of tosylate 62 with Collins reagent (CrO3,
pyridine and Ac2O) gave β-keto tosylate 56 (94%) as a precursor for fluorination.
Compound 56 was relatively unstable, lasting only a few weeks when kept solid in the
refrigerator. This instability is thought to be due to the high reactivity of the α-carbon in
carbonyls.206
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Scheme 19. Synthesis of 4-N-alkyl gemcitabine bearing β-keto tosylate moiety
4-N-Alkyl β-keto tosylate gemcitabine analogue: Attempted
fluorination
Treatment of the reactive β-keto tosylate 56 with KF in the presence of 18-crown-6 in
MeCN (65 oC, 1h) gave fluorinated 63 in 38% yield after column chromatography, in
addition to unchanged starting material (~50%), giving a practical yield of 76% for the
conversion of 56 to 63. It is important to note that β-keto tosylate 56 provided a clean
fluorination with virtually no formation of side products. The three set of signals in

19

F

NMR were diagnostic for the presence of three fluorine atoms in 63 [-119.41 (d, J = 245.1
Hz, 1F) and -120.17 ppm (br d, J = 245.1 Hz, 1F) for the C2' gem-difluoro unit and triplet
at -227.42 (J = 47.7, 1F) for the terminal CH2F]. Deprotection of 63 with MeOH/NH3 (0
C to rt, 2h) gave α-fluoromethyl ketone 64 (52%, Scheme 20).206

o
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Scheme 20. Fluorination of 4-N-alkyl β-keto tosylate gemcitabine analogue
Fluorination employing

18

F-PET radiolabeling protocols was then attempted for 56.

Therefore, treatment of 56 with KF/Kryptofix 2.2.2. (75 oC, MeCN, 30 min), followed
immediately by deprotection of the crude 63 with MeOH/NH3 (r.t., 45 min) gave 64 in low
yield [~5% by Thin Layer Chromatography (TLC)] with formation of several byproducts.
Separation of 64 from the side products required extensive HPLC purification, making this
method unfeasible for the development of [18F]-64 as a potential radiotracer. Most likely,
during the deprotection of 63, ammonia reacts with unchanged β-keto sulfonate substrate
56 and/or with the reactive α-fluoroketone moeity leading to a primary amine and/or the
formation of imine byproducts.32
3.1.2 4-N-Alkyl gemcitabine conjugated to NOTA 68Ga chelators
The problematic fluorination by standard

18

F-radiolabeling protocols which we

observed in the 4-N-alkylgemcitabine β-keto tosylate analogue 56, prompted us to search
for other gemcitabine conjugates suitable for PET imaging. Recent advances in aza-crown
ethers bifunctional chelators with the ability to bind gallium generated significant interest
in 68Ga-based radiopharmaceuticals72-76 and radiotracers.76,77 Thus, we began to explore
the idea of 4-N-alkylgemcitabine analogues linked to bifunctional gallium chelators.
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4-N-Alkyl gemcitabine NOTA 68Ga chelators: Synthesis
Since 4-N-alkylgemcitabine derivatives are resistant to chemical hydrolysis as well as
enzymatic deamination by dCDA,33 we began to explore such derivatives, which would
allow for facilitated addition of a radioactive nuclei (11C, 18F, 64Cu, 68Ga, etc.). Given recent
literature of

68

Ga based radiopharmaceuticals, with the facile condensation of

commercially available SCN-Bn-NOTA to the N-terminal of amino acids77 and highly
accommodating coordination cavity of the NOTA moiety to gallium,81,82 we undertook an
effort to prepare gemcitabine-NOTA ligand conjugated via 4-N-alkyl linker (65, Figure
35).207

Figure 35. 4-N-alkylgemcitabine-NOTA analogue for 68Ga-radiolabeling
Similarly to previously synthesized 4-N-alkyl gemcitabine analogues, synthesis began
with displacement of p-toluenesulfonamido in protected 4-N-tosylgemcitabine 58a
(prepared from gemcitabine in 96% yield)33 with commercially available N-Boc-1,3propanediamine in 1,4-dioxane affording as main product the partially deprotected 4-N-(3N'-Boc-3-aminopropanyl)gemcitabine 66 (59%, Scheme 21) in addition 3',5'-di-O-Boc
protected product 66a (31%). Subsequent deprotection of 66 with TFA yielded the 4-N-(3aminopropanyl) derivative 67 (93%), with a primary amine group suitable for condensation
with NOTA ligands. Alternatively, compound 67 was prepared efficiently in a "one-pot"
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synthesis from 58 without isolation of 66. This method involved the reaction of 58 with NBoc-1,3-propanediamine and Et3N in 1,4-dioxane at 75°C, followed by immediate
treatment with trifluoroacetic acid (TFA) to afford 94% of 67.207

Scheme 21. Preparation of the gemcitabine-NOTA conjugate with 4-N-alkyl linker207
Condensation of 67 with commercially available SCN-Bn-NOTA in 0.1 M Na2CO3
buffer (pH = 11) at ambient temperature for 48-72 h afforded the 4-N-(3-SCN-Bn-NOTApropanyl)gemcitabine conjugate 65 in 54% yield, as identified by HRMS (ESI+) m/z
771.2879. The 4-N-alkylgemcitabine-NOTA conjugate 65 was found to be stable as a solid,
however some minor deterioration back to 67 (TLC/HPLC) was observed after some time
(few weeks) even when stored at -20 ºC (Figures 36-38). This showed again that
gemcitabine analogues with 4-N-alkyl chains have better stability that the corresponding
4-N-acyl counterparts, which usually decomposed during condensation reactions with
NOTA analogues.207
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Figure 36. HPLC purification of conjugate 65 from the crude reaction mixture
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Figure 37. Stability studies of compound 65 after 2 weeks in a -20°C fridge

Figure 38. Stability studies of solid 65 after 2 weeks on bench
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Incubation of 65 with excess of gallium(III) chloride (GaCl3) mimicking radiosynthetic
conditions (0.6 N AcONa/H2O, pH = 9.3) over 15 min gave the Gallium NOTA-4-Nalkylgemctiabine complex 68, characterized by HRMS (ESI+) m/z 837.1977 (Scheme 22).
The reaction products were isolated by HPLC on a Phenomenex Gemini semi-preparative
RP-C18 column [0% → 100% ethanol gradient in 0.01% TFA/H2O from 0 to 30 min at a
flow rate = 5 mL/min] giving 65 (tR = 14.1 min) and 68 (tR = 12.4 min), respectively. The
gallium complexation met criteria for working with [68Ga]3+ (half-life 68 min.) and was
applied towards the radiosynthesis of the [68Ga]-68 radioligand.

Scheme 22. Labeling of 4-N-alkylgemcitabine-NOTA conjugate with Gallium
4-N-Alkyl gemcitabine NOTA 68Ga chelators: Labeling and Imaging
Following success with the chelation of gallium to 4-N-alkylgemctiabine-NOTA
chelator, we explored 68Ga-radiolabeling. The 68Ga was eluted from an IGG-100 68Ge/68Ga
generator. Purified [68Ga]+3 (10 mCi in 1 mL of ≈0.1 N HCl) for the labeling was obtained
following previously described conditions.208
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Scheme 23. Labeling of 4-N-alkylgemcitabine-NOTA conjugate with 68Ga
The [68Ga]-labeling of 65 was completed within 15 min and analyzed by developing
TLC plates eluted with 0.1 M citric acid on a phosphoscreen (Figure 39). Phosphoscreen
analysis (Table 6) indicated a high labeling efficiency (94% to 96%) for the complexation
of the NOTA-4-N-alkylgemcitabine 65 with [68Ga]3+ to yield [68Ga]-68.207 The distribution
coefficient of [68Ga]-radioligand 68 was evaluated in octanol/H2O and EtOAc/H2O. This
ligand was almost exclusively found in the aqueous layer, with less <5% of the observed
counts occurring in the organic phase of either system. The hydrophilic character of [68Ga]radioligand 68 suggested that the radioligand would be rapidly excreted.207

Figure 39. TLC for complexation of NOTA-4-N-alkylgemcitabine 65 with
[68Ga]3+ (lane A) and [68Ga]-complexed-68 (lane B)

65

68

Ga. Free

Table 6. Labeling values for 4-N-alkylgemcitabine-NOTA ligand 9 with 68Ga
Trial 1
Control
68

Trial 2
Cmpd

68

Control
68

Trial 3
Cmpd

68

Control
68

Cmpd
68

(Free Ga)

[ Ga]-14

(Free Ga)

[ Ga]-14

(Free Ga)

[ Ga]-14

Counts organic

363069018

25232330

240306449

10064331

219716549

6458287

Counts aqueous

7970885

374787348

4208914

256461215

3319270

166566169

Labeling Yield

≈ 2% Appl.

94%

≈ 2% Appl.

96%

≈ 1% Appl.

96%

Point

Point

Point

Labeling of 65 with 68Ga was repeated to test for distribution of [68Ga]-68 in BALB/c
mice. Chelation of 68Ga to NOTA moiety in 65 was quantitative after 5 minutes incubation.
However, a shoulder and some minor impurities peaks can be observed. The purity did not
change after Sep-Pak purification, showing a shoulder (RT: 3.27 min) and a minor peak
(RT: 4.55 min) that are still visible and quantifiable (Figure 40). However, these impurities
were not expected to have a large effect on imaging studies.207

Figure 40. HPLC purification of [68Ga]-68 from minor impurities after Sep-Pak
purification
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Interestingly, in contrast with previously published studies with 18F-FAC,62 compound
[68Ga]-68 showed only minimal hepatobiliary excretion during in vivo mice studies. The
rapid renal clearance of [68Ga]-68 is most likely due to the increased hydrophilicity caused
by the addition of the NOTA chelator. Although not within the scope of the present work,
this compound could result in higher contrast images due to higher lesion to background
ratio, which could produce significant clinical impact. The one hour post-injection images
are presented in Figure 41.207

Figure 41. BALB/c maximum intensity projection (MIP) μPET/CT mice images at onehour post injection showing rapid renal clearance
Synthesis of Clofarabine 5'-diphosphate prodrugs
3.2.1 Clofarabine 5'-diphosphate prodrugs: significance and specifications
Clofarabine, although highly effective, undergoes certain rate-limiting metabolisms in
the cell. This includes rate-limiting phosphorylation from clofarabine 5'-monophosphate to
clofarabine 5'-diphosphate by purine nucleotide monophosphate kinase,15,20 unlike other
drugs whose first phosphorylation event by dCK is usually rate-limiting. Clofarabine 5'monophosphate ProTides have been previously synthesized to bypass dCK metabolism.45

67

Little is known about the exact mechanism of 5’-nucleotidases; however, it has been
found that there is an increased concentration of this enzyme in common acute
lymphoblastic leukemia (ALL) cell lines causing dephosphorylation of adenosine
monophosphate (AMP).22 This important because clofarabine is an adenosine analogue
used to treat ALL, and possible clofarabine 5'-monophoshate ProTides experience
dephosphorylation back to the parent drug in the cell.209 Thus, it is beneficial to synthesize
diphosphate prodrug of clofarabine, which may overcome dephosphorylation by 5'nulceotidases and bypass rate-limiting phosphorylation.
In order to synthesize Clofarabine 5’-diphosphate produgs, certain specification should
be taken into consideration based on recent literature findings:
•

α-phosphate should contain no modification because oxygen anion prevents
nucleophilic attack that causes release of Clofarabine monophosphate by cleavage
of the phosphorous anhydride bond.47

•

β-phosphate should contain lipophilic modifications that allow uptake of ProTide
into the cell and can be metabolized to release unmasked clofarabine 5'diphosphate.39

Figure 42. Clofarabine diphosphate and proposed Clofarabine diphosphate prodrugs.
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Because of recent literature by Dr. Meier's group based on the design and synthesis of
diphosphate prodrugs (DiPPro) for use in anti-viral therapy, we decided to focus our efforts
on synthesis of clofarabine diphosphosphate prodrugs of this type (e.g., XVI). Taking into
account Meier's design of DiPPro, we divided the synthesis of our diphosphate analogues
into three steps (Scheme 24).
The first step involved the synthesis of clofarabine using a variety of methods available
in literature.15 The second step was synthesis of clofarabine 5'-monophosphate, by
phosphorylation of the 5'-OH of clofarabine using Yoshikawa method.210 The third step
was

the

coupling

of

clofarabine

5'-monophosphate

to

a

bis(acyloxybenzyl)

phosphoramidite. The results clofarabine 5'-diphosphate prodrug might be able to
incorporate into the cell and release the unmasked clofarabine 5'-diphosphate by a
mechanism as shown in Section 1.2 of this dissertation.52

Scheme 24. Overall route to clofarabine 5'-diphosphate prodrugs
3.2.2 Clofarabine
We began by exploring available synthetic protocols to prepare the building blocks for
our diphosphate prodrugs. Thus, synthesis of clofarabine was attempted using two
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methods; 1. using multi-step protocols to synthesize 2-chloroadenosine from guanosine
(Schemes 25-26),211-213 followed by regioselective protection of 2-amino, and 3'- and 5'
hydroxyl groups in order to perform substitution of the C2' hydroxy group with fluorine
with inversion of stereochemistry using DAST214 (Scheme 27), or 2. using protocols to
couple

2-deoxy-1-α-bromo-2-β-fluoro-3,5-di-O-benzoyl-d-ribofuranose

and

2-

chloroadenine units, followed by deprotection (Scheme 28).15,215
Linear synthesis of clofarabine from guanosine
Synthesis of clofarabine by method 1, began by acetylation of guanosine 69 with
Ac2O/pyridine in DMF at 70 °C for 4 hours to afford 70 (88%, Scheme 25). Then,
phosphorylation to activate hydroxyl group at 6-position, followed by replacement with
chlorine using POCl3/Et4NCl/N,N-dimethylaniline in ACN at reflux for 30 mins gave 71
(70%). Once compound 71 was made, the solubility in organic solvents was improved for
further elaboration of the purine base.211

Scheme 25. Synthesis of protected 6-chloroadenosine from guanosine
Subsequently, treatment of 71 with benzyltriethylammonium nitrite (BzEt3N-NO2) and
trimethylsilyl chloride (TMS-Cl) gave a diazonium salt that was replaced with chlorine
yielding 2,6-dichloro derivative 72 (58%, Scheme 26).212 The 6-position chlorine was then
replaced by amine using ammonia gas (NH3) saturated in 1,2-dimethoxyethane to afford
protected 2-chloroadenosine 73 (85%). The previously mentioned reaction afforded a small
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amount of partially deprotected 73, which could be used in the following reaction to yield
fully deprotected 2-chloroadenosine 74. It is noteworthy that the reaction of 72 using
MeOH/NH3 gave some of amine substituted product 73, along with a large amount of 6position methoxy substituted byproduct. Deprotection of 73, fully or partially protected,
using MeOH/NH3 gave 2-chloroadenosine 74 (95%).211

Scheme 26. Transformation of 6-chloro-2-aminopurine nucleoside to 2-chloroadenosine
Next, we attempted transform 2-chloroadenosine 74 to clofarabine 77 by regioselective
protection of the sugar 3',5'-OH groups and 6-NH2 group using TrCl/pyridine/DMAP at
80 °C followed by stereoselective fluorination (Scheme 27).214 After 96 hours, the reaction
mixture showed presence of 75a (R= Tr) but in low yield (<5% by TLC), along with several
partially protected byproducts, which required extensive column chromatography for
separation. Alternatively, protection of 3',5'-OH and 6-NH2 was attempted using benzoyl
chloride (BzCl) pyridine at -5 °C for 30 mins to afford 75b (R= Bz) in very low yields
(5% after column chromatography), with several byproducts. Due to the low efficiency of
the reactions leading up to compound 75, we then explored methods for a more rapid and
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efficient synthesis of clofarabine 77 employing coupling of commercially available 1,3,5tri-O-benzoyl-2-deoxy-2-fluoro-α-D-arabinofuranose with 2-chloroadenine base.216

Scheme 27. Attempted synthesis of clofarabine from 2-chloroadenosine
Synthesis of clofarabine by sugar/base coupling
Bromination of the 1 position of commercially available 1,3,5-tri-O-benzoyl-2-deoxy2-fluoro-α-D-arabinofuranose 78 using HBr gave pure 2-deoxy-1-α-bromo-2-β-fluoro-3,5di-O-benzoyl-d-ribofuranose 79 (99%, Scheme 28). Subsequent coupling of 79 with 2chloroadenine in the presence of KOt-Bu/CaH2 afforded a mixture of protected βclofarabine 80 (55%) and its α-anomer 80a (40%). Addition of a drying agent, such as
CaH2, and use of a polar aprotic solvent like MeCN led to the higher yield of β-isomer.
Finally, deprotection of 80 with NaOMe/MeOH afforded clofarabine 77 (95%, overall:
52% from 78).216
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Scheme 28. Synthesis of clofarabine by coupling of 2-deoxy-1-α-bromo-2-β-fluoro-3,5di-O-benzoyl-β-ribofuranose to 2-chloroadenine
3.2.3 Synthesis of clofarabine 5'-monophosphate
Synthesis of clofarabine 5'-monophosphate triethylammonium acetate salt 81 was achieved
using two methods: (i) Standard Yoshikawa method (POCl3/PO(OMe)3)15 and (ii)
Modified Yoshikawa method in the presence Proton Sponge.210,217 These reactions were
attempted under ambient conditions, or anhydrous conditions with freshly distilled POCl3.
Ultimately, it was found that use of distilled POCl3 in anhydrous conditions, using standard
Yoshikawa method was the most successful producing 81 in high yield with less rigorous
purification needed (Scheme 29). Thus, treatment of clofarabine 77 in PO(OMe)3 at 0 °C
with POCl3 followed by Sephadex column with TEAB buffer, and HPLC purification
yielded pure 81 in 35% yield (Figure 43).
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Scheme 29. Phosphorylation of clofarabine using Yoshikawa method
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Figure 43. HPLC purification of clofarabine 5'-monophosphate
3.2.4 Symmetric phosphoramidites
Although asymmetric bis(acyloxybenzyl) phosphoramidites were found to be much
more effective in releasing the unmasked diphosphate without cleavage to the
monophosphate,51 we initially explored synthesis of symmetric phosphoramidites to
become familiar with the protocol and chemistry. To acquire symmetric phosphoramidites
to use in coupling to clofarabine 5'-monophosphate, benzoyloxy benzyl alcohol 83 was
synthesized by treatment of 4-hydroxybenzyl alcohol 82 with benzoyl chloride (BzCl) in
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the presence of Et3N in THF at -20 °C for 2 hours (50%, Scheme 30). The moderate yield
was attributed to the formation of dibenzoylated byproduct, and some unreacted starting
material.
Then, dry solid 83 was reacted with anhydrous Et3N and PN(iPr)2Cl2, under nitrogen,
in THF at -20 °C for 30 mins to yield bis(benzoyloxybenzyl) phosphoramidite 84 [31P
NMR δ 147.9 ppm; Figure 44].50 Purification of this compound using a 2% Et3N in hexane
silica gel column was explored with varied success. Larger scale reactions (>200mg)
proved much more successful in yield and purification. However, crude product 84 was
used in coupling reactions for simplicity and reproducibility purposes.47,53

Scheme 30. Synthesis of bis(benzoyloxybenzyl) phosphoramidite
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Figure 44. 31P NMR of crude bis(benzoyloxybenzyl)phosphoramidite
3.2.5 Model studies: adenosine 5'-diphosphate prodrug
To determine a proper method for synthesis of clofarabine 5’-diphosphate prodrugs
(DiPPro), model studies were conducted using adenosine 85 and simple symmetric
phosphoramidite unit 84. Synthesis of prodrug 87 began by monophosphorylation of
adenosine 85 using Yoshikawa method [POCl3/PO(OMe)3]15 at 0°C for 6 hours to yield
adenosine 5’-monophosphate triethyl ammonium salt 86 after Sephadex purification
(Scheme 31). Alternatively, commercially available adenosine 5'-monophosphate sodium
salt 86a was converted to 86, using Dowex (H+)/TEAB buffer, to increase solubility in
organic solvent like DMF.
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Scheme 31. Synthesis of adenosine 5'-monophosphate triethylammonium salt
Next, phosphoramidite 84 was coupled with adenosine 5'-monophosphate salt 86
(Scheme 32) using 5-phenyl-1-H-tetrazole activator218 [31P NMR for P(III) δ 126.2 ppm,
P(V) δ -9.7 ppm; Figure 46 Panel A], followed by oxidation of the resulting 87a with
t-BuOOH53 to form adenosine 5’-diphosphate prodrug 87 [31P NMR δ -12.07 ppm (d, J =
19.8 Hz, Pα), -12.71 (d, J = 19.8 Hz, Pβ); Figure 46 Panel B]. Coupling of 84 with 86 was
attempted using 4,5-dicyanoimidazole (DCI) as previously reported for other diphosphate
prodrugs;50-53 however, this method yielded a complex reaction mixture along with some
starting material. Purification of 87 proved to be quite difficult, with decomposition back
to the adenosine 5'-monophosphate observed during HPLC purification using both
MeCN/H2O systems and 20mM TEAA buffer systems (Figure 45). Crystallization using
ethyl acetate proved the most effective method for purification providing 87 with 95%
purity as analyzed by NMR.
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Figure 45. HPLC purification of DiPPro 87 using CH3CN/H2O system
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Scheme 32. Coupling of bis(benzoyloxybenzyl) phosphoramidite to adenosine 5'monophosphate
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Panel A: formation of new P(III)-P(V) bond in 87a with peaks at 126 ppm and -9 ppm;
Panel B: displays formation of new P(V)-P(V) bond in 87 showing two doublets in the
-12 ppm region
Figure 46. 31P NMR analysis of the formation of adenosine DiPPro before and after
oxidation.
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3.2.6 Attempted synthesis of clofarabine 5'-diphosphate ProTides
Given our success with the adenosine DiPPro model 87, coupling of phosphoramidite
84 to clofarabine 5'-monophosphate triethylammonium acetate salt 81 was attempted using
5-phenyl-1-H-tetrazole218 as an activator in DMF, followed by oxidation using t-BuOOH.53
This was expected to yield clofarabine 5'-diphosphate prodrug 88 (Scheme 33) in similar
yield to adenosine prodrug 87. However, the results for this reaction showed low yields of
88 as evidenced by lack of formation of two doublets in the -12 ppm region in 31P NMR
spectra in higher than 3-5%. A large amount of unreacted starting material 81 was seen
with 31P NMR peaks in the 2 ppm region, along with byproducts in the 8-10 ppm region
which may be identified as H-phosphonate byproducts of 84.

Scheme 33. Attempted coupling of symmetric phosphoramidite to clofarabine 5'monophosphate
Changes in synthesis/purification of clofarabine 5'-monophosphate 81 and
phosphoramidite 34 may be needed to yield desired 88. The presence of the acetate anion
in 81, which is formed by HPLC purification with tetraethylammonium acetate (TEAA)
buffer, may discourage nucleophilic attack of phosphate anion towards phosphoramidite
84. This can explain the presence of starting material and byproducts after coupling

81

reactions. It may be beneficial to explore conversion of 81 to triethylammonium salt 81a
using Dowex H+/TEAB buffer (Scheme 34), and re-attempted coupling (Scheme 35).

Scheme 34. Conversion of monophosphate counterions in clofarabine 5'-monophosphate
Although using crude phosphoramidite 84 in coupling reactions with adenosine 5'monophosphate 86 was successful, to prevent formation of byproducts, purification of 84
may be advantageous. The phosphoramidite 84 is not stable for column chromatography,
but Et3N can be used to avoid decomposition to H-phosphonate. We have obtained varied
results using 2% Et3N in hexane columns; with larger scale reactions showing less
decomposition. It might be beneficial to use a higher amount of Et3N for purification (i.e.
5%) and prevent decomposition and achieve better reproducibility.

Scheme 35. Improved synthesis of clofarabine 5'-diphosphate prodrugs
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Synthesis of azido-modified nucleosides for elucidation of structure of aminyl
radicals
3.3.1 Synthesis of 2-azidopurine nucleosides for elucidation of the guanyl aminyl
radical
The guanyl aminyl radical (G(N2-H)•), as explained in Section 1.4.1 of this
dissertation, is of extreme importance in the study of DNA damage and repair pathways.
This radical has been characterized by EPR spectroscopy in dsDNA-oligomers but not
unequivocally in 2'-deoxyguanosine (dGuo) monomers.90-93,95,219 Characterization of the
(G(N2-H)•) at all level DNA-models (i.e. monomers, oligomers, quadruplexes, etc.) is of
high importance in understanding the chemistry of this radical in DNA. The EPR spectrum
of an aminyl radical via radiation-produced electron-addition to a nucleoside was first
discovered from 3'-AZT (3'-azido-3'-deoxythymidine), whose azido group present at the 3'
position of the sugar can form a reactive aminyl radical (for mechanism see Section 1.4).104
The high-electron affinity of the azide moiety makes it the most likely to capture an
electron during irradiation. Given this reactivity, and our lab's previous experience in the
synthesis azido-modified carbohydrate and nucleoside analogues,105,106 we proposed the
synthesis of 2-azido-2'-deoxyinosine, and other 2-azido substituted purines, in order to
elucidate the structure of the elusive aminyl radical on the guanine base by EPR (Figure
47).
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Figure 47. Proposed mechanism for the formation of aminyl radical in 2-azido-2'deoxyinosine upon irradiation with solvated electrons
We hypothesize that the azido group present at the C2-position of inosine will undergo
a similar mechanism to that of the azide in 3'-AZT104 and AmdU.106 The azide will capture
an electron forming an unstable azide anion radical (RN3•-, 89a), which will then lose N2,
leaving a nitrene anion radical (RN•-, 89b). This nitrene anion radical will then abstract a
hydrogen to become an aminyl radical (RNH•, 89c). Reactive aminyl radicals have been
shown to cause DNA strand breakage via free radical reactions.85,220 Thus, if the structure
of the reactive aminyl radical is determined by EPR, we would like to explore 89 as
anticancer radiotherapy agent.
Synthesis of 2-azidoinosine analogues from 2-azidoadenosine analogues
We explored synthesis of 2-azido-2'-deoxyinosine 89, also named in this dissertation
as 2-azido-2'-deoxyguanosine because azido group in 89 can directly generate aminyl
radical postulated to be formed from 2'-deoxyguanosine upon electron addition,120 in order
to study closely the aminyl radical formed from 2'-deoxyguanosine in DNA. Retrosynthetic
analysis of compound 89 (Figure 48), shows that it can be conveniently synthesized from
2-azido-2'-deoxyadenosine 90, which we can also investigate for the formation of aminyl
radical for comparison purposes. An alternative synthesis of compound 89 was explored
from O6-NPE protected 2'-deoxyguanosine. The 2-azidoinosine derivative 91, deemed 2-
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azidoguanosine for our purposes, was synthesized from its respective 2-azidoadenosine
precursor 92.

Figure 48. Retrosynthetic analysis of 2-azido-2'-deoxyinosine and 2-azidoinosine for the
study of the elusive guanylyl aminyl radical
Analogue 89 was synthesized using literature protocols previously explored for the
synthesis of clofarabine (e.g., Scheme 9 in Section 3.2.2.1). To begin with, 2'deoxyguanosine 93 was protected at the 3' and 5' sugar hydroxyls using Ac2O/pyridine to
yield diacetylated 2'-deoxyguanosine 94 (70%; Scheme 36).211 Lower yield was attained
during acetylation mainly due to N-acetylated byproduct as analyzed by TLC. Subsequent
treatment of 94 with POCl3/Et4NCl/PhNMe3 effected phosphorylation of the hydroxyl
group at C6 (from tautomeric enol form), which releases a chloride anion that affects
replacement at C6 giving 2-amino-6-chloropurine 95 (44%).211,213 Conversion of guanylyl
ring into a standard purine ring can greatly improve solubility in organic solvent, and thus
reactivity.
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Scheme 36. Synthesis of 2-azido-2'-deoxyadenosine from 2'-deoxyguanosine
Diazotization of the 2-amino group in 95 with t-BuONO gave a diazonium salt, and
subsequent replacement with azido group generated from TMS-N3 reagent, afforded 2azido-6-chloropurine nucleoside 96 in 63% yield. Treatment of 96 with EtOH/NH3
afforded replacement of the 6-chloro with amine, and deprotection of the sugar hydroxyls
to give 2-azido-2'-deoxyadenosine 90 (84% yield).146 Finally, deamination of 90 with
adenosine deaminase afforded 2-azido-2'-deoxyinosine 89 (85%; Scheme 37). The reaction
of 90 with adenosine deaminase was quite slow (7 days for 85% conversion), which is in
agreement with slow deamination previously seen in 2-substituted adenosine analogues.221

Scheme 37. Synthesis of 2-azido-2'-deoxyinosine from 2-azido-2'-deoxyadenosine
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Alternatively, synthesis of 2-azido-2'-deoxyinosine 89 was attempted starting with
diacetylated 2'-deoxyguanosine 94. This method involved the protection/activation of 6hydroxyl group in 94 with NPE.222,223 Thus, analogue 94 was treated with NPE-OH,
triphenyl phosphine, and diisopropyl azodicarboxylate (DIAD) in dioxane at room
temperature overnight to give 72% yield of O6-NPE-protected 2'-deoxyinosine 97 (Scheme
38). The use of molecular sieves powder in this reaction was imperative to the formation
of product. Analogues 97 was then subjected to diazotization with t-BuONO reagent
followed by displacement with azide generated from TMS-N3 reagent to afford 45% of 2azido

compound

98.

Finally,

removal

of

O6-NPE

protection

using

1,8-

diazabicyclo[5.4.0]undec-7-ene (DBU) followed by deprotection of sugar hydroxyls using
MeOH/NH3 afforded quantitative yield of 2-azido-2'-deoxyguanosine 89. It is noteworthy
that performing deprotection steps subsequently without isolation of 99 yielded product 89
with some impurities. To ensure purity, 99 was column chromatographed after DBU
deprotection (10% MeOH/CH2Cl2). After deprotection of sugar hydroxyls, HPLC
purification (10% MeCN in H2O system) of 89 provided a high purity sample for EPR
studies.
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Scheme 38. Alternative synthesis of 2-azido-2'-deoxyinosine from 2'-deoxyguanosine
Analogous to the synthesis of 89, the 2-azidoguanosine derivative 91 was synthesized
from 2-azidoadenosine 92. Synthesis of adenosine analogue 92 was achieved by formation
of 6-chloro-2-amino protected purine 71, previously synthesized as a precursor to 2chloroadenosine in the route to clofarabine (e.g., Scheme 25 in Section 3.2.2.1). Thus,
treatment of 71 with t-BuONO afforded diazonium salt which was replaced with azido
group generated from TMS-N3 to give 100 (78%; Scheme 39). Deprotection and exchange
of 6-chloro for amino group with EtOH/NH3 gave 2-azidoadenosine 92 in 52% yield.146
This reaction gives a practical yield of 86% given the presence of partially deprotected
byproducts, which upon reaction with fresh EtOH/NH3 yielded additional amounts of
product 92. Finally, adenosine deaminase was also used to convert 92 to 2-azidoguanosine
91 (85%, Scheme 40). Reaction of 2-azidoadenosine with adenosine deaminase was
significantly faster than that of 2-azido-2'-deoxyadenosine (three days rather than seven
days) as expected given the affinity of the enzyme.221
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Scheme 39. Synthesis of 2-azidoadenosine from 6-chloro-2-amino protected purine

Scheme 40. Synthesis of 2-azidoguanosine from 2-azidoadenosine
Interestingly, 2-azidoadenosine analogues (e.g., 90 or 92) showed two sets of peaks in
1

H NMR, unlike 2-azidoinosine analogues which only displayed one set of peaks. The two

sets of signals in 2-azidoadenosine analogues has been previously reported and highlight
the tautomerization into their respective tetrazolo isomer (e.g., 90a and 92a; Scheme 41).
The more deshielded peaks in NMR spectra were assigned to the tetrazole isomer.141,142
We were then interested in the effect that the stable tetrazole might have on formation of
the aminyl radical upon electron addition. Azido analogues were sent to our collaborators
in Oakland University to study formation of radicals upon irradiation with solvated
electrons and to conduct EPR studies.

89

Scheme 41. Tautomerization of 2-azidoadenosine analogues
3.3.2 Synthesis of 6-azidopurine nucleoside to study adenylyl aminyl radical
We then set our sights on synthesizing other azidopurine analogues which might afford
important aminyl radicals upon reaction with radiation produced electrons. One example
is the N6-aminyl radical formed from adenosine, which has been shown in recent years to
be integral in the formation of lesions in DNA.124,224 Thus, synthesis of 6-azido-2'deoxypurine nucleoside 101 would be advantageous for the study of the adenylyl N6aminyl radical. As in 2-azido purine analogues, the azido group in 101 is thought to
generate an aminyl radical through an analogous mechanism as presented in Figure 47 for
89 (Figure 49).

Figure 49. Proposed mechanism of aminyl radical formation from 6-azidopurine 2'deoxynucleoside analogue
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Several methods for the synthesis of 6-azidopurine 2'-deoxynucleoside 101 have been
reported in literature.131,140,148 Given our previous experience with the synthesis of 6chloropurine nucleoside analogues, we first attempted synthesis of 101 from precursor 104
by replacement of 6-chloro substituent with azide and subsequent deprotection of sugar
hydroxyls (Figure 50).

Figure 50. Retrosynthesis of 6-azidopurine 2'-deoxynucleoside from 2'-deoxyinsoine
Synthesis of 6-azidopurine analogue 101 was elaborated by three methods. Method 1
involves the acetylation of 2'-deoxyinosine 102 using Ac2O/DMAP to give 95% of 103,
followed by chlorodeoxygenation with POCl3 to give 104.211 Ultimately, method 1 lead to
the minimal formation of product 104 (15%, Scheme 42) with major decomposition of
substrate 103 observed. We then explored method 2, which involved chlorination of 103
with SOCl2, which also gave 104 (45%, Scheme 42).225 Method 2 proved to be more
efficient with less decomposition. Method 3, then, employed acetylation of 2'deoxyadenosine

105

(Ac2O/Pyr,

80%),

followed

by

diazotization

using

benzyltriethylammonium nitrite (BTEA-NO2) and replacement with chloride from TMSCl reagent to give less than 10% of product 104 (as analyzed by TLC).212 Method 2 proved
to be the most effective for synthesis of 104; despite the moderate yield. Lastly, compound

91

104 was treated with NaN3 in DMF at 50°C to afford replacement of chloride by azide
giving 55% of 107.

Scheme 42. Routes for the synthesis of 6-azidopurine 2'-deoxynucleoside from 2'deoxyinosine
During proton NMR analysis of 107, two sets of peaks were observed, much like those
of 2-azidoadenosine analogues, which highlighted the tautomerization of 107 to 107a
(Scheme 43). The more deshielded protons were assigned to the tetrazole tautomer.

Scheme 43. Tautomerization of 6-azidopurine derivatives
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Deprotection of sugar hydroxyls in 107 was attempted using two methods: 1. with
methanolic ammonia, and 2. using methanol saturated with HCl gas (Scheme 44). Both
these methods showed complete decomposition of 107 after only 30 minutes at 0°C based
on TLC analysis. We decided then to send our protected 6-azidopurine nucleoside analogue
107 to test for aminyl radical formation by EPR.

Scheme 44. Attempted deacetylation of 6-azidopurine 2'-deoxynucleoside caused
complete decompostion
3.3.3 Synthesis of 4-azidopyrimidine nucleosides to study cytidyl aminyl radical
Having explored a series of azido modified purine nucleoside analogues, we turned our
attention to azido-modified pyrimidine nucleosides. As explained in Section 1.4.3, the
formation of a syn-aminyl radical at the N4 position of cytidine is a highly important
intermediate and precursor to the σ-iminyl radical that causes damage in double-stranded
DNA (Figure 51). As with previous analogues, literature suggests that presence of azide at
the 4-position of cytidine can capture electrons and form an aminyl radical. In this case,
studies suggest that the aminyl radical 108c may tautomerize to the corresponding iminyl
radical 108d.125 We therefore targeted synthesis of 4-azidopyrimidine 2'-deoxynucleoside,
also named 4-azido-2'-deoxycytidine, 108 to test the aminyl radical formation that might
occur in 2'-deoxycytidine in DNA.
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Figure 51. Proposed mechanism for the formation of aminyl radical followed by
tautomerization to iminyl radical in 4-azidopyrimidine analogues
The synthesis of 4-azidopyridimidine analogues has been previously published,129,151
utilizing Divakar & Reese protocols154 via elaboration of 1,2,4-triazole group at the 4position of pyrimidine ring as a leaving group. This triazole group can then be replaced
with an azide anion from NaN3 or LiN3 in organic solvent. Figure 52 shows the
retrosynthetic approach for formation of 4-azidopyridimidine analogue 108.

Figure 52. Retrosynthesis for formation of 4-azidopyridimidine from 2'-deoxyuridine
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Synthesis of 4-azido-2'-deoxypyrimidine nucleoside 108 started with acetylation of the
sugar hydroxyls of 2'-deoxyuridine 109 with acetic anhydride/DMAP to give protected 2'deoxyuridine 110 (90%; Scheme 45). Treatment of 110 with POCl3 followed by
substitution with 1,2,4-triazole gave 111 in 75% yield. Replacement of triazole moiety with
azide proved to be more complicated than previously expected. This reaction was
attempted by three methods. Method 1 involves utilizing NaN3 in DMF solvent. This
method proved unsuccessful even upon heating as high as 100°C and did not yield product
112 (as observed by TLC analysis). Solubility was thought to be a problem with NaN3
reagent, and thus, method 2 utilized LiN3 generated in situ from LiF and TMS-N3 in
tetramethylethylenediamine was attempted.129 The more covalent nature of the lithiumazide bond, when compared to the sodium azide bond, was expected to solubilize better
in organic solvents. The high temperature used for this reaction (105-110°C) caused
some decomposition but gave moderate (40%) yield of product 112. Method 3 proved
to the most successful, with 85% yield of 112, by utilizing acetic acid in order to
protonate 1,2,4-triazole moiety to afford a better leaving group. A combination of
solvent [H2O/DMF (1:4)] was used to afford better solubility of the NaN3 reagent.
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Scheme 45. Synthesis of 4-azidopyrimidine 2'-deoxy nucleoside
Bicyclic tetrazole analogues
Attempted deprotection of 112 with methanolic ammonia, NaOMe, and NaCN/ethanol
yielded decomposition products as reported by Kotra et al.151 However, deprotection using
methanol saturated with HCl was found to give deacetylated 4-tetrazolo product 113
quantitatively128 (Scheme 46). Identification by UV absorption showed the protected 4azido 112 had λmax= 255 nm and 265 nm, while deprotected 4-tetrazolo 113 was had λmax=
257 nm and 267 nm. Furthermore, NMR analysis of 112 and 113 showed that peaks for
H5, H6, and H1' were much more deshielded in 113 than in 112, which would suggest
formation of tetrazole tautomer. Presence of azide functionality in 112 was determined by
performing a strain-promoted click-reaction using a cyclooctyne analogue on TLC, which
showed conversion (~60%) to a "click" higher moving product. Given these finding, we
decided to test formation of aminyl radical on protected 112, and tetrazolo 113.
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Scheme 46. Deprotection of 3',5'-di-O-acetyl protected 4-azidopyrimidine nucleoside
giving 4-tetrazolopyrimidine nucleoside product
We also explored synthesis of ribose counterpart of the 4-azido-2'-deoxyuridine 112,
and 4-tetrazolo-2'-deoxyuridine 113 to test for possible differences in the radical formation
during irradiation. Much like the synthesis of 112 and 113, synthesis of protected 4azidouridine 114 and 4-tetrazolouridine nucleoside 115 was achieved through addition of
1,2,4-triazole at the 4 position, followed by replacement with azide. Thus, uridine 116 was
treated with acetic anhydride and DMAP to yield tri-acetylated uridine 117 (90%; Scheme
47). Then, compound 117 was treated with POCl3, Et3N, and 1,2,4-triazole to form 4triazole substituted derivative 118 in roughly 78% yield. Subsequent treatment with acetic
acid/NaN3 in DMF/H2O afforded protected 4-azidouridine 114 (80%). Given our
experience with decomposition during deprotection of 4-azido-2'-deoxyuridine analogue,
114 was simply treated with MeOH/HCl to form 4-tetrazolo derivative 115 in 90% yield.
Both compounds 114 and 115 were sent to collaborators to test for aminyl radical formation
and comparison with 2'-deoxy analogues.
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Scheme 47. Synthesis of 4-azidopyrimidine and 4-tetrazolopyrimidine nucleosides
3.3.4 ESR studies of radicals generated from azido-modified nucleosides
From azido-modified pyrimidine nucleosides
Radiation-produced electron addition to the protected 4-azido-2'-deoxyuridine 112 and
triazole compound 113 (concentration = 2-3 mg/mL) allowed to identify novel radicals.
ESR spectra (absorbed dose = 600 Gy at 77 K; homogeneous glassy or supercooled
homogeneous 7.5 M LiCl/D2O solutions) were recorded at 77 K just after irradiation and
subsequently by gradually warming these samples up to 145 K (Figure 53).226 It is evident
from the ESR spectra that the center of the spectra, lineshape and overall hyperfine splitting
(i.e., total spectral width) did not change before (i.e., at 77 K) and after warming (i.e., at
145 K). Figure 53 is matched with a simulated spectrum (black line, Figure 53, Panel B).
Simulated spectrum has been obtained employing a mixed (Lorentzian/Gaussian=10) line
shape with two axially symmetric anisotropic
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14

N (nuclear spin = 1) hyperfine coupling

constant (HFCC) values of (22.0, 0, 0) G and (20, 0, 0) G, gzz, gxx, gyy (2.0017, 2.0041,
2.0041) along with an isotropic Gaussian line-width of 6 G. Even the 77 K ESR spectrum
obtained after subsequent photoexcitation of sample 112 at 145 K for 45 min remains
unchanged. These results establish that the same radical is formed via reaction of radiationproduced prehydrated electron in both compounds.

ESR spectra obtained from matched homogeneous glassy samples (2-3 mg/ml in 7.5 M
LiCl/D2O (pH/pD ca. 5) of tetrazole (113, blue) and of protected 4-azidocytidine (112,
pink). The first spectrum in panel (A) and in panel (B) shows RN3•- formation via radiationproduced (absorbed dose = 600 Gy) prehydrated electron attachment at 77 K in the dark.
Second set of spectra in panel (A) and in panel (B) were obtained after warming or
annealing the samples for 15 min in the dark at 135 K and at 145 K. The simulated spectrum
(black) is shown in panel (B) and for simulation parameters, consult text. Similarities of
the Azz HFCC in the spectra of both compounds were shown by vertical solid lines.
Figure 53. ESR spectra obtained from compounds 112 and 113 via irradiation with
radiation-produced prehydrated electrons.
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Theoretical calculations (Figures 54 and 55) propose a particular conformation of the
observed radical which give rise to two high anisotropic N-couplings (Azz = ca. 27 G and
34 G, Axx = Ayy =0) compared to the experimentally observed Azz values of aniosotropic Ncouplings (Azz = 22 G, and 20 G, Axx = Ayy =0, vide supra) for irradiation of 112 and 113
(Figure 53). Moreover, these spectra are different from the reported spectrum of -type
neutral aminyl radical (C(N4−H)•) from 1-methylcytosine.69 Thus, we assign these spectra
to the azido anion radical (RN3•-). These ESR spectral results show that (a) in tetrazole,
RN3•- formation occurs via dissociative electron attachment, where the radiation-produced
electron attaches to the tetrazole ring at 77 K and is followed by breakage of the cytosine
ring N3-azido bond in the anion radical (Scheme 48), and (b) under the experimental
conditions of ESR spectroscopic investigations [homogeneous glassy solutions at low
temperatures (77 K to 145 K)] RN3•- from these compounds do not get converted to the
expected neutral aminyl radical, C(N4−H)• (radical 108c in Figure 51) in the ground state
as expected from earlier studies with azido-DNA-models.104-106

Scheme 48. Reaction of tetrazole 113 and azido 112 with radiation produced electrons to
form RN3•-.
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The azido anion radical (RN3•-) in 1-methylcytosine was geometry-optimized employing
DFT/B3LYP/6-31G** method. Spin density distributions and hyperfine coupling
constants were calculated considering full solvation (IEF-PCM) under Gaussian’09 suit of
program.
Figure 54. Theoretical calculations of azide anion radical (RN3•-) in 1-methylcytosine.

The azido anion radical (RN3•-) in N3-protonated 1-methylcytosine was geometryoptimized employing DFT/B3LYP/6-31G** method. Spin density distributions and
hyperfine coupling constants were calculated considering full solvation (IEF-PCM) under
Gaussian’09 suit of program.
Figure 55. Theoretical calculations of azide anion radical (RN3•-) in N3-protonated 1methylcytosine.
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3.3.4.1.1 Proposed conversion RN3•- to C5'• sugar radical via UV
photoexcitation
UV-photoexcitation of the RN3•-, produced from tetrazole 113 at 77 K, for 14 min led
to the formation of ca. 20% conversion to C5'• (Figure 56), due to similarities of the
anisotropic doublet from anisotropic alpha-proton at C5'. Overall spectral width of this
anisotropic doublet; however, is ca. 14.5 G for 113 (center of black spectrum) versus ca.
19 G of the authentic C5'• produced via photoexcitation of guanine cation radical in
dGuo227 (red spectrum). Owning to a number of possible conformation of C5'•, the
orientation of the radical site p-orbital at C5' with respect to the anisotropic alpha C5'-H
proton can change and as a result, HFCC value of the anisotropic alpha C5'-H proton can
vary.228 This could be attributed to the conversion of RN3•- to the neutral aminyl radical in
the excited state and subsequent formation of the sugar radical via either intramolecular or
intermolecular H-atom abstraction reaction from C5' by the excited aminyl radical (Scheme
49). It is established in literature, that the excited aminyl radicals from one-electron
oxidized pyrimidines and purines produce sugar radicals.94,227,228 Due to the experimental
condition (i.e., photoexcitation at 77 K of the homogeneous glassy system), it is proposed
that the H-atom abstraction reaction should occur via a fast proton-coupled electron
transfer process. These results further establish that, RN3•- from 112 or from 113 are found
to be stable and hence not reactive in comparison to the reactivities of neutral aminyl
radicals that were produced via electron addition to azides which are either in the sugar
moiety104,105 or in the base as azidomethyl or azidovinyl.106
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The first spectrum (panel A) is obtained after γ-irradiation of tetrazole 113 (absorbed dose
= 600 Gy) at 77 K in the dark followed by annealing for 15 min in the dark at 140 K. (B)
Spectrum of this sample was obtained at 77 K after UV-radiation at 77 K for 14 min. (C)
The black spectrum is obtained after 80% subtraction of spectrum (A) from spectrum (B).
The red spectrum is that of C5'•, produced from G•+ in 8-D-3'-dGMP via
photoexcitation.227 All spectra were recorded at 77 K.
Figure 56. ESR spectra obtained after γ-irradiation and subsequent UV photoexcitation of
the tetrazole 113.

103

Scheme 49. Proposed mechanism for the formation of C5'-sugar radical upon
photoexcitation of the RN3•- in tetrazole 113 and azido 112.
We then ran samples from commercially available 5-azidouridine (5-AzU) to check
whether the unexpected formation of the azide anion radical would also occur upon
radiation-produced electron addition to 5-AzU. The ESR spectral results are presented in
Figure 57.
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77 K ESR spectrum of the aminyl radical (U(C5)-ND•/(U(C5)-NH•)) formed via radiationproduced one-electron attachment (absorbed dose = 600 Gy at 77 K) to 5-AzU (Panel A)
(U(C5)-ND•) (green) in 7.5 M LiCl (D2O), (Panel B) (U(C5)-NH•) (red color) in 7.5 M
LiCl (H2O). The simulated spectra (blue) (for simulation ESR parameters, see text) are
superimposed on the top of the experimentally recorded spectrum. Comparison of the
experimentally recorded spectra with those obtained via simulation clearly show that the
Azz component ca. 17 G due to the -N-H proton of the aminyl radical in H2O (U(C5)-NH•)
(red color) is lost in the D2O glasses (green color). All spectra were recorded at 77 K and
the line components due to Cl2•- are subtracted from these recorded spectra.
Figure 57. ESR spectrum of aminyl radical formed upon radiation-produced electron
addition to 5-azidouridine (5-AzU)
In Figure 57 Panel A, the ESR spectrum (green) of the aminyl radical (U(C5)-ND•)
from 5-AzU in D2O (7.5 M LiCl), recorded at 77 K and after subtraction of the line
components from Cl2•-, is shown. In Figure 57 Panel B, ESR spectrum of the aminyl radical
(U(C5)-NH•) (red) is obtained under identical conditions from 5-AzU in H2O (7.5 M LiCl).
Comparison of widths of these two spectra clearly shows that an additional 17 G proton
hyperfine coupling in the aminyl radical in H2O (U(C5)-NH•) (red) is present in the H2O
glasses and is missing in the D2O glasses (green). These results show that the source of the
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proton in the formation of the aminyl radical (U(C5)-NH•) via protonation of the nitrene
anion radical (U(C5)-N•-)), is the solvent (H2O). This additional hyperfine coupling of 17
G is the Azz component of the N-H (-H) coupling that contributes to the outer line
components and this component adds to the Azz component of the anisotropic hyperfine
coupling of the N-atom of U(C5)-NH•. Thus, from the experimentally recorded spectrum
(red) of U(C5)-NH• (Figure 57 Panel B), only the Azz component of the − (-H)
hyperfine coupling could be determined by experiment.
The spectrum of U(C5)-ND• in Figure 57 Panel A and that of the U(C5)-NH• in Figure
57 Panel B have been simulated (blue). For U(C5)-ND•, the simulation parameters are: C6H HFCC (14.5, 6.0, 11.0) G, radical site anisotropic axially symmetric N HFCC (0, 0, 23
G) G, N-D (for the exchangeable -H = 4.0, 1.0, 2.5) G, gxx, gyy, gzz =(2.0043, 2.0043,
2.0020), a mixed (Lorentzian/Gaussian=1.0) lineshape, and an isotropic linewidth of 7 G.
For U(C5)-NH•, the simulation parameters are: C6-H HFCC (17.0, 6.0, 13.6) G, radical
site anisotropic axially symmetric N HFCC (0, 0, 20 G) G, N-H (for the exchangeable H = 25.0, 6.0, 17.0) G, gxx, gyy, gzz =(2.0043, 2.0043, 2.0020), a mixed
(Lorentzian/Gaussian=1.0) lineshape, and an isotropic linewidth of 9 G. The simulated
spectra match quite well with that of the experimentally observed spectra.
In 5-AzU, the azido group is at meta position with respect to the N1 and N3 ring
nitrogens; on the other hand, in 4-azidopyrimidine analogues , the azido group is at the
ortho and para positions with respect to the N1 and N3 ring nitrogens. Based on our ESR
studies and theoretical results of HFCC as well as spin density distribution calculations,
the azido group at C4 in the pyrimidine base makes the azide anion radical more
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delocalized and hence more stable in comparison to other azido-modified nucleosides
previously studied104-106 and to the azido group in 5AzU.
From azido-modified purine nucleosides (2-N3-dGuo)
We also irradiated 2-azido-2'-deoxyinosine (89, 2-Az-dGuo) to test for formation of
the elusive guanyl aminyl radical (G(N2-H)•).90-93,95,219 The ESR spectrum obtained from
2-Az-dGuo sample is compared with the ESR spectrum found from a matched sample of
the tetrazole compound and to the authentic spectrum of G(N2-H)• that was obtained via
one-electron oxidation of 1-methyl-dGuo and in DNA-oligomers.92,93,219
The spectra in panel A of Figure 58 shows that the ESR spectrum obtained from
radiation-produced electron addition at 77 K to 2-Az-dGuo 89 followed by annealing to
135 K for 15 min is very similar to the corresponding spectra found from tetrazole 113.
This result concludes that addition of radiation-produced electron to 2-Az-dGuo 89 and to
tetrazole 113 (analogous to protected 4-azido-2'-deoxyuridine 112) led to RN3•- formation.
The HFCC values of the two axially symmetric anisotropic N of RN3•- from 89 are very
close to those for RN3•- from 113.
Comparison of the authentic spectrum of G(N2-H)• that was obtained via one-electron
oxidation of 1-methyl-dGuo (black spectrum in panel B, Figure 58) with the ESR spectrum
obtained from radiation-produced electron addition to 2-Az-dGuo 89 (panel A) clearly
shows that the two spectra are not identical in terms of lineshape, overall hyperfine
splitting, and the center of the spectra. Thus, electron addition to 2-Az-dGuo does not lead
to the formation of G(N2-H)• unlike the reaction of radiation-produced electron with
azides that are directly linked to the sugar moiety104,105 or with azides at C5 of the
pyrimidine ring,106 including 5-AzU.
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Panel (A) ESR spectrum obtained from radiation-produced (absorbed dose of -radiation
= 600 Gy in the dark) electron addition at 77 K to matched samples of 89 (2-Az-dGuo;2-3
mg/mL, blue) followed by annealing to 145 K for 15 min in the dark and of tetrazole 113
(2-3 mg/mL, pink) followed by annealing to 135 K for 15 min in the dark. The line
components due to Cl2•- are subtracted from these recorded spectra. Panel (B) authentic
ESR spectrum of the G(N2-H)• from 1-methyl-dGuo (1-Me- G(N2-H)•) (-irradiation
absorbed dose at 77 K = 2.5 kGy) via one-electron oxidation by Cl2•– due to annealing at
ca. 155 K for 15 min in the dark at pD ca. 9 in homogeneous glass (7.5 M LiCl in D2O) in
the presence of the electron scavenger K2S2O8 (6-8 mg/mL).
Figure 58. Comparison of EPR spectra acquired for 2-azido-2'-deoxyinosine 89, 4tetrazolo-2'-deoxyuridine 113, and 2'-deoxy-N1-methylguanosine.
In 2-Az-dGuo, the azido moiety is at the ortho position with respect to either N1 or N3
of the guanine ring, similar to how the azide group is ortho to N3 in 112 . Therefore,
formation of the azide anion radical, as found in the tetrazole 113 and in 4-azido 112, is
expected also from 2-Az-dGuo samples rather than the neutral aminyl radical and is indeed
observed.
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3.3.4.2.1 Photoexcitation of RN3•- from 2-Az-dGuo leads to the formation of
sugar radicals, possibly C5'•
Similar to our findings of sugar radical formation via photoexcitation of RN3•- from
tetrazole 113 and in 4-azido 112 (Figure 56), and to the work of Adhikary-Sevilla
laboratory showing that excited states of purine and pyrimidine cation radicals can lead to
formation of sugar radicals93-95,219,227,229, photoexcitation of a separately prepared and
matched 2-Az-dGuo sample was carried out employing a photoflood lamp at 77 K. The
results are presented in Figure 59 below.
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(A) Spectrum (black) is obtained at 77 K after -irradiation (absorbed dose = 600 Gy) at
77 K in the dark. (B) Spectrum (black) after subtraction of line components of Cl2•- from
spectrum (A). The green spectrum is the spectrum of RN3•- from 2-Az-dGuo in Figure 53A
which is superimposed on the black spectrum for comparison. (C) Spectrum (black)
recorded at 77 K after photoexcitation at 77 K for 150 min. (D) Spectrum (black) after
subtraction of line components of Cl2•- from spectrum (C). (E) The red spectrum is that of
C5'•, produced from G•+ in 8-D-3'-dGMP via photoexcitation.227 (F) The simulated
spectrum of C3'• (for details of simulation parameters, see text). The line components of
C3'• and C5'• in spectrum (D) are indicated by solid lines.
Figure 59. ESR spectra obtained from a 2-Az-dGuo 89 after radiation-produced electron
addition and UV photoexcitation

The black spectrum in panel A was immediately recorded after -radiation at 77 K of
the homogeneous glassy sample of 2-Az-dGuo 89 (2-3 mg/ml in 7.5 M LiCl/D2O (pH/pD
ca. 5)) The black spectrum in panel (B) was obtained after subtraction of line components
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of Cl2•- from spectrum (A) following procedures published in previous work.94 For
comparison, the spectrum (green) of RN3•- from 2-Az-dGuo (blue spectrum in Figure 59A)
is superimposed on the black spectrum and it is assigned to RN3•-. Subsequently, the glassy
sample was subjected to visible photoexcitation at 77 K employing a photoflood lamp for
150 min and the ESR spectrum (black) is shown in panel (C). Analogous to spectrum (B),
spectrum (D) was obtained after subtraction of line components of Cl2•- from spectrum (C).
Comparison of spectra (C) and (D) obtained after photoexcitation with spectra (A) and
(B) obtained before photoexcitation, clearly show development of new line components.
The red spectrum (E) of C5'• (an anisotropic doublet due to alpha proton at C5' of ca. 19
G), produced from G•+ in 8-D-3'-dGMP via photoexcitation,227

and the simulated

spectrum of C3'• [blue spectrum (F)] were used to compare against our obtained spectrum
(D). Using these as standards, our results shows ca. 40% conversion of RN3•- from 2-AzdGuo 89 to sugar radicals (C3'• (ca. 30%) and C5'• (ca. 10%)) upon photoexcitation. The
line components of C3'• and C5'• in spectrum (D) are indicated by solid lines. These results
show the low reactivity of RN3•- from purine nucleosides, similar to our findings on low
reactivity of RN3•- from pyrimidine nucleosides.
The blue spectrum in panel F is simulated employing 1 isotropic beta H HFCC (19.2
G, at C4') and 2 isotropic beta H HFCC (25.7 G each, at C2') with 4.0 G isotropic linewidth
and g= 2.0031. The outer lines of the simulated C3'• spectrum match those in spectrum (D)
as indicated by solid lines. Depending upon the conformation of the beta hydrogens with
respect to the radical site p-orbital at C3' in C3'•, the HFCC values of beta H would vary
and hence a number of C3'• spectra with different beta H HFCC values have been reported
in the literature.219,227,229,230
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The mechanism of sugar radical formation from excited RN3•- from 2-Az-dGuo 89
(Scheme 50) is similar to that in pyrimidines (scheme 49). Predominant formation of C3'•
via photoexcitation of RN3•- from 89 is found to be similar to significant formation of C3'•
via photoexcitation of guanine cation radical from dGuo and from 5'-dGMP at low
temperatures.227

Scheme 50. Proposed mechanism for the formation of C5' and C3' centered carbon radicals
upon UV-photoexcitation of the RN3•- in 2-azidoguanosine derivatives.
In conclusion, ESR studies of electron addition to azido- or tetrazole-modified
nucleosides clearly establish that position of the azido group in the base moiety dictates its
reactivity towards electron addition. If the azido group is "isolated" (e.g., in the "meta
position" to pyrimidine nitrogen's as in 5-AzU, in the sugar moiety as in 3'-AZT, or
indirectly attached to the aromatic ring as in 5-AmdU or 5-AvdU), then it is rapidly
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converted to neutral aminyl radical and is expected to cause radiosensitization based on the
studies of AmdU in EMT6 cancer cells.106 However, if the azido group is in ortho/para
position to ring nitrogens as in 4-azido 112, or tetrazole 113 as well as in 6-azidopurine
XX , these compounds produce RN3•- which is stable and does not rapidly convert to the
aminyl radical except in their excited state. Hence, these compounds are not expected to
show much radiasensitization in comparison to the significant radiosensitization observed
from 5-AmdU. Of course, 5-AzU is predicted to show significant radiosensitization as it
produces aminyl radical immediately after irradiation at 77 K.85
3.3.5 Biological evaluation of azido-modified nucleosides in vivo
Given our discovery of the nitrogen and sugar carbon centered radicals, we tested the
radiosensitizing potential of these azido compound in vivo. Each class of azido-modified
nucleosides were tested in Dr. Pathak's laboratory in University of Arkansas for Medical
Sciences. These included 2-azido-2'-deoxyinosine 89, 6-azido-2'-deoxypurine nucleoside
107, 4-azido-3',5'-di-O-acetyl-2'-deoxyuridine 112, and 4-tetrazolo-2'-deoxyuridine 113.
The azido analogues were tested in MDA-MB-231 (epithelial breast cancer cell line),
MCF7 (breast cancer cell line) and U87 (glioblastoma cell line) cells. MDA-MB-231,
MCF7 and U87 cells were seeded in 96 well plate (10,000 cells/well). Cells were incubated
with 100 µM of compound. After 24 h of treatments, cells were irradiated with 2 Gy (Grey)
and 4 Gy of gamma radiation. After 24 h and 48 h of irradiations cell viability was checked
with MTS cell proliferation assay (Promega). The results in Figures 60-62 show that all
the compounds tested showed only minor radiosensitizing effects in any of the cancer cell
lines tested. These results are supported by the fact that C5' centered radicals have been
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known to be quite stable and form oxidation products which do not results in DNA strand
breakage.231

Figure 60. Survival data of MDA-MB-231 cell lines after incubation with azido modified
nucleosides and gamma radiation. Data is shown for survival rates after 24 and 48 hours.

Figure 61. Survival data of MCF7 cell lines after incubation with azido modified
nucleosides and gamma radiation. Data is shown for survival rates after 24 and 48 hours.

114

Figure 62. Survival data of U87 cell lines after incubation with azido modified
nucleosides and gamma radiation. Data is shown for survival rates after 24 and 48 hours.
3.3.1 Synthesis of 4-azido-2'-deoxy-5',5''-dideuteropyrimidine nucleoside to study
formation of C5' centered radical
Given our preliminary results showing formation of a C5' centered radical in EPR
studies of the azido-modified nucleosides, we made an effort to synthesize 5',5''-dideutero
analogues of the 4-azidopyrimidine 112 and 4-tetrazolopyrimidine 113 nucleosides to
verify our findings through EPR. We expected that the anisotropic doublet seen from the
coupling of the carbon centered radical to C5'-hydrogen would be eliminated in EPR
studies of 5',5''-dideutero analogues. Retrosynthetic analysis shows that synthesis of 119
and 120 could be undertaken by coupling 1-O-acetate-3,5-di-O-acetyl-5,5'-dideutero-2deoxyribofuranose 123 with persilylated uracil base 122 (Figure 63). Further elaboration
of the 4-position hydroxyl group of uracil ring in 3',5'-di-O-acetyl-2'-deoxy-5',5'dideuterouridine 121 should afford desired azido analogues in similar yield as described
above.
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Figure 63. Retrosynthetic analysis for the synthesis of 4-azido-2'-deoxy-5',5''dideuteropyrimidine nucleoside
Synthesis of 3',5'-di-O-acetyl-2'-deoxyuridine for model studies
In order to develop an effective protocol for synthesis of 4-azido-2'-deoxy-5',5''dideuteropyrimidine nucleoside (e.g. 119 and 120), we first attempted synthesis of
undeuterated 3',5'-di-O-acetyl-2'-deoxyuridine 110 by coupling of 1-O-acetate-3,5-di-Oacetyl-2'-deoxyribofuranosyl 128 with persilylated uracil 122. Synthesis of 1,3,5-tri-Oacetyl-2'-deoxyribose was undertaken through multistep protocols previously described in
literature.232-235 Thus, 2-deoxyribose 125 was methylated using catalytic amounts of
concentrated H2SO4 in methanol to give 126 (85% as a mixture of α/β anomers of
deoxyribofuranose and deoxyribopyranose derivatives; Scheme 51). Treatment of the
mixture of methyl 2-deoxyribofuranosides 126 with acetic anhydride and pyridine resulted
in acetylation of the 3 and 5 positions to give 127 in 61% yield. Acetolysis with sulfuric
acid

in

acetic

anhydride/acetic

acid

yielded

1-O-acetate-3,5-di-O-acetyl-2'-

deoxyribofuranose 128 (79%). All sugar products were obtained in a mixture of α/β
anomers of deoxyribofuranose and deoxyribopyranose products, which were not separated
for the subsequent steps.
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(for simplicity only deoxyribofuranose isomers are shown)
Scheme 51. Synthesis of 1,3,5-tri-O-acetyl-2'-deoxyribose for coupling reaction
Persilylation of uracil 129 with chlorotrimethylsilane and hexamethyldisilazane gave
122 (Scheme 52). Yield was expected to be quantitative based on literature.105 Coupling of
sugar 128 and persilylated uracil 122, in CH3CN, in the presence of trimethylsilyl
trifluoromethanesulfonate (TMSOTf) catalyst afforded 82% overall conversion to the
mixture of protected uridine analogues. This mixture contained desired β-uridine product
110 (as confirmed with NMR standard) as well as α-uridine anomer, along with α/β
deoxyribopyranosyl

nucleoside byproducts. Purification by silica

gel

column

chromatography afforded 3',5'-di-O-acetyl-2'-deoxyuridine 110 (20% as analyzed by
NMR) in mixture with its β-deoxyribopyranosyl derivative 110a

Scheme 52. Synthesis of 3',5'-di-O-acetyl-2'-deoxyuridine
Synthesis of 3',5'-di-O-acetyl-2'-deoxy 5',5''-dideuterouridine and its 4azido and 4-tetrazolo derivatives
Once we developed an adequate protocol for the synthesis of 3',5'-di-O-acetyl-2'deoxyuridine 110, we set out synthesize 3',5'-di-O-acetyl-2'-deoxy-5',5''-dideuterouridine
121 through analogous methods. We began by methylation of commercially available 2deoxy-D-5,5'-dideuteroribose 130 using H2SO4 in methanol to give 131 in 94% yield
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(Scheme 53). Subsequent acetylation of the 3 and 5 position using Ac2O/pyridine yielded
80% of 132. Finally, acetolysis of 132 using H2SO4 in a mixture of Ac2O/AcOH (1:2) gave
82% of 1,3,5-tri-O-acetyl-2-deoxy-5,5'-dideuteroribose 123. All sugar products were
obtained as a mixture of deoxyribofuranose and deoxyribopyranose anomers but were not
separated throughout the reaction sequense. It is interesting to note that unlike in the
synthesis of 128, where each step produced four isomers in roughly equal yield (α/β
deoxyribofuranose and α/β deoxyribopyranose), synthesis of 123 produced only two major
products which accounted for >90% of yield. These products were attributed to βdeoxyribofuranose 123 and β-deoxyribopyranose.

(for simplicity only deoxyribofuranose isomers are shown)
Scheme 53. Synthesis of 1,3,5-tri-O-acetyl-2-deoxy-5,5'-dideuteroribose for subsequent
coupling reaction
Coupling of sugar 123 with persilylated uracil 122 in the presence of TMSOTf in
CH3CN gave roughly 50% of desired 2'-deoxyuridine 121 (Scheme 54) along with
deoxyribopyranosyl derivative 121a. Yield of 121 was calculated based on 1H NMR
analysis. The mixture of 121 with other isomers was not separable through column
chromatography and, thus, was used for the subsequent reactions.
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Scheme 54. Synthesis of 3',5'-di-O-acetyl-2'-deoxy-5',5''-dideuterouridine
Treatment of 121 with POCl3, Et3N, and 1-H-1,2,4-triazole in CH3CN overnight gave
roughly 25% of triazole 133 along with its deoxyribopyranosyl analogue.151 Then, 133 was
reacted with NaN3 and CH3COOH in a mixture of DMF/H2O for several days to yield azide
134 (45%). HRMS confirmed the molecular formula and mass of compound 134 and its
1

H NMR was identical to 112 except for the disappearance of peaks for H5',5" and

simplification of H4' splitting. Azide 134 was sent for EPR studies to confirm C5' radical
formation. Depending on the EPR results from azide 134, the latter is envisioned to be
converted to tetrazole 135 by reaction with saturated HCl in MeOH, analogously to
protocol described for the synthesis of 113. Attempts will be also made to obtain pure
tetrazole 135 from other isomers by reverse phase HPLC for further EPR studies.

(for simplicity only deoxyribofuranosyl products are shown)
Scheme 55. Synthesis of 3',5'-di-O-acetyl-4-azido-5’,5’’-dideutero-2’-deoxyuridine
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4 EXPERIMENTAL PROCEDURES
General procedures
The 1H (400 MHz), 13C (100 MHz), or 19F (376 MHz) NMR spectra were recorded at
ambient temperature in deuterated solvents, as specified. Reactions were carried out under
N2 atmosphere unless otherwise indicated. The reactions involving non-radioactive
materials were followed by TLC with Merck Kieselgel 60-F254 sheets and products were
detected with a 254 nm UV lamps. Column chromatography was performed using Merck
Kieselgel 60 (230-400 mesh). Perkin Elmer high-performance liquid chromatography
(HPLC) was used for purification on RP-C18 semi-preparative Phenomenex Gemini or
preparative XTerra columns with mobile phase and flow rate as indicated. High-resolution
mass spectra (HRMS) were obtained with a Solarix instrument (FT-MS). The SCN-BnNOTA and NODA-GA(tBu)3 bifunctional chelators were purchased from Macrocyclics
Inc, TX, USA and CheMatech, Dijon, France, respectively. Gemcitabine hydrochloride
was purchased from LC Laboratories, MA, USA. All other reagent grade chemicals were
purchased from Sigma Aldrich. Data in section 4.2 has been reprinted with permission
from the publisher236 and authors.206,207
Synthesis and evaluation of 4-N-Alkyl gemcitabine analogues
4.2.1 Synthesis of 4-N-alkylgemcitabine with terminal fluoromethyl ketone
4-N-(p-Toluenosulfonyl)-2′-deoxy-2′,2′-difluorocytidine (58). Gemcitabine 57 (600
mg, 2.0 mmol) was dried for several hours over P2O5, then dissolved in 10 mL of anhydrous
pyridine in a flame dried flask. TMS-Cl (5.1 mL) was added to the suspension. After 2h,
tosyl chloride (TsCl, 3.8 g, 20 mmol) was added, and the reaction was gradually heated to
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60°C with stirring. After 20 h, the volatiles were evaporated, and the resulting mixture was
treated with MeOH/NH3 (10 mL) and stirred at room temperature for 24 h. The volatiles
were then evaporated and the mixture was column chromatographed (90% EtOAc/Hex) to
give 5833 (714 mg, 85%) as a white solid: 1H NMR (CD3OD) δ 2.42 (s, 3H,CH3), 3.78 (dd,
J = 3.4, 12.8 Hz, 1H, H5′), 3.90−3.95 (m, 2H, H4,H5″), 4.28 (dt, J = 8.4, 12.0 Hz, 1H,
H3′), 6.13 (dd, J = 5.3, 9.5 Hz,1H, H1′), 6.65 (d, J = 8.2 Hz, 1H, H5), 7.36 (d, J = 8.0 Hz,
2H, Ar), 7.79 (d, J = 8.3 Hz, 2H, Ar), 7.99 (d, J = 8.1 Hz, 1H, H6);
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C NMR δ 21.43,

60.34 (C5′), 70.21 (dd, J = 18.8, 27.2 Hz, C3′), 82.99 (d, J = 8.4, C4′), 85.46 (dd, J = 23.9,
41.3 Hz, C1′), 98.46 (C5), 123.84 (t, J = 258.7 Hz, C2′), 127.58 (Ar), 130.52 (Ar), 140.71
(Ar), 142.62 (C6), 144.66 (Ar), 150.21 (C2), 160.54 (C4); 19F NMR δ −120.17 (br d, 1F),
−119.41 (dd, J = 4.1, 12.7 Hz, 1F).
4-N-(Undec-10-en-1-yl)-2′-deoxy-2′,2′-difluorocytidine (59). To a stirred solution of
58 (200 mg, 0.48 mmol) in 1,4-dioxane (5 mL) and Et3N (134 µL, 97.2 mg, 0.96 mmol)
was added 10-undecene amine (301 µL, 243.8 mg, 1.44 mmol). The mixture was stirred at
65°C for 48 hours. Then, the volatiles were evaporated under reduced pressure, and the
resulting residue was column chromatographed (5% MeOH/CHCl3) to yield 5933 (170 mg,
85%): 1H NMR (CD3OD) δ 1.30−1.43 (m, 12H, 6 × CH2), 1.56−1.65 (m, 2H, CH2),
2.03−2.09 (m, 2H, CH2), 3.39 (t, J = 7.1 Hz, 2H, CH2), 3.80 (dd, J = 3.3, 12.6 Hz, 1H, H5′),
3.89 (td, J = 2.8, 8.3 Hz, 1H, H4′), 3.95 (d, J = 12.6 Hz, 1H, H5″), 4.26 (dt, J = 8.3, 12.1
Hz, 1H, H3′), 4.91−5.02 (m, 2H, CH2), 5.82 (tdd, J = 6.7, 10.3, 17.0 Hz, 1H, CH), 5.87 (d,
J = 7.6 Hz, 1H, H5), 6.23 (t, J = 8.0 Hz, 1H, H1′), 7.74 (d, J = 7.6 Hz, 1H, H6); 13C NMR
δ 28.01, 29.98, 30.12, 30.19, 30.42, 30.51, 30.63, 34.88, 41.75, 60.56 (C5′), 70.67 (dd, J =
22.4, 23.8 Hz, C3′), 82.26 (dd, J = 3.6, 5.0 Hz, C4′), 85.94 (dd, J = 26.0, 38.0 Hz, C1′),
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97.33 (C5), 114.68, 124.05 (t, J = 258.4 Hz, C2′), 140.16, 140.77 (C6), 158.30 (C2), 165.37
(C4); 19F NMR δ −119.89 (br d, J = 240.1 Hz, 1F), −118.80 (br d, J = 240.1 Hz, 1F).
4-N-(10-Undecenyl)-3′,5′-di-O-benzoyl-2′-deoxy-2′,2′-difluorocytidine (60). BzCl
(140 μL, 168.68 mg, 1.2 mmol) was added to a stirred solution of 59 (200 mg, 0.48 mmol)
containing 2,6-lutidine (223 μL, 205.73 mg,1.92 mmol), and 4-dimethylaminopyridine
(DMAP; 117.3 mg, 0.96 mmol) in CH2Cl2 (10 mL) at room temperature. The resulting
mixture was stirred at 35 °C for 6 h. The reaction mixture was then diluted with CH2Cl2
(40 mL) and partitioned with H2O, and the aqueous layer was extracted with CH2Cl2 (2 ×
15 mL). The organic layer was sequentially washed with 1 M HCl (15 mL), saturated
NaHCO3/H2O (15 mL), and brine (15 mL), dried over Na2SO4, and evaporated. The
resulting residue was column chromatographed (0 → 2% MeOH/CHCl3) to give 60206 (230
mg, 78%) as a mixture of rotamers (7:3). The major rotamer had: 1H NMR (CDCl3) δ
1.16−1.41 (m, 12H, 6 × CH2), 1.49−1.76 (m, 2H, CH2), 1.93−2.07 (m, 2H, CH2), 3.29 (t, J
= 7.1 Hz, 2H, NH-CH2), 4.48-4.58 (m, 1H, H4′), 4.62-4.82 (m, 2H, H5′, 5′′), 4.89-5.03 (m,
2H, CH2), 5.57-5.64 (m, 1H, H3′), 5.73 (d, J = 7.6 Hz, 1H, H5), 5.80 (tdd, J = 6.7, 10.3,
17.0 Hz, 1H, CH), 6.49-6.56 (m, 1H, H1′), 7.33 (dd, J = 0.6, 7.3 Hz, 1H, H6), 7.42-7.52
(m, 4H, Ar), 7.57-7.68 (m, 2H, Ar), 8.03-8.13 (m, 4H, Ar); 13C NMR δ 26.67, 28.65, 28.87,
29.02, 29.28, 29.34, 29.69, 33.78, 43.97, 62.55 (C5′), 71.35 (dd, J = 17.1, 35.2 Hz, C3′),
79.57 (C4′), 83.54 (br s, C1′), 91.04 (C5), 114.17, 120.93 (t, J = 263.1 Hz, C2′), 126.78,
128.48, 128.73, 128.83, 129.36, 129.63, 129.72, 130.17, 133.58, 134.50, 139.16 (C6),
157.82 (C2), 165.99 (C4), 171.67;
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F NMR δ −120.35 (br d, J = 203.2 Hz, 1F), −115.31

(br d, J = 246.5 Hz, 1F). HRMS (ESI+) m/z calcd for C34H40F2N3O6 [M+H]+, 624.2880;
found 624.1860.
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The minor rotamer had: 1H NMR (CDCl3) δ 6.61-6.68 (m, 1H, H1'), 3.47-3.54 (m, 2H,
NH-CH2).
4-N-(10,11-Dihydroxyundecanyl)-3′,5′-di-O-benzoyl-2′-deoxy-2′,2′difluorocytidine (61). OsO4 (4 wt % in water; 0.016 mmol, 4.02 mg, 100 μL) and Nmethylmorpholine-N-oxide (56.2 mg, 0.48 mmol) were added to a stirred solution of 60
(200 mg, 0.32 mmol) in a mixture of acetone (3 mL) and water (0.3 mL) at 0 °C. The
resulting mixture was stirred at ambient temperature for 2 h, and then diluted with CH2Cl2
(30 mL) and partitioned with H2O. The organic layer was washed with saturated
NaHCO3/H2O (15 mL) and brine (15 mL), dried over Na2SO4, and evaporated. The
resulting residue was column chromatographed (50 → 90% EtOAc/hexane) to give 61206
(202 mg, 96%) as a mixture of isomers (7:3). The major isomer had: 1H NMR (CDCl3) δ
1.21−1.37 (m, 12H, 6 × CH2), 1.38-1.45 (m, 2H, CH2), 1.52-1.63 (m, 2H, CH2), 3.40-3.48
(m, 2H, NH-CH2), 3.61-3.66 (m, 1H, CH), 3.68-3.73 (m, 1H, CH2), 4.49-4.55 (m, 1H, H4′),
4.70 (dd, J = 4.6, 12.2 Hz, 1H, H5', 5''), 5.5-5.67 (m, 1H, H3′), 5.71 (d, J = 7.6 Hz, 1H,
H5), 6.55-6.62 (m, 1H, H1′), 7.32 (d, J = 7.0 Hz, 1H, H6), 7.39-7.51 (m, 4H, Ar), 7.527.67 (m, 2H, Ar), 8.01-8.10 (m, 4H, Ar);
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C NMR δ 25.28, 26.41, 26.61, 28.57, 28.70,

28.85, 29.19, 33.02, 43.70, 62.55 (C5′), 66.85, 71.61 (m, C3′), 72.22, 77.81, 79.25, 91.34
(C5), 121.14 (t, J = 263.1 Hz, C2′), 127.64, 128.70, 128.80, 129.07, 129.71, 130.15, 133.56,
133.72, 134.17, 134.43, 158.82, 164.79, 165.97; 19F NMR δ −120.42 (br d, J = 243.4 Hz,
1F), −115.30 (br d, J = 260.1 Hz, 1F). HRMS (ESI+) m/z calcd for C34H42F2N3O8 [M+H]+,
658.2934; found 658.2930.
The minor isomer had: 1H NMR (CDCl3) δ 6.48-6.55 (m, 1H, H1'), 3.22-3.28 (m, 2H, NHCH2).
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4-N-[10-Hydroxy-11-(4-methylphenylsulfoxy)undecanyl]-3′,5′-di-O-benzoyl-2′deoxy-2′,2′-difluorocytidine (62). TsCl (29.6 mg, 0.15 mmol) was added to a stirred
solution of 61 (100 mg, 0.15 mmol) in anhydrous CH2Cl2 (4 mL) in the presence of Et3N
(32 µL, 23 mg, 0.23 mmol). The mixture was then heated at 40 °C for 15 hours. After
cooling, the reaction mixture was diluted with CH2Cl2 and partitioned with HCl (0.1 M)
and H2O. The organic layer was washed with saturated NaHCO3/H2O (15 mL) and brine
(15 mL), dried over Na2SO4, and evaporated. The resulting residue was column
chromatographed (20 → 50% EtOAc/hexane) to give 62206 (76 mg, 62%) as a mixture of
isomers (6:4). The major isomer had: 1H NMR (CDCl3) δ 1.21-1.31 (m, 12H, 6 × CH2),
1.40-1.47 (m, 2H, CH2), 1.55-1.68 (m, 2H, CH2), 2.46 (s, 3H, CH3), 3.48-3.55 (m, 2H, NHCH2), 3.82-3.88 (m, 1H, CH), 3.89-3.95 (m, 1H, CH), 4.05 (dd, J = 2.9, 9.8 Hz, 1H, CH),
4.53-4.64 (m, 1H, H4′), 4.68 (dd, J = 4.4, 12.2 Hz, 1H, H5′), 4.81 (dd, J = 3.4, 12.3 Hz,
1H, H5′′), 5.38-5.45 (m, 1H, H3′), 5.61 (d, J = 7.6 Hz, 1H, H5), 6.63-6.70 (m, 1H, H1′),
7.31-7.39 (m, 3H, H6, Ar), 7.42-7.54 (m, 4H, Ar), 7.59-7.68 (m, 2H, Ar), 7.73 (d, J = 8.3
Hz, 2H, Ar), 8.05-8.12 (m, 4H, Ar); 13C NMR δ 21.80, 25.21, 26.87, 29.32, 29.35, 29.41,
29.58, 29.85, 32.77, 41.17, 63.03 (C5′), 69.62, 71.15 (m, C3′), 74.14, 96.02 (C5), 121.19
(t, J = 262.8 Hz, C2′), 128.11, 128.75, 128.89, 129.45, 129.49, 129.86, 130.10, 130.33,
132.91, 133.65, 134.32, 145.19, 164.85, 165.09, 166.11;
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F NMR δ −120.51 (br d, J =

241.2 Hz, 1F), −115.34 (d, J = 246.8 Hz, 1F).
The minor isomer had: 1H NMR (CDCl3) δ 6.53-6.60 (m, 1H, H1′), 3.26-3.33 (m, 2H, NHCH2).
4-N-[11-(4-Methylphenylsulfoxy)-10-oxoundecanyl]-3′,5′-di-O-benzoyl-2′-deoxy2′,2′-difluorocytidine (56). A freshly prepared solution of Collins reagent [CrO3 (24.6 mg,
124

0.246 mmol), pyridine (5 µL, 24.6 mg, 0.246 mmol), and Ac2O (45 µL, 51 mg, 0.493
mmol) in CH2Cl2 (2 mL)] was added to a stirred solution of 62 (50 mg, 0.062 mmol) in
CH2Cl2 (4 mL) at ambient temperature. The resulting mixture was stirred for 1 h. and was
immediately column chromatographed (EtOAc) to give 56206 (47 mg, 94%). The major
(6:4) rotamer had: 1H NMR (CDCl3) δ 1.20−1.38 (m, 12H, 6 × CH2), 1.41-1.65 (m, 2H,
CH2), 2.44 (s, 3H, CH3), 2.45-2.51 (m, 2H, CH2), 3.46-3.53 (m, 2H, NH-CH2), 4.48 (s, 2H,
CH2), 4.52-4.62 (m, 1H, H4′), 4.67 (dd, J = 4.4, 12.1 Hz, 1H, H5′), 4.79 (dd, J = 3.4, 12.2
Hz, 1H, H5′′), 5.26-5.31 (m, 1H, H3′), 5.58 (d, J = 7.6 Hz, 1H, H5), 6.60-6.68 (m, 1H,
H1′), 7.32-7.38 (m, 3H, H6, Ar), 7.41-7.51 (m, 4H, Ar), 7.57-7.66 (m, 2H, Ar), 7.81 (d, J
= 8.3 Hz, 2H, Ar), 8.03-8.12 (m, 4H, Ar); 13C NMR δ 21.72, 22.77, 26.77, 28.82, 28.99,
29.00, 29.08, 29.11 38.93, 41.01, 62.91 (C5′), 71.53 (dd, J = 17.2, 35.4 Hz, C3′), 71.83,
77.36 (C4′), 84.01 (br s, C1′), 96.17 (C5), 120.90 (t, J = 263.1 Hz, C2′), 125.99, 128.72,
128.82, 128.94, 129. 38, 129.41, 129.45, 129.57, 130.03, 130.54, 130.86, 130.91, 133.16,
134.28, 134.35, 135.12, 135.24, 140.69 (C6), 146.42 (C4), 156.51, 164.39, 165.88, 166.99,
203.43; 19F NMR δ −120.69 (br d, J = 252.5 Hz, 1F), −115.28 (d, J = 248.2 Hz, 1F). HRMS
(ESI+) m/z calcd for C41H46F2N3O10S [M+H]+, 810.2866; found 810.2891.
The minor rotamer had: 1H NMR (CDCl3) δ 6.51-6.58 (m, 1H, H1′), 3.23-3.31 (m, 2H,
NH-CH2).
4-N-(11-Fluoro-10-oxoundecanyl)-3′,5′-di-O-benzoyl-2′-deoxy-2′,2′difluorocytidine (63). Tosylate derivative 56 (30 mg, 0.03 mmol) was treated with KF (8.4
mg, 0.15 mmol), K2CO3 (19.5 mg, 0.15 mmol), 18-Crown-6 (38.1 mg, 0.15 mmol) in
CH3CN (3 mL) with stirring for 1 h at 65°C. The reaction mixture was quickly cooled in a
water bath and filtered. The solvent was evaporated under vacuum, and the resulting
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residue was column chromatographed (20 → 40% EtOAc/hexane) to give 63206 (8 mg,
38%), as a mixture of rotamers (6:4), and unchanged 56 (~50%). A practical yield of 76%
was achieved for the conversion of 56 to 63. The major rotamer had: 1H NMR (CDCl3) δ
1.19−1.38 (m, 12H, 6 × CH2), 1.55-1.78 (m, 2H, CH2), 2.55 (t, J = 7.3 Hz, 2H, CH2), 3.333.41 (m, 2H, NH-CH2), 4.54-4.65 (m, 1H, H4′), 4.76 (dd, J = 4.6, 12.3 Hz, 1H, H5′), 4.79
(d, J = 47.7 Hz, 2H, CH2F), 4.81 (dd, J = 3.6, 12.1 Hz, 1H, H5′′), 5.59 (d, J = 7.6 Hz, 1H,
H5), 5.85-5.92 (m, 1H, H3′), 6.42-6.48 (m, 1H, H1′), 7.43-7.55 (m, 4H, Ar), 7.56-7.69 (m,
2H, Ar), 7.76 (d, J = 7.3 Hz, 1H, H6), 8.01-8.12 (m, 4H, Ar); 13C NMR δ 22.72, 26.69,
28.68, 28.97, 29.06, 29.21, 29.85, 38.30, 38.32, 38.41, 44.03, 62.66 (C5′), 71.65 (dd, J =
17.2, 35.4 Hz, C3′), 79.38 (C4′), 83.91 (br s, C1′), 85.04 (d, J = 185.2 Hz, CH2F), 91.13
(C5), 120.67 (t, J = 263.1 Hz, C2′), 127.62, 128.89, 128.98, 129.12, 129.85, 130.31, 133.77,
133.45, 134.39, 134.67, 137.68 (C6), 145.20 (C4), 158.00, 164.93, 166.11, 203.34;
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F

NMR δ -227.42 (t, J = 47.7, 1F), −120.37 (br d, J = 217.9 Hz, 1F), −115.21 (dd, J = 245.1
Hz, 1F). HRMS (ESI+) m/z calcd for C34H39F3N3O7 [M+H]+, 658.2747; found, 658.2745.
The minor rotamer had: 1H NMR (CDCl3) δ 6.55-6.64 (m, 1H, H1′), 3.51-3.58 (m, 2H,
NH-CH2).
4-N-(11-Fluoro-10-oxoundecanyl)-2′-deoxy-2′,2′-difluoro-cytidine

(64).

Compound 63 (20 mg, 0.03 mmol) was dissolved in methanolic ammonia (2 mL) at 0 °C,
then stirred at ambient temperature for 2 h. Volatiles were evaporated under reduced
pressure, and the resulting residue was chromatographed (0 → 5% MeOH/CHCl3) to give
64206 (7 mg, 52%) as a clear oil: 1H NMR (MeOD-d4) δ 1.22−1.35 (m, 12H, 6 × CH2),
1.47-1.62 (m, 2H, CH2), 2.43 (t, J = 7.3 Hz, 2H, CH2), 3.30-3.42 (m, 2H, NH-CH2), 3.693.75 (m, 1H, H4′), 3.85 (dd, J = 4.6, 12.3 Hz, 1H, H5′), 3.95 (dd, J = 3.6, 12.1 Hz, 1H,
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H5′′), 4.19-4.28 (m, 1H, H3'), 4.79 (d, J = 47.7 Hz, 2H, CH2F), 5.92 (d, J = 7.9 Hz, 1H,
H5), 6.08-6.15 (m, 1H, H1′), 7.98 (d, J = 7.3 Hz, 1H, H6); 13C NMR δ 23.88, 27.94, 29.94,
30.17, 30.31, 30.72, 38.55, 41.70, 60.56 (C5′), 71.43 (m, C3′), 82.22 (C4′), 85.04 (d, J =
185.2 Hz, CH2F), 87.96 (C1′), 97.36 (C5), 124.00 ("m", C2′), 140.77 (C6), 158.29 (C2),
165.35 (C4), 202.21; 19F NMR δ -227.44 (t, J = 47.7 Hz, 1F), -119.98 (d of m, J = 239.1
Hz, 1F), -119.75 (d of m, J = 244.1 Hz, 1F). HRMS (ESI+) m/z calcd for C20H30F3N3O5
[M + H]+, 450.2210; found 450.2244.
Note: Treatment of 56 (15 mg, 0.019 mmol) with KF (4 eq.) in the presence of
Kryptofix 2.2.2. (4 eq.), rather than 18-Crown-6, in CH3CN at 75 oC for 30 min followed
by a quick filtration and evaporation of the mother liquor gave oily residue containing 63.
Immediate treatment (45 min/rt) of this crude mixture with NH3/MeOH (2 mL) gave a
complex mixture with product 64 in low yields (~5%; based on TLC and crude NMRs).
4.2.2 Synthesis of 4-N-alkylgemcitabine NOTA 68Ga chelators
4-N-[3-N-(tert-Butoxycarbonyl)-3-aminopropanyl]-2′-deoxy-2′,2′difluorocytidine (66). In a tightly sealed vessel, mixture of 58a33 (11.5 mg, 0.018 mmol)
and commercially available N-Boc-1,3-propanediamine (150 µl, 150 mg, 0.86 mmol) in
1,4-dioxane was stirred at 65 °C. After 48 h, the volatiles were evaporated the resulting
residue was column chromatographed (30% EtOAc/hexane→5% MeOH/EtOAc) to give
fully protected 3′,5′-di-O-Boc-4-N-(3-N'-Boc-3-aminopropanyl)gemcitabine 66a [3.6 mg,
31%; MS (ESI+) m/z 621 (100, [M+H]+)] followed by partially protected 66207 (3.5 mg,
59%) as colorless oil: 1H NMR δ 1.43 (s, 9H, 3×CH3), 1.74 (“quint”, J = 6.8 Hz, 2H, CH2),
3.10 (t, J = 6.7 Hz, 2H, CH2), 3.41 (t, J = 6.9 Hz, 2H, CH2), 3.77 (dd, J = 3.2 Hz, 12.6 Hz,
1H, H5′), 3.87 (dt, J = 2.8, 8.3 Hz, 1H, H4′), 3.93 (“d”, J = 2.1, 12.6 Hz, 1H, H5″), 4.24
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(dt, J = 8.4, 12.1 Hz, 1H, H3′), 5.85 (d, J = 7.6 Hz, 1H, H5), 6.21 (“t”, J = 8.0 Hz, 1H, H1′),
7.75 (d, J = 7.6 Hz, 1H, H6); 19F NMR δ −119.94 (br. d, J = 240.6 Hz, 1F), −118.83 (dd, J
= 10.3, 238.3 Hz, 1F); MS (ESI) m/z 421 (100, [M+H]+).
4-N-(3-Aminopropanyl)-2'-deoxy-2',2'-difluorocytidine

(67).

Method

A.

Compound 66 (3.4 mg, 0.008 mmol) was dissolved in TFA (1.0 mL) and the mixture was
stirred at ambient temperature overnight. After 15 h, the reaction mixture was diluted with
toluene, the volatiles were evaporated, and the residue co-evaporated with a fresh portion
of toluene. The resulting residue was then column chromatographed [EtOAc → 50%
EtOAc/SSE (EtOAc/i-PrOH/H2O, 4:2:1; upper layer)] to give 67207 (2.4 mg, 93%) as a
white solid: 1H NMR δ 1.95 ("quint", J = 6.8 Hz, 2H, CH2), 3.19 (t, J = 6.8 Hz, 2H, CH2),
3.51-3.57 (m, 2H, CH2), 3.81 (dd, J = 3.1, 12.0 Hz, 1H, H5'), 3.91-3.99 (m, 2H, H4', H5''),
4.28 (dt, J = 8.2, 12.1 Hz, 1H, H3'), 5.92 (d, J = 7.5 Hz, 1H, H5), 6.25 ("t," J = 8.1 Hz, 1H,
H1'), 7.88 (d, J = 7.1 Hz, 1H, H6); 13C NMR δ 34.7, 38.6, 39.1, 60.5 (C5′), 70.1 (dd, J =
21.0, 24.2 Hz, C3′), 82.8 (dd, J = 4.1, 5.1 Hz, C4′), 86.2 (C1), 97.8 (C5), 125.0 (t, J = 256.8
Hz, C2′), 140.1 (C6), 158.9 (C2), 165.9 (C4); 19F NMR δ -118.92 (br. d, J = 241.2 Hz, 1F),
-120.11 (dd, J = 10.4, 237.8 Hz, 1F); HRMS (ESI+) m/z calcd for C12H19F2N4O4 [M+H]+,
321.1369, found 321.1346.
Method B. In a tightly sealed container, a solution of 5833 (19.6 mg, 0.048 mmol),
commercially available N-Boc-1,3-propanediamine (100 µL, 100 mg, 0.58 mmol) and
TEA (3 mL) in 1,4-dioxane was stirred at 75 ºC. After 96 h, the volatiles were evaporated
and the resulting residue was treated with TFA (1.5 mL) and stirred at ambient temperature
overnight. After 15 h, the reaction mixture was diluted with toluene, the volatiles were
evaporated, and the residue co-evaporated with a fresh portion of toluene. The resulting
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residue was then column chromatographed (10% MeOH/EtOAc) to give 67207 (15.6 mg,
94%) with data as reported above.
4-N-[3-N-(SCN-Bn-NOTA)aminopropanyl]-2'-deoxy-2',2'-difluorocytidine (65).
A mixture of SCN-Bn-NOTA (10 mg, 0.031 mmol) and 67 (10 mg, 0.018 mmol) in 3 mL
of 0.1 M Na2CO3 buffer (pH 11) was stirred at ambient temperature for 60 h. The reaction
mixture was injected into a Phenomenex Gemini semi-preparative RP-C18 column (5µ, 25
cm x 1 cm) via 2 mL loop and eluted with 0% → 100% ethanol gradient in 0.01% TFA/H2O
from 0 to 30 min at a flow rate = 3 mL/min. Product 65 (12.5 mg, 54% yield) eluted with
rt = 12.8 min: 1H NMR δ 1.90 ("quint", J = 6.5 Hz, 2H, CH2), 2.68-2.75 (m, 2H), 2.87-2.95
(m, 4H), 3.06-3.15 (m, 3H), 3.17-3.29 (m, 5H), 3.41-3.48 (m, 4H), 3.50-3.62 (m, 1H), 3.653.72 (m, 4H), 3.79 (dd, J = 3.2 Hz, 12.5 Hz, 1H, H5''), 3.88-3.98 (m, 2H, H4, H5'), 4.204.29 (m, 1H, H3'), 5.89 (d, J = 7.6 Hz, 1H, H5), 6.26 ("t", J = 8.0 Hz, H1'), 7.22-7.28 (m,
2H, Ar), 7.31-7.37 (m, 2H, Ar), 7.79 (d, J = 7.6 Hz, 1H, H6); 19F NMR δ -118.80 (d of m,
J = 242.1 Hz, 1F), -119.45 (d of m, J = 244.1 Hz, 1F). MS (ESI+) m/z 771 (100, [M+H]+);
HRMS (ESI+) m/z calcd for C32H45F2N8O10S [M+H]+ 771.2942; found 771.2879.
Gallium-4-N-[3-N-(SCN-Bn-NOTA)aminopropanyl]-2'-deoxy-2',2'difluorocytidine (68). Gallium(III) chloride (5.1 mg, 0.029 mmol) was added to a stirred
solution of 65 (1.0 mg, 0.001 mmol) in 0.6 N NaCH3CO2/H2O (1 mL, pH = 9.3) at ambient
temperature. After 30 min, the reaction mixture was diluted to a total volume of 1.5 mL
with H2O and injected into a Phenomenex Gemini semi-preparative RP-C18 column (5µ,
25 cm x 1 cm) via 2 mL loop and eluted with 0 → 100% ethanol gradient in 0.01%
TFA/H2O from 0 to 30 min at a flow rate = 3 mL/min. Product 68 (0.5 mg, 46% yield)
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eluted with tR = 11.5 min. HRMS (ESI+) m/z calcd for C32H42F2GaN8NaO10S [M+H]+
837.1963; found 837.1977.
68Ga

radiolabeling and in vivo imaging of 4-N-alkyl gemcitabine-SCN-

Bn-NOTA
68

Ge/68Ga Radioisotopic Generator: Two different 68Ge/68Ga generators were used in

this study, a 50 mCi IGG-100 (Eckert & Ziegler, Germany), based on the TiO2 resin
technology; and a 50 mCi ITG generator (ItM, Germany), based on a modified silica resin.
Labeling with IGG-100 68Ge/68Ga Generator: The generator was eluted with 5 mL of
0.1 M ultrapure HCl (Sigma-Aldrich, USA) solution. Since the elution contains metal
contaminants, a combination of chromatographic exchange resins were used for prepurification of the eluent as described previously.208 Briefly, two luer-fitting column beds
were prepared. First, 40 mg of AG-50Wx8 cation exchange (Eichrom, USA) column was
connected to a three-way stopcock. Next, 15 mg of UTEVA anion exchange (Eichrom,
USA) resin in a column was positioned. Finally, another three-way stopcock was located
at the end. The system was designed to be used in four simple steps: elution (from the
generator, 5mL of 0.1 M HCl); cleaning (1 mL of 0.1 M HCl); purification (1 mL of 5 M
HCl); extraction (1 mL of Millipore Water).
The purified 68Ga elution (1 mL, pH = 0.6-1; activity = 10-20 mCi) obtained from the
purification system was collected in a 15 mL centrifuge tube. A solution containing 65 (10
μg, or 10 μl of a 1 mg/ml solution in DMSO) was later added and immediately buffered
using 0.3 mL of 3 N ultrapure sodium acetate (Sigma-Aldrich, USA). Labeling was
performed using a thermomixer stirring at 750 rpm for 15 minutes at room temperature
(Eppendorf, Germany), taking samples at 5, 10 and 15 minutes of incubation. No further
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purification was done for initial testing. Final quality control was performed in Silicagel
60 TLC plates with 0.1 M citric acid as the mobile phase. Plates were quantified in
OptiQuant software (Perkin Elmer, USA) by exposing a phosphoscreen for 5 min and
reading it in a Packard Cyclone Phosphorimager (Perkin Elmer, USA). This labeled
product was not used for imaging.
Labeling with the ITG 68Ge/68Ga Generator: This generator was eluted using 4 ml of
0.05M HCl and collected in a 15 ml sterile centrifuge tube. The obtained solution
containing up to 1850 MBq (50 mCi) of 68Ga was directly used for labeling by adding 25
µl of a 1 mg/ml compound 65 stock solution in DMSO, followed by 80 µl of a 3N NaOAc
solution for buffering (pH = 4-5). The mixture was then placed in a thermomixer
(FisherSci, USA) at 95 ºC and 750 rpm shaking for 15 minutes. A sample of the reaction
was taken and analyzed by radio HPLC to confirm the labeling. Immediately after labeling
confirmation, a purification/reformulation was performed by trapping the labeled product
in a C-18 Sep-Pak Plus Lite (Waters, USA) followed by a wash with 5 ml of saline solution.
The product was then eluted with 200 µl of a 50 % EtOH/saline solution, followed by 0.9
ml of saline to produce a final injectable solution containing 8-9% EtOH in 1 ml saline. A
final QC HPLC was performed to assess purity.
Quality Control: Radiochemical and chemical purity were determined on a dual pump
Varian Dynamax HPLC (Agilent Technologies, USA) fitted with an Agilent ProStar 325
Dual Wavelength UV-Vis Detector and a NaI(Tl) flow count detector (Bioscan, USA). UV
absorption was monitored at 220 nm and 280 nm. Solvent A was 0.01 % trifluoroacetic
acid (TFA) in H2O and solvent B was 0.01 % TFA in 90:10 v/v MeCN:H2O. Analytical
(radio)HPLC was performed a Symmetry® C18, 4.6x50 mm column (Waters, USA), a
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flow rate of 2 mL/min and a gradient of 0% B 0–1 min., 0–100% B 1–8 min and 100–0%
B 8–10 min. Compound identity was confirmed by co-injection with known standards.
Imaging: Animals (BALB/c) were injected with 100 µl of the final solution and placed
immediately in the camera under 2% isoflurane anesthesia. Imaging was performed in a
Siemens Inveon µPET/CT for 30 min from 45 to 75 minutes post injection. Final Maximum
Intensity Projection (MIP/μPET CT) images are presented for 4 animals.
Synthesis of adenosine 5'-diphosphate prodrug (AdeDiPPro)
6-Amino-2-chloro-9-(2′-deoxy-2′-fluoro-3′,5′-di-O-benzoyl-β-D-arabino
furanosyl)-9H-purine (80). Commercially available 1,3,5-tri-O-benzoyl-2-deoxy-2fluoro-α-D-arabinofuranose 78 (200 mg, 0.43 mmol) was placed in a flame-dried flask
under N2 atmosphere and treated with HBr (33% in acetic acid, 1 mL) in 5 mL of CH2Cl2
for 12 h. The resulting mixture was neutralized using a concentrated NaHCO3 solution,
followed by evaporation of the organic layer to give pure alpha C1' brominated sugar 79216
(99%, 180 mg). Next, 2-chloroadenine (71.2 mg, 0.42 mmol) was placed in a flame-dried
flask under N2 atmosphere and dissolved with anhydrous MeCN followed by addition of
KtOBu (catalytic) and CaH2 (17.4 mg, 0.42 mmol). The suspension was stirred for 40
minutes at 50°C, then 79 (generated in situ, 180 mg, 0.42 mmol) was added and stirring
was continued. After 24 h, the residue was filtered with celite, solvents were evaporated,
and immediately column chromatographed (65% EtOAc/Hex) to give pure protected βclofarabine 80216 (55%, 118 mg) as a solid: 1H NMR (CDCl3) δ 4.53-4.58 (m, 1H, H4'),
4.79-4.83 (m, 2H, H5', H5''), 5.85 (dd, J = 2.6, 49.8 Hz, 1H, H2'), 5.75 (dd, J = 2.8, 17.1
Hz, 1H, H3'), 6.17 (br s, 2H, NH2), 6.57 (dd, J = 2.7, 22.6 Hz, 1H, H1'), 7.42-7.68 (m, 6H,
Ar), 8.05-8.13 (m, 5H, H8, Ar). 19F NMR- H decoupled (CDCl3) δ -197.7 (s).
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Note:

The

6-Amino-2-chloro-9-(2′-deoxy-2′-fluoro-3′,5′-di-O-benzoyl-α-D-arabino

furanosyl)-9H-purine 80a216 was also isolated (55% EtOAc/Hex) in 40% yield: 1H NMR
(CDCl3) δ 4.71-7.78 (m, 2H, H5', H5''), 4.98 (dd, J = 8.7, 4.4 Hz, H4'), 5.82 (dd, J = 17.8,
1.8 Hz, H3'), 6.00 (s, 2H, 6-NH2), 6.21 (d, J = 48.9 Hz, H2'), 6.46 (d, J = 14.3 Hz, H1'),
7.43 (t, J = 7.8 Hz, 2H, Ar), 7.48 (t, J = 7.8 Hz, 2H, Ar), 7.60 (q, J = 7.5 Hz, 2H, Ar), 7.80
(d, J = 7.3 Hz, 2H, Ar), 8.04 (s, 1H, H8), 8.12 (d, J = 7.6, 6.6 Hz, 2H, Ar). 19F NMR- H
decoupled (CDCl3) δ -187.7 (s).
Clofarabine (77). Dibenzoylated clofarabine 80 (50 mg, 0.098 mmol) was dissolved
in MeOH (3 mL) followed by addition of 30% w/w NaOMe/MeOH (1 mL) and stirred at
30°C for 30 minutes. Then, solvent was evaporated, and the reaction was immediately
column chromatographed (10% MeOH/CH2Cl2) to give 77216 (95%, 28.6 mg) as a solid:
1

H NMR (DMSO-d6) δ 3.60-3.71 (m, 2H, H5', H5''), 3.81-3.87 (m, 1H, H4'), 4.42 (dt, J =

4.6, 19.0 Hz, 1H, H3'), 5.23 (dt, J = 4.4, 52.6 Hz, 1H, H2'), 6.33 (dd, J = 4.6, 13.7 Hz, 1H,
H1'), 7.88 (br s, 2H, NH2), 8.27 (d, J = 2.0 Hz, 1H, H8); 13C NMR (DMSO-d6) 60.7 (C5'),
72.5 (d, J C-F = 23.2 Hz, C3'), 81.1 (d, J C-F = 17.0 Hz, C1'), 83.5 (d, J C-F = 5.6 Hz, C4'),
94.8 (d, J C-F = 192.2 Hz, C2'), 117.4 (C5), 140.1 (C8), 150.2 (C6), 153.3 (C4), 156.9 (C2);
19

F NMR- H decoupled (DMSO-d6) δ -198.1 (s).
Clofarabine 5'-monophosphate (81). Clofarabine 77 (26 mg, 0.086 mmol) was

dissolved in PO(OMe)3 (1 mL) and cooled to 0°C in an ice bath. After this fully dissolved,
POCl3 (24µL, 39.6 mg, 0.258 mmol) was added and the reaction was stirred at 0 °C for
roughly six hours, when TLC using Todd's system showed full conversion. The reaction
was quenched using 0.2M TEAB (triethylammonium bicarbonate) buffer, followed by
washing with EtOAc to remove the high boiling point solvent [PO(OMe)3]. The aqueous
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layer was then was then passed through Sephadex column for initial purification (0 to 0.5M
TEAB buffer in H2O), followed by HPLC [A: 20mM TEAA in (1:1) ACN/H2O, B: 20mM
TEAA in H2O; System → 0-25% A in 10 mins, 25% A for 30 mins; r.t. = 35 min] to yield
pure 81 in 35% yield (21.2 mg): 1H NMR (CD3OD) δ 4.12-4.20 (m, 3H, H4', H5', H5''),
4.56-4.64 (m, 1H, H3'), 5.15 (dt, J = 3.5, 52.1 Hz, 1H, H2'), 6.43 (dd, J = 4.1, 15.7 Hz, 1H,
H1'), 8.34 (s, 1H, H8);

19

F NMR- H decoupled (CD3OD) δ -199.7 (s, 1F); 31P NMR- H

decoupled (CD3OD) δ 1.01 (s, 1P)
Bis(4-benzoyloxybenzyl)-N,N-diisopropylaminophosphoramidites (84). Phenyl
benzoate 83 (232.7mg, 1.174 mmol) and freshly distilled Et3N (180 µL, 130.6 mg, 1.291
mmol) were dissolved in THF (2 mL) in a flame dried flask under N2 atmosphere at -20°C.
In a separate flame dried flask under N2, commercially available dichloroN,N,diisopropylaminophosphoramidite (130 µL, 118.7 mg, 0.587 mmol) was dissolved in
2 mL THF at -20°C. Then, the phenyl benzoate solution was added dropwise to the dichloro
phosphoramidite reagent with formation of a precipitate and gas. The mixture was stirred
at -20°C for 30 minutes, when TLC (10% EtOAc/Hex + 3 drops TEA) confirmed formation
of product. The solvent was then evaporated and the crude reaction mixture was used for
synthesis of DiPPro 87. NMR showed roughly 85% conversion to 8452 with decomposition
of roughly 30% per day of storage: 1H NMR (CDCl3) δ 1.25-136 (m, 12H, 4-CH3), 3.663.72 (m, 2H, 2-CH), 4.70-4.83 (m, 4H, 2-CH2), 7.17-7.20 (m, 4H, Ar), 7.40-7.45 (m, 4H,
Ar), 7.49-7.53 (m, 4H, Ar), 7.61-7.66 (m, 2H, Ar), 8.18-8.23 (m, 4H, Ar);

31

P NMR- H

decoupled (CDCl3) δ 147.94 (s, 1P)
Adenosine bis(benzoyloxybenzyl)-5'-diphosphate DiPPro (87). Phosphoramidite
84 (~200mg, generated in situ in excess) was stirred in a solution containing 5-phenyl-1-
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H-tetrazole activator (0.309 mmol, 45 mg) in 5 mL DMF. Then, after 10 minutes, this
mixture was added to a solution of adenosine 5'-monophosphate triethylammonium salt 86
(0.103 mmol, 60 mg) in 5 mL DMF. After 1 h, tBuOOH (5 eq, 0.515 mmol, 46.4 mg, 50
µL) was added to oxidize and stirred for an additional hour. Solvents were evaporated
under vacuum, and compound 87 was separated by crystallization using ethyl acetate: 1H
NMR δ 3.4-3.52 (m, 4H, 2CH2), 4.20-4.34 (m, 2H, H5', H5''), 4.39-4.42 (m, 1H, H4'), 4.564.61 (m, 1H, H3'), 5.12-5.21 (m, 1H, H2'), 6.11 (d, J = 5.7 Hz 1H, H1'), 7.19-7.23 (m, 4H,
Ar), 7.43-7.47 (m, 4H, Ar), 7.53-7.58 (m, 4H, Ar), 7.67-7.72 (m, 2H, Ar), 8.14-8.18 (m,
4H, Ar), 8.22 (s, 1H, H8), 8.53 (s, 1H, H2); 13C NMR δ 19.43, 70.6, 72.1, 76.2, 85.5, 91.1,
121.5, 123.0, 129.8, 130.5, 130.7, 131.1, 134.9, 135.0, 141.2, 149.8, 152.3, 152.8, 156.5,
166.4; 31P NMR δ -12.07 (d, J = 19.8 Hz, Pα), -12.71 (d, J = 19.8 Hz, Pβ); LRMS (ESI+)
m/z calcd for C38H34N5O14P2 [M - H]-, 846.1583; found 846.2.
Synthesis of azido nucleoside analogues
4.4.1 2-Azido purine analogues
2-Azido-6-chloro-9-(3,5-di-O-acetyl-2-deoxy-β-D-erythro-pentofuranosyl)purine
(96). Compound 95237 (0.121 mmol, 45 mg) was dried for several hours under vacuum,
and then placed in a flame dried flask under N2 atmosphere. Then, it was dissolved in 5
mL of MeCN and cooled to -20°C in a salt ice bath. To this mixture, tBuONO (5 eq, 0.605
mmol, 62.4 mg, 72 µL) was added and stirred for five minutes. Then, TMS-N3 (5 eq, 0.605
mmol, 69.7 mg, 80 µL) was added, and the mixture was allowed to stand in a -20°C freezer.
After 12 hours, the reaction was placed in a 0°C refrigerator for an additional 24 hours.
Solvents were evaporated under vacuum, and crude mixture was column chromatographed
using a hexane/ethyl acetate gradient (10% → 70% EtOAc) to give 96 (63%, 30.1 mg): 1H
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NMR (CDCl3) δ 2.09 (s, 3H, CH3), 2.14 (s, 3H, CH3), 2.60-2.67 (m, 1H, H2'), 2.71-2.79
(m, 1H, H2''), 4.30-4.41 (m, 3H, H4', H5', H5''), 5.38-5.41 (m, 1H, H3'), 6.41 (dd, J = 6.1,
7.7 Hz, 1H, H1'), 8.21 (s, 1H, H8).
2-Azido-2'-deoxyadenosine (90). Compound 96 (0.076 mmol, 30 mg) was dried under
vacuum and placed in an ice salt bath to cool. Then, it was dissolved in 5 mL of cold
EtOH/NH3 saturated solution, sealed tightly, and placed in a 30°C oil bath to stir for 2 days.
The reaction was then cooled, and pressure was released to evaporate solvent under
vacuum. Then, fresh EtOH/NH3 reagent was added, the flask was sealed tightly, and
stirring at 30°C was continued. After an additional 2 days, the solvent was evaporated and
the crude mixture was column chromatographed using CHCl3/MeOH gradient (0% → 10%
MeOH). Further purification by HPLC was performed using H2O/MeCN system (0% →
20% MeCN gradient over 30 mins, then 20% MeCN from 30-40 mins), to give 90142 (80%,
17.8 mg): 1H NMR (CD3OD) δ 2.32-2.40 (m, 1H, H2'), 2.71-2.79 (m, 1H, H2''), 3.63 (dd,
J = 4.1, 12.2 Hz,1H, H5'), 3.74 (dd, J = 3.3, 12.2 Hz,1H, H5'), 4.02-4.08 (m, 1H, H4'),
4.53-4.58 (m, 1H, H3'), 6.32-6.39 (dd, J = 6.3, 7.5 Hz, 1H, H1'), 8.20 (s, 1H, H8).
Note: Compound 90 is in equilibrium with corresponding tetrazole derivative (90a,
13.5%) as judged by the analysis of proton NMR spectra: 1H NMR (CD3OD) δ 6.47-6.52
(m, H1'), 8.48 (s, H8).
2-Azido-2'-deoxyinosine (89). Compound 90 (0.017 mmol, 5 mg) was dissolved in 2
mL 0.05 M phosphate buffer (K3PO4, pH = 7.4), and stirred at 0°C until dissolved. To this,
1 mg (~ 22.1 units as specified by manufacturer) of adenosine deaminase enzyme was
added and stirred at 30°C for 24 h. Conversion was determined by TLC with formation of
fluorescence spot. To achieve full conversion, an additional 2 mg (~ 44.2 units) of
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adenosine deaminase was added to the reaction. After stirring for 7 days total, the reaction
was filtered and solution was purified with reverse phase HPLC (H2O/MeCN, 0% → 15%
MeCN in 30 mins) to give 89222 (4 mg, 81%): 1H NMR (CD3OD) δ 2.46-2.53 (m, 1H,
H2'), 2.85-2.92 (m, 1H, H2''), 3.79 (dd, J = 3.7, 12.2 Hz,1H, H5'), 3.92 (dd, J = 3.2, 12.2
Hz,1H, H5'), 4.09-4.13 (m, 1H, H4'), 4.63-4.69 (m, 1H, H3'), 6.48 (dd, J = 6.2, 7.6 Hz, 1H,
H1'), 8.22 (s, 1H, H8).
2-Azidoadenosine (92). Protected 2-azido-6-chloro purine 100146,211 (0.088 mmol, 40
mg) was dried under vacuum, cooled in an ice salt bath, and 7 mL EtOH/NH3 reagent was
added. Then, the flask was sealed tightly, and placed in a 30°C oil bath to stir for 2 days,
with addition of more EtOH/NH3 if based on TLC analysis of product formation. After an
additional 2 days, the solvent was evaporated, and the crude mixture was column
chromatographed using CHCl3/MeOH gradient (0% → 10% MeOH), followed by
purification on reverse phase HPLC with H2O/MeCN gradient (0% → 20% MeCN gradient
over 30 mins, then 20% MeCN from 30-40 mins) to give 92146 (70%, 19 mg): 1H NMR
(CD3OD) δ 3.75 (dd, J = 3.2, 12.4 Hz, 1H, H5'), 3.87 (dd, J = 2.8, 12.4 Hz, 1H, H5''), 4.124.15 (m, 1H, H4'), 4.28-4.33 (m, 1H, H3'), 4.65-4.71 (m, 1H, H2'), 5.80 (d, J = 6.1 Hz, 1H,
H1'), 8.25 (s, 1H, H8).
Note: Compound 92 is in equilibrium with corresponding tetrazole derivative (92a,
9.0%) as judged by the analysis of proton NMR spectra: 1H NMR (CD3OD) δ 6.08 (d, J =
5.4 Hz, H1'), 8.49 (s, 1H, H8).
2-Azidoinosine (91). Compound 92 (0.081 mmol, 25 mg) was dissolved in 10 mL 0.05
M phosphate buffer (K3PO4, pH = 7.4), and stirred at 0°C until dissolved. To this, 3 mg (~
66.3 units as specified by manufacturer) of adenosine deaminase enzyme was added and
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stirred at 30°C for 1 day. To achieve full conversion, as seen by formation of a fluorescence
spot on TLC, an additional 2 mg (~ 44.2 units) of adenosine deaminase was added to the
reaction. After stirring for 3 days total, the reaction was filtered and solution was injected
directly onto HPLC. A gradient of water/MeCN (0% → 10% MeCN in 40 mins) was used
to elute compound 91 (20 mg, 80%). 1H NMR (CD3OD) δ 3.77 (dd, J = 3.0, 12.5 Hz, 1H,
H5'), 3.92 (dd, J = 2.6, 12.5 Hz, 1H, H5''), 4.14-4.18 (m, 1H, H4'), 4.32-4.38 (m, 1H, H3'),
4.61 (b, 1H, NH), 4.78 (t, J = 5.5 Hz, 1H, H2'), 5.98 (d, J = 5.9 Hz,1H, H1'), 8.15 (s, 1H,
H8).
4.4.2 6-Azido purine analogues
6-Azido-9-(2-deoxy-3,5-di-O-acetyl-β-D-ribofuranosyl)purine

(107).

The

6-chloropurine 104 (36 mg, 0.10 mmol) and NaN3 (65 mg, 1 mmol) were dissolved in DMF
(5 mL) and placed in at 80°C with stirring for 3 hours. Then, DMF was separated from the
organic products by separation with EtOAc and water, followed by evaporation of the
organic layer. The resulting residue was column chromatographed (85% EtOAC/Hex) to
give 107140 (55%, 19.1 mg) (as a mixture of azido/tetrazole tautomers in a nearly 1:1 ratio).
The azido tautomer had: 1H NMR (CDCl3) δ 2.10 (s, 3H, CH3), 2.12 (s, 3H, CH3), 2.642.72 (m, 1H, H2'), 2.92-2.99 (m, 1H, H2''), 4.38-4.45 (m, 3H, H4', H5', H5''), 5.46-5.52 (m,
1H, H3'), 6.51 (dd, J = 6.1, 7.8 Hz, 1H, H1'), 8.21 (s, 1H, H8), 8.43 (s, 1H, H2).
Note: Compound 107 was found to be in equilibrium with its tetrazole tautomer (107a,
76%) as judged by analysis of proton NMR spectra: 1H NMR (CDCl3) δ 2.17 (s, 3H, CH3),
2.19 (s, 3H, CH3), 2.77-2.83 (m, 1H, H2'), 3.00-3.05 (m, 1H, H2''), 4.46-4.49 (m, 3H, H4',
H5', H5''), 5.53-5.56 (m, 1H, H3'), 6.63 (dd, J = 6.2, 7.6 Hz, 1H, H1'), 8.71 (s, 1H, H8),
9.55 (s, 1H, H2).
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4.4.3 4-Azido pyrimidine analogues
1-(3,5-Tri-O-acetyl-β-D-deoxyribofuranose)-4-azido-2-pyrimidinone (112). The 4triazolo 111 (250 mg, 0.69 mmol) was dissolved in 4 mL DMF/H2O (3:1) and CH3COOH
(500 µL, 525 mg, 8.74 mmol) was added. The NaN3 (280.4 mg, 4.31 mmol) was dissolved
in H2O (1 mL) and added to the reaction. The mixture was stirred at 50°C for roughly 72
h. Then, the solution was diluted with 20 mL EtOAc, and washed with NaHCO3, H2O, and
brine. The organic layer was evaporated and column chromatographed (80% EtOAc/Hex)
to give 112 (85%, 198 mg): 1H NMR (CDCl3) δ 2.11 (s, 3H, CH3), 2.16 (s, 3H, CH3), 2.222.31 (m, 1H, H2'), 2.72-2.80 (m, 1H, H2''), 4.33-4.41 (m, 2H, H4', H5'), 4.45 (dd, J = 3.4,
11.4 Hz, 1H, H5''), 5.27-5.31 (m, 1H, H3'), 6.52 (dd, J = 5.6, 8.1 Hz, 1H, H1'), 6.95 (d, J =
7.9 Hz, 1H, H5), 7.77 (d, J = 7.9 Hz, 1H, H6).
6-(2-Deoxy-β-D-ribosyl)tetrazolo[l,5-c]pyrimidin-5(6H)-one (113). Compound 112
(50 mg, 0.15 mmol) was dissolved in 2 mL of MeOH and cooled to 0°C, then roughly 2
mL of MeOH saturated with HCl was added. The solution was stirred for 3 h at 0°C. The
solvent was evaporated, and the residue was immediately column chromatographed (5%
MeOH/CH2Cl2) to give 113 (95%, 36.1 mg): 1H NMR (CD3OD) δ 2.43-2.48 (m, 1H, H2'),
2.52-2.55 (m, 1H, H2''), 3.72 (dd, J = 3.5, 12.1 Hz, 1H, H5'), 3.87 (dd, J = 3.1, 12.1 Hz,
1H, H5''), 4.05-4.10 (m, 1H, H4'), 4.43-4.49 (m, 1H, H3'), 6.52 (t, J = 6.5 Hz, 1H, H1'),
7.02 (d, J = 7.8 Hz, 1H, H5), 8.33 (d, J = 7.9 Hz, 1H, H6).
1-(2',3',5'-Tri-O-acetyl-β-D-ribofuranosyl)-4-azidopyrimidin-2(1H)-one

(114).

Compound 118 (150 mg, 0.36 mmol) was dissolved in 4 mL DMF/H2O (3:1) and
CH3COOH (261 µL, 274 mg, 4.56 mmol) was added. The NaN3 (146.3 mg, 2.25 mmol)
was dissolved in H2O (1 mL) and added to the reaction. The mixture was stirred at 50°C
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for roughly 48 h. Then, the solution was diluted with 20 mL EtOAc, and washed with
NaHCO3, H2O, and brine. The organic layer was evaporated and column chromatographed
(90% EtOAc/Hex) to give 114238 (75%, 107 mg): 1H NMR (CDCl3) δ 2.11 (s, 3H, CH3),
2.21 (s, 3H, CH3), 4.39-4.43 (m, 1H, H5'), 4.48-4.55 (m, 2H, H4', H5''), 5.43-5.48 (m, 2H,
H2', H3'), 6.37 (d, J = 5.0 Hz, 1H, H1'), 6.98 (d, J = 7.8 Hz, 1H, H5), 7.64 (d, J = 7.9 Hz,
1H, H6).
6-(β-D-ribofuranosyl)tetrazolo[l,5-c]pyrimidin-5(6H)-one (115). Compound 114
(85 mg, 0.22 mmol) was dissolved in 2 mL of MeOH and cooled to 0°C, then roughly 2
mL of MeOH saturated with HCl was added. The solution was stirred for 3 h at 0°C. The
solvent was evaporated, and the residue was immediately column chromatographed (5%
MeOH/CH2Cl2) to give 115 (90%, 53.2 mg). 1H NMR (CD3OD) δ 3.83 (dd, J = 2.7, 12.3
Hz, 1H, H5'), 3.96 (dd, J = 3.1, 12.1 Hz, 1H, H5''), 4.13-4.16 (m, 1H, H4'), 4.23-4.27 (m,
1H, H3'), 4.32-4.35 (m, 1H, H2'), 6.18 (d, J = 3.9 Hz, 1H, H1'), 7.01 (d, J = 7.9 Hz, 1H,
H5), 8.39 (d, J = 7.9 Hz, 1H, H6).
ESR studies of azido-modified nucleosides
4.5.1 Sample preparation and methodology
Transparent glassy samples of azido-modified nucleosides were prepared.
Subsequently, γ-irradiation and ESR spectral analyses of these samples were performed.
Compounds purchased: Lithium chloride (LiCl) (ultra-dry, 99.995% (metals basis)) was
obtained from Alfa Aesar (Ward Hill, MA, USA). Deuterium oxide (D2O) (99.9 atom %
D) was purchased from Aldrich Chemical Company Inc. (Milwaukee, WI, USA). All
compounds were used without further purification.
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Glassy sample preparation: As per the ongoing studies of Sevilla-Adhikary lab at
Oakland University,93,94,104-106,227,229 transparent homogeneous glassy sample were
prepared as follows: (i) Preparation of homogeneous solutions: First, homogeneous
solution was prepared by dissolving ca. 1.0 to 2.4 mg/mL of a compound (e.g., 4) in either
7.5 M LiCl in D2O. The native pH of 7.5 M LiCl in D2O is ca. 5 and pH of these solutions
was not adjusted. (ii) Preparation of glassy samples and their storage: Homogenous
solutions of azido compounds (as indicated in (i)) were thoroughly bubbled with nitrogen
gas to avoid formation of peroxyl radicals. Subsequently, those solutions were immediately
drawn into 4 mm Suprasil quartz tubes (Catalog no. 734-PQ-8, WILMAD Glass Co., Inc.,
Buena, NJ, USA). Thereafter, the quartz tubes containing these solutions were rapidly
immersed in liquid nitrogen (77 K). Owing to rapid cooling at 77 K, the homogeneous
liquid solutions formed transparent homogeneous glassy solutions. Subsequently, these
transparent homogeneous glassy solutions were γ-irradiated at 77 K and were subjected to
progressive annealing experiments or photoexcitation along with ESR spectral studies. All
glassy samples were stored in the dark at 77 K in Teflon containers prior to and after γirradiation.
γ-Irradiation of glassy samples and their storage: As per well-established methodology
of γ-irradiation of glassy samples of DNA and RNA-models,93-95,209,222,224,225 the glassy
samples were γ (60Co)-irradiated (absorbed dose = 600 Gy (2.5 h)) at 77 K and stored at
77 K in Teflon containers in the dark. Following our previous work with 3′-AZT,104 azidopentofuranoses,105 and other azido-nucleosides,106 the solute concentrations were kept low
(2-3 mg/mL) of 7.5 M LiCl glass (D2O). As a result, Cl2•¯ is formed owing to scavenging
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of radiation-induced holes by the matrix (7.5 M LiCl) and the radiation-produced electrons
in the glass are scavenged by the solute of azido compounds.
Annealing of glassy samples: As per previous studies,93-95,209,222,224,225 a variable
temperature assembly that passed liquid nitrogen cooled dry nitrogen gas past a thermister
and over the glassy sample was employed for annealing. Stepwise (either 5 K or 10 K step)
annealing of each glassy sample was conducted in the range (140-170) K for 15 min. The
matrix radical, Cl2•¯, did not react with sample. Thus, by employing ESR spectroscopy,
we were able to study directly the formation of RNH• via reaction of radiation-produced
electron with azido compounds and subsequent reactions of RNH•.
Photoexcitation: Following our works that involve photoexcitation,93,94,227 a thermoelectrically cooled blue laser (TECBL-30G-405, World Star Tech., Lot 6880, λ = 405 nm,
30 mW), a helical quartz low-pressure argon-mercury vapor lamp (90% emission at 254
nm), and a photoflood lamp were employed for photoexcitation experiments at 77 K.
Electron Spin Resonance: As per ongoing studies in Sevilla-Adhikary laboratory,9395,209,222,224,225

we used a Varian E-Century Series X-band (9.3 GHz) ESR spectrometer with

an E-4531 dual cavity, 9-inch magnet, and a 200 mW Klystron. For the field calibration,
Fremy’s salt (gcenter = 2.0056, A(N) = 13.09 G) was employed. All ESR spectra were
recorded at 77 K and at 45 dB (6.3 μW) as well as 40 dB (20 μW). We note here that
recording of ESR spectra at 77 K maximizes the signal height and allows for comparison
of signal intensities.
Employing the Bruker programs (WIN-EPR and SimFonia) and ongoing studies on
DNA and RNA-radicals, anisotropic simulations of experimentally recorded ESR spectra
were carried out. The ESR parameters (e.g., hyperfine coupling constant (HFCC) values,
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linewidth, etc.) were adjusted to obtain the “best fit” simulated spectrum that matched the
experimental ESR spectrum well.
Method of theoretical Calculations: Employing optimized geometries of radicals,
energies of radicals and hyperfine coupling constant (HFCC) values were calculated using
DFT/B3LYP/6-31+G** method in Gaussian 09. Theoretically predicted HFCC values
obtained employing B3LYP/6-31+G** method agree well with those obtained using
experiment. Jmol molecular modeling freeware was used to plot optimized molecular
structures.
In vivo biological evaluation of azido-modified nucleosides
The MB-MDA-231, MCF7 and U87 cells were seeded in 96 well plate (10,000
cells/well). Azido-modified nucleosides were dissolved in DMSO, and 200 µM stock
solutions of each were prepared. The next day, cells were treated with 100 µM of each
compound (i.e. compounds 112, 113, 107, and 89) by diluting them in culture media. After
24 h of compound treatment, the cells were irradiated with 2Gy and 4Gy of gamma
irradiation in Shepherd Mark I 137Cs irradiator (Model 25, J. L. Shepherd & Associates,
San Fernando, CA, USA). After 24 and 48 h of irradiation, cell viability was checked with
MTS cell proliferation assay (Promega). For the assay, the old media were discarded, and
the cells were washed with fresh media. Then, 20 µL of MTS and 1µL of PES solution was
added with 100 µL of fresh media in each well. After 1h in incubation, absorbance was
measured in BioTeK microplate reader at 490 nm.
Synthesis of 3',5'-di-O-acetyl-4-azido-5’,5’’-dideutero-2’-deoxyuridine
Methyl 2-Deoxy-5,5'-dideuteroriboside (131). The dry commercially available 2deoxy-5,5'-dideuteroribose 130 (200 mg, 1.47 mmol) was added to a dry flask and
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dissolved in 5 mL methanol. The mixture was place in a 0°C ice bath, and concentrated
H2SO4 (20 µL, 36.8 mg, 0.375 mmol) was added. The reaction was stirred for 1.5 hours at
0°C, followed by neutralization with pyridine (760 µL). After evaporation under vacuum,
the dry residue was column chromatographed (0% → 10% MeOH/CH2Cl2) to give 207 mg
(94%) as mixture of isomers. The methyl deoxyribofuranoside derivative 131 (45%) had:
1

H NMR (CDCl3) δ 2.12-2.17 (m, 2H, H2, H2' pyranose), 2.32 (ddd, J = 2.1, 6.9, 14.0 Hz,

1H, H2'), 3.45 (s, 3H, CH3), 4.09-4.12 (m, 1H, H3), 4.56-4.59 (m, 1H, H4), 5.17 (dd, J =
2.0, 5.7 Hz, 1H, H1).
The methyl deoxyribopyranoside derivative (55%) had: 1H NMR (CDCl3) δ 1.87-1.93 (m,
1H, H2), 2.12-2.17 (m, H, H2', H2 furanose), 3.42 (s, 3H, CH3), 4.16-4.19 (m, 2H, H3,
H4), 5.14 (d, J = 4.5 Hz, 1H, H1).
Methyl 3,5-Di-O-acetyl-2-deoxy-5,5'-dideuteroriboside (132). Pure 131 (207 mg,
1.38 mmol) was dissolved in 4 mL of pyridine and cooled to 0°C on an ice bath. Slowly, 2
mL of Ac2O was added, and the mixture was allowed to warm to room temperature. This
was stirred for 2 days, and upon reaction completion based on TLC analysis, the solvents
were evaporated under vacuum. The residue was dissolved in CH2Cl2 and washed with
dilute HCl, NaHCO3, and brine. Then, the mixture was column chromatographed (0% →
50% EtOAc/Hexane) to give 258 mg (80%) as a mixture of isomers. The
deoxyribofuranoside derivative (132, 38%) had: 1H NMR (CDCl3) δ 2.11 (s, 3H, Ac), 2.12
(s, 3H, Ac), 2.37-2.45 (m, 2H, H2, H2'), 3.35 (s, 3H, CH3), 4.23 (d, J = 3.0 Hz, 1H, H4),
5.25 (dd, J = 2.3, 5.5 Hz, 1H, H1), 5.22-5.26 (m, 1H, H3).
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The deoxyribopyranoside derivative (62%) had: 1H NMR (CDCl3) δ 2.09 (s, 3H, Ac), 2.11
(s, 3H, Ac), 2.14-2.21 (m, 2H, H2, H2'), 3.43 (s, 3H, CH3), 4.27 (d, J = 4.1 Hz, 1H, H4),
5.05-5.08 (m, 1H, H3), 5.12 (d, J = 4.9 Hz, 1H, H1).
1,3,5-Di-O-acetyl-2-deoxy-5,5'-dideuteroribose (123). Acetolysis of 132 (258 mg,
1.10 mmol) was carried out by dissolving it in 2 mL of acetic acid with 1 mL of acetic
anhydride. The mixture was placed on a 0°C ice bath, and H2SO4 (40 µL, 77.2 mg, 0.75
mmol) was added dropwise. The reaction was brought to room temperature and allowed to
stir until it turned a deep purple color (roughly 15 mins). The residue was then stirred with
crushed ice, followed by washing with CH2Cl2 two times. The organic layer was then
washed with NaHCO3 twice and evaporated. The remaining oil was column
chromatographed (40% →80% EtOAc/Hexane) to give 236 mg (82%) as a mixture of
isomers. The deoxyribofuranose derivative 123 (38%) had: 1H NMR (CDCl3) δ 2.08 (s,
3H, Ac), 2.10 (s, 3H, Ac), 2.12 (s, 3H, Ac), 2.33-2.37 (m, 1H, H2), 2.49-2.54 (m, 1H, H2'),
4.32 (d, J = 3.5 Hz, 1H, H4), 5.38-5.41 (m, 1H, H3) 6.43 (dd, J = 2.4, 5.7 Hz, 1H, H1).
The deoxyribopyranoside derivative (62%) had: 1H NMR (CDCl3) δ 2.10 (s, 3H, Ac), 2.11
(s, 3H, Ac), 2.13 (s, 3H, Ac), 2.49-2.54 (m, 2H, H2, H2'), 4.44 (d, J = 3.0 Hz, 1H, H4),
5.14-5.18 (m, 1H, H3), 6.38 (d, J = 5.3 Hz, 1H, H1).
3',5'-Di-O-acetyl-2'-deoxy-5',5''-dideuterouridine (121). Protected sugar 123 (236
mg, 0.902 mmol) was placed in a flame-dried flask under N2 atmosphere and dissolved in
5 mL CH3CN. Then, the crude TMS-protected uracil 122, synthesized in situ as previously
described,105 was dissolved in 5 mL CH3CN and added to the mixture. TMSOTf (30 µL,
18.4 mg, 0.083 mmol) was added and the reaction was stirred for 15 mins at room
temperature. Next, the mixture was placed in a 70°C oil bath to stir for 2 hrs under N2. The
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solvent was then evaporated under vacuum, and the residue was dissolved in EtOAc
followed by washing with NaHCO3 (X2) and brine. Column chromatography (0% → 5%
MeOH/CH2Cl2) gave 170 mg (60%) of the mixture of isomers. The deoxyribofuranosyl
derivative 121 (51%) had: 1H NMR (CDCl3) δ 2.08 (s, 3H, Ac), 2.09 (s, 3H, Ac), 2.48-2.53
(m, 1H, H2'), 2.74-2.81 (m, 1H, H2''), 4.25 (d, J = 2.5 Hz, 1H, H4), 5.21-5.27 (m, 1H, H3'),
5.76 (d, J = 8.1 Hz, 1H, H5), 6.26 (dd, J = 5.7, 8.3 Hz, 1H, H1'), 7.49 (d, J = 8.2 Hz, 1H,
H6).
The corresponding deoxyribopyranosyl derivative (49%) had: 1H NMR (CDCl3) δ 2.08 (s,
3H, Ac), 2.09 (s, 3H, Ac), 2.13-2.18 (m, 1H, H2', H2''), 4.57-4.59 (m, 1H, H4), 5.21-5.27
(m, 1H, H3'), 5.74 (d, J = 8.2 Hz, 1H, H5), 6.19 (dd, J = 1.5, 7.0 Hz, 1H, H1'), 7.47 (d, J =
8.2 Hz, 1H, H6).
1-(3,5-Di-O-Acetyl-2-deoxy-5,5'-dideutero-β-D-ribofuranos-1-yl)-4-triazolyl-2pyrimidinone (133). Protected uridine 121 (170 mg, 0.541 mmol) was dissolved in 3 mL
of CH3CN. In a separate flask, 1,2,4-1-H-triazole was dissolved in 8 mL CH3CN and placed
at 0°C. Then, Et3N (646 µL, 469 mg, 4.64 mmol) and POCl3 (96 µL, 157.3 mg, 1.03 mmol)
were added. Once the formation of triethylammonium chloride salt was observed, the
solution of 121 was added and stirring was continued overnight. The reaction was
quenched with Et3N (451 µL) and H2O (248 µL) and stirred for 10 min. Next, the solvent
was evaporated, and the residue dissolved in EtOAc. The organic layer was washed with
NaHCO3, H2O, and brine. This mixture was column chromatographed (50% →100%
EtOAc/Hexane) to give 45 mg (23%) of a mixture of isomers. The deoxyribofuranosyl
derivative 133 (65%) had: 1H NMR (CDCl3) δ 2.11 (s, 3H, Ac), 2.16 (s, 3H, Ac), 2.90-2.95
(m, 1H, H2'), 2.95-3.01 (m, 1H, H2''), 4.43 (d, J = 2.6 Hz, 1H, H4), 5.24-5.29 (m, 2H, H3'),
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6.28-6.32 (m, 1H, H1'), 7.11 (d, J = 7.4 Hz, 1H, H5), 8.17 (s, 1H, triazole), 8.31 (d, J = 7.3
Hz, 1H, H6), 9.31 (s, 1H, triazole).
The deoxyribopyranosyl derivative (35%) had: 1H NMR (CDCl3) δ 2.14 (s, 3H, Ac), 2.16
(s, 3H, Ac), 2.53-2.54 (m, 1H, H2'), 2.56-2.57 (m, 1H, H2''), 4.57 (d, 1H, J = 2.7 Hz, H4),
4.72-4.74 (m, 1H, H3'), 5.30 (d, J = 7.3 Hz, 1H, H5), 6.28-6.32 (m, 1H, H1'), 7.13 (d, J =
7.3 Hz, 1H, H6), 8.15 (s, 1H, triazole), 9.29 (s, 1H, triazole).
1-(3,5-Di-O-acetyl-2-deoxy-5,5'-dideutero-β-D-ribofuranos-1-yl)-4-azido-2pyrimidinone (134). The 4-triazolyl 133 (45 mg, 0.123 mmol) was dissolved in 5 mL
DMF, and heated at 50°C. Acetic acid (89 µL, 93.7 mg, 1.56 mmol) was added to the
mixture. Then, NaN3 (50 mg, 0.769 mmol) was dissolved in 1 mL of H2O and added to the
reaction. The resulting mixture was stirred at 5 0°C for 3 days. Once cooled, the mixture
was partitioned between EtOAc and H2O, followed by washing of the organic layer with
NaHCO3 and brine. The resulting residue was column chromatographed (50% → 90%
EtOAc/Hex) to give 18 mg (45%) as a mixture of isomers. The deoxyribofuranosyl
derivative 134 (68%) had: 1H NMR (CDCl3) δ 2.14 (s, 3H, Ac), 2.17 (s, 3H, Ac), 2.78
(ddd, J = 2.0, 5.7, 14.4 Hz, 1H, H2'), 2.95-3.01 (m, 1H, H2''), 4.42 (d, J = 2.5 Hz, 1H, H4),
5.28-5.31 (m, 1H, H3'), 6.52 (dd, J = 5.7, 8.1 Hz, 1H, H1'), 6.98 (d, J = 7.9 Hz, 1H, H5),
7.79 (d, J = 7.9 Hz, 1H, H6); 13C NMR (CDCl3) δ 20.9 (CH3 x 2), 38.7 (C2'), 63.5 (C5';
low intensity pentet due to splitting to two deuterons), 73.9 (C4'), 83.4 (C3'), 87.1 (C1'),
93.2 (C5), 133.6 (C6), 142.5 (C4), 150.7 (C2), 169.8 (CO), 170.2 (CO); HRMS m/z calc
for C13H13D2N5O6 [M+Na]+ 362.1046, found 362.1030.
The deoxyribopyranosyl derivative (32%) had: 1H NMR (CDCl3) δ 2.15 (s, 3H, Ac), 2.19
(s, 3H, Ac), 2.26-2.32 (m, 1H, H2', H2''), 4.74-4.76 (m, 1H, H4), 5.33-5.35 (m, 1H, H3'),
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6.47 (dd, J = 1.5, 7.0 Hz, 1H, H1'), 6.94 (d, J = 7.9 Hz, 1H, H5), 7.71 (d, J = 7.9 Hz, 1H,
H6)

5 CONCLUSION
Two classes of gemcitabine analogues with lipophilic 4-N-alkyl chains have been
synthesized. One class, bearing β-keto sulfonate moiety which has been utilized for
subsequent 18F-fluorination (e.g., 56). The second, bearing a SCN-Bn-NOTA chelator has
been employed for

68

Ga complexation (e.g., 65). These analogues were designed and

synthesized to study their stability during 18F- or 68Ga-radiolabeling to potentially serve as
new PET imaging radiotracers for gemcitabine.
The synthesis of 4-N-alkylgemcitabine bearing a β-keto tosylate moiety was
undertaken to overcome the in vivo defluorination experienced by similar 4-N-alkyl
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gemcitabine analogues due to the hydrogens present on carbon-β to fluorine. Synthesis of
this analogue began with the displacement of p-toulenesulfonylamino group in 4-Ntosylgemcitabine with 1-amino-10-undecene to afford 4-N-alkylgemcitabine with a
terminal olefin. Elaboration of the terminal alkene by dihydroxylation, regioselective
tosylation, and oxidation gave the desired β-keto tosylate analogue (e.g., 56). Displacement
of the tosylate group with fluorine was achieved using non-radiolabeling protocols to give
4-N-alkylgemcitabine analogue bearing a terminal α-fluoromethyl ketone (e.g., 64).
However, treatment of the protected β-keto tosylate, using standard
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F-radiolabeling

protocols, followed by immediate deprotection with gave α-fluoromethyl ketone in low
yields.
Synthesis of 4-N-alkylgemcitabine conjugated to SCN-Bn-NOTA was achieved by
replacement of tosylamide in 4-N-tosylgemcitabine with N-Boc-1,3-propanediamine,
followed deprotection to acquire 4-N-alkylgemcitabine with a reactive terminal amine (e.g.
67). Subsequent condensation with SCN-Bn-NOTA chelator gave novel NOTA-4-Nalkylgemcitabine analogue (e.g., 65). Ligand 65 was efficiently complexed with
gallium(III) chloride (GaCl3) giving the Gallium NOTA-4-N-alkylgemcitabine complex 68
in quantitative yield after 15 mins, as characterized by HRMS. Radiolabeling of 65 with
68

Ga gave [68Ga]-68 quantitatively after 5 mins. This radiotracer was injected onto BALC/c

mice where it showed only minimal hepatobiliary excretion, and rapid renal clearance most
likely due to the increased hydrophilicity due to the addition of the NOTA chelator.
Despite the fact that synthesis of the model adenosine 5'-diphosphate prodrug (e.g., 87)
was successful, coupling of clofarabine 5'-monophosphate 81 with bis(benzoyloxy benzyl)
phosphoramidite reagent 84 under several reaction conditions failed to produce desired
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diphosphate prodrug 88. Improvement of the purity of phosphoramidite, and exchange of
triethylammonium acetate to simply triethylammonium counter ions in clofarabine 5'monophosphate may help with the synthesis of desired 88. Since no effective protocols for
synthesis of 88 has been developed, our goals of synthesis of C2'
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F-clofarabine

diphosphate prodrugs as potential new PET imaging radiotracers has not been further
explored.
In my dissertation, I have reported the synthesis of several azido modified purine and
pyrimidine analogues for use in EPR studies to characterize the guanyl, adenyl, and cytidyl
aminyl radicals. The first class of azido analogues synthesized were the 2-azidopurine
nucleosides including: 2-azido-2'-deoxyinosine 89, 2-azidoinsosine 91, 2-azido-2'deoxyadenosine 90, and 2-azidoadenosine 92 that were prepared for EPR elucidation of
the guanyl-type 2-aminyl radical. The second class includes protected 6-azido-2'deoxyadenosine 107, which was synthesized to characterize the adenyl 6-aminyl radical
that has been shown to be the source of certain lesions in DNA.124 The third class of
compound were the azido-modified pyrimidine analogues that includes: 4-azido-3',5'-diO-acetyl-2'-deoxyuridine 112, 4-tetrazolo-2'-deoxyuridine 113, 4-azido-2',3',5'-tri-Oacetyluridine 114, and 4-tetrazolouridine 115, synthesized for the EPR investigation of the
cytidyl 4-aminyl radical.
The ESR studies of electron addition to 2-azidoinosine analogues 89 and 90, or 4-azido
112 and tetrazole 113 clearly establish that position of the azido group in the base moiety
dictates its reactivity towards electron addition. If the azido group is at the ortho position
to ring nitrogens (N1 or N3) as in 89 and 90, or in ortho/para positions as in 6-azido-2'deoxyadenosine 107, 4-azido 112, or tetrazole 113, these compounds produce RN3•- which

150

is stable and does not rapidly convert to the aminyl radical, except in their excited state.
Hence, these compounds did not show much radiasensitization in comparison to the
significant radiosensitization observed from 5-AmdU,106 (in which "isolated" from
heterocyclic nucleobase azido group is readily converted to reactive aminyl radical) in our
in vivo biological studies of these compounds in MDA-MB-231, MCF7 and U87 cell lines.
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